KOL | Charles L LoprinziMayo Clinic, Rochester, MN; | Division of Medical Oncology, Mayo Clinic, Rochester, MN 55902, USA;, cloprinzi@mayo.edu | Department of Oncology, Mayo Clinic, Rochester, MN ... |
CV Kol pour Charles L Loprinzi
| Year | |
|---|---|
| 2022 | Mayo Clinic, Rochester, MN; |
| 2021 | Department of Oncology, Mayo Clinic, Rochester, MN 55905, United States. Electronic address: Mayo Clinic, Rochester, MN, USA |
| 2020 | Department of Oncology, Mayo Clinic Comprehensive Cancer Center, Rochester, United States of America Division of Medical Oncology, Mayo Clinic, Rochester, USA North Central Cancer Treatment Group, Mayo Clinic, Rochester, Minnesota Mayo Clinic, Rochester, MN, United States. |
| 2019 | Department of Oncology; Mayo Clinic; Rochester, Minnesota Mayo Clinic Rochester, Florida, USA Medical Oncology |
| 2018 | Department of Medical Oncology, Mayo Clinic, 200 First St SW, 55905, Rochester, MN, USA Division of Medical Oncology, Mayo Clinic, Rochester, MN |
| 2017 | Division of Medical Oncology, Mayo Clinic, Rochester, MN. Timothy Gilligan, Cleveland Clinic, Cleveland, OH ; Nessa Coyle, Memorial Sloan Kettering Cancer Center, New York; Ronald M. Epstein, University of Rochester School of Medicine, Rochester, NY; Richard M. Frankel, Regenstrief Institute, Indiana University School of Medicine, Indianapolis, IN; Donna L. Berry and Christopher S. Lathan, Dana-Farber Cancer Institute, Harvard Medical School; Vicki A. Jackson, Massachusetts General Hospital, Harvard Medical School, Boston; Carole Seigel, Patient/Advocacy Representative, Brookline, MA; Kari Bohlke, American Society of Clinical Oncology, Alexandria, VA; Esme Finlay, University of New Mexico School of Medicine, Albuquerque, NM; Charles L. Loprinzi, Mayo Clinic, Rochester, MN; and Lynne H. Nguyen and Walter F. Baile, The University of Texas MD Anderson Cancer Center, Houston, TX. Mayo Clinic Minnesota Department of Oncology Rochester Minnesota The Cancer Center |
| 2016 | Alliance Statistics and Data Center, Mayo Clinic (R.Q., H.L.), and Mayo Clinic (K.J.R., J.M.L., C.L.L.), Rochester, MN Mayo Clinic Cancer Center, Rochester, Minnesota |
| 2015 | Departments of Neurology, Oncology, Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, MN, USA Mayo Clinic Division of Medical Oncology Rochester Minnesota |
| 2014 | Mayo Clinic Cancer Center Rochester MN |
| 2013 | From the Department of Oncology and Cancer Center Statistics, Mayo Clinic, Rochester, MN. Mayo Clinic Rochester, 200 First Street, SW, 55905, Rochester, MN, USA |
| 2012 | Department of Oncology, Mayo Clinic, 55905, Rochester, MN, USA Mayo Clinic, Rochester, MN, United States |
Charles L Loprinzi: Statistiques d'influence
Rapport d'exécution
| Concept | World rank |
|---|---|
| doxepin mouthwash patients | #1 |
| infliximab lung | #1 |
| cachexia cancer anorexia | #1 |
| phase iii evaluation | #1 |
| background hot | #1 |
| toxicity agent | #1 |
| baseline assessment week | #1 |
| evidence cipn | #1 |
| aes placebo arm | #1 |
| daily questionnaires | #1 |
| leucovorin breast cancer | #1 |
| topic peripheral neuropathy | #1 |
| paclitaxel favor | #1 |
| n01c9 | #1 |
| bothersome hot | #1 |
| eortc cipn20 | #1 |
| n08c1 | #1 |
| ulabtka placebo cream | #1 |
| accru trial | #1 |
| ru221408i | #1 |
| antineoplastic agents nrs | #1 |
| isae anthracycline | #1 |
| megestrol acetate | #1 |
| pilot evaluation | #1 |
| oral mucosa study | #1 |
| preceding 2 months | #1 |
| alliance n08c1 | #1 |
| therapy hot | #1 |
| authors 30 minutes | #1 |
| arhgef10 cipn | #1 |
| bellergal | #1 |
| fluoxetine hot | #1 |
| toxicity anecdotal observations | #1 |
| recurrences clinical histories | #1 |
| paresthesia peripheral | #1 |
| records adult patients | #1 |
| flashes pilot | #1 |
| cinv day | #1 |
| n08ca | #1 |
| induced neurotoxicity oct2 | #1 |
| placebo pilot trials | #1 |
| cancers prevalence | #1 |
| nonhormonal agent | #1 |
| hormone deprivation | #1 |
| 95 increased difficulty | #1 |
| score baseline values | #1 |
| flaxseed hot flashes | #1 |
| isae | #1 |
| study dmc assay | #1 |
| chamomile mouthwash | #1 |
| differences neuropathy syndromes | #1 |
| 5fu adjuvant | #1 |
| device 5 weeks | #1 |
| overview oncology providers | #1 |
| bakplo symptoms | #1 |
| patients 10 range | #1 |
| olanzapine arm emesis | #1 |
| neuropathy prevention | #1 |
| paclitaxel study arms | #1 |
| megestrol acetate weeks | #1 |
| prestudy hypothesis | #1 |
| prevention oral cryotherapy | #1 |
| gabapentin hot | #1 |
| managing hot | #1 |
| symptoms hands | #1 |
| toxicity gabapentin | #1 |
| mouthwash diphenhydramine | #1 |
| bridging editorial | #1 |
| burden alopecia | #1 |
| management hot | #1 |
| symptoms hormone deprivation | #1 |
| antiemetic prescribing practices | #1 |
| compassionate honesty | #1 |
| flashes breast | #1 |
| cipn20 sensory | #1 |
| cancerrelated fatigue interventions | #1 |
| δ − 95 | #1 |
| uncertain gbu gbu | #1 |
| replacement testosterone andropause | #1 |
| 95 doxepin mouthwash | #1 |
| 5fuinduced ocular toxicity | #1 |
| purpose hot | #1 |
| peripheral neuropathy paclitaxel | #1 |
| management hot flashes | #1 |
| loe prevention | #1 |
| understanding potential benefits | #1 |
| digital melt curve | #1 |
| antiemetic prescribing | #1 |
| skin dermatitis trials | #1 |
| gene arhgef10 | #1 |
| creatine placebo groups | #1 |
| tested interventions lymphedema | #1 |
| life cipn | #1 |
| painful oxaliplatininduced cipn | #1 |
| stomatitis administration | #1 |
| modalities cancer patients | #1 |
| 5 methylphenidate | #1 |
| ganglion surveys | #1 |
| numerical analogue scale | #1 |
| lymphedemafree rates | #1 |
| life leap | #1 |
| stellate ganglion block | #1 |
| patients nasal vestibulitis | #1 |
| burning pain | #1 |
| adjuvant numeracy | #1 |
| isae data | #1 |
| anorexia appetite | #1 |
| anorexia antineoplastic agents | #1 |
| symptom intervention | #1 |
| purposepaclitaxel | #1 |
| tools hypothetical scenarios | #1 |
| effects limited efficacy | #1 |
| vaginal dehydroepiandrosterone dhea | #1 |
| balance gait testing | #1 |
| cyclohexanecarboxylic acids gamma | #1 |
| hot flashes quality | #1 |
| joints syndrome | #1 |
| flashes common | #1 |
| flashes quality | #1 |
| patients cancer anorexia | #1 |
| purposehot | #1 |
| stomatitis scores | #1 |
| data clinical histories | #1 |
| cipn20 data | #1 |
| neuronal uptake transporters | #1 |
| grade peripheral neuropathy | #1 |
| cipn common | #1 |
| hormone deprivation symptoms | #1 |
| bortezomib alters | #1 |
| pilot trial hands | #1 |
| 2007 guidelines suggestion | #1 |
| education lymphedema prevention | #1 |
| developed mucositis | #1 |
| judicious tpn | #1 |
| leucovorin breast | #1 |
| − fsfi | #1 |
| 22 nonestrogenic management | #1 |
| weight loss investigation | #1 |
| bothersome hot flashes | #1 |
| antidepressive agents gamma | #1 |
| response relationship odc | #1 |
| placebo 15 glutathione | #1 |
| individuals cipn | #1 |
| purposehot flashes | #1 |
| hot flash score | #1 |
| antibiotic lozenge placebo | #1 |
| cryotherapy auc | #1 |
| fourth treatment week | #1 |
| gait testing patients | #1 |
| minocycline cipn | #1 |
| aps paclitaxel | #1 |
| life megestrol acetate | #1 |
| toxicity prospective trial | #1 |
| neoplasms placebos | #1 |
| vte recurrence enoxaparin | #1 |
| dmc mutations | #1 |
| hormonal ablation andropause | #1 |
| highdose melphalan intervention | #1 |
| glutamine toxicity | #1 |
| relatedness treatment | #1 |
| acetate appetite | #1 |
| acute pain syndrome | #1 |
| ulabtka arm | #1 |
| life qlqcipn20 | #1 |
| oral cryotherapy management | #1 |
| therapy numbness | #1 |
| crc patients 95 | #1 |
| 65 day | #1 |
| snv rs9657362 | #1 |
| pilot study minocycline | #1 |
| hot flashes weeks | #1 |
| treatment hot | #1 |
| topic rectum surveys | #1 |
| neoplasms climacteric | #1 |
| subsequent chemotherapy cycles | #1 |
| qlq cipn20 | #1 |
| median δ qs | #1 |
| dfs 5fu | #1 |
| rs17683288 | #1 |
| fsfi udi | #1 |
| managing hot flashes | #1 |
| doubleblinded manner | #1 |
| cachexia dexamethasone | #1 |
| oxybutynin doses | #1 |
| udi δ − | #1 |
| cipn20 | #1 |
| oral cryotherapy patients | #1 |
| treatment attribution | #1 |
| 12 months anticoagulation | #1 |
| oral mucositisrelated pain | #1 |
| oxybutynin hot flashes | #1 |
| incurable cancer records | #1 |
| impaired postural control | #1 |
| oil nasal | #1 |
| cyproheptadine appetite | #1 |
| attribution clinical trials | #1 |
| flashes treatment | #1 |
| mascc isoo guidelines | #1 |
| estimated benefit dfs | #1 |
| lidocaine antacid | #1 |
| studies cyproheptadine | #1 |
| cryotherapy mucositis | #1 |
| individual patients understanding | #1 |
| paclitaxel coasting phenomenon | #1 |
| hot flash mechanism | #1 |
| balance impairments patients | #1 |
| numbness hands | #1 |
| accru study | #1 |
| study stool samples | #1 |
| disease patient factors | #1 |
| amines antidepressive | #1 |
| aminobutyric acid hec | #1 |
| uncertain gbu | #1 |
| newer antidepressants gabapentin | #1 |
| aes relatedness | #1 |
| prevention cipn | #1 |
| papsmethodspatients | #1 |
| a151408 | #1 |
| shooting burning | #1 |
| survival tpn initiation | #1 |
| bakplo placebo | #1 |
| nonhormonal agents treatment | #1 |
| cipn trials | #1 |
| leap 12 months | #1 |
| cachexia megestrol | #1 |
| flashes week | #1 |
| darbepoetin alfa head | #1 |
| paclitaxel weekly cryotherapy | #1 |
| nonhormonal | #1 |
| gas menopause patient | #1 |
| alleviating hot | #1 |
| patients paclitaxel polyneuropathy | #1 |
| hot flash frequency | #1 |
| drowsiness doxepin mouthwash | #1 |
| cisplatin therapy cinv | #1 |
| symptoms feet | #1 |
| hot flash data | #1 |
| weeks hot flashes | #1 |
| drowsiness unpleasant taste | #1 |
| dmc assay | #1 |
| neuropathy 20 | #1 |
| women megestrol acetate | #1 |
| hot flashes treatment | #1 |
| adam vte | #1 |
| prevention induced cipn | #1 |
| treating hot | #1 |
| nasal vestibulitis | #1 |
| supportive nsclc | #1 |
| chemotherapy neuropathy | #1 |
| adt cyclohexanecarboxylic acids | #1 |
| week tamoxifen | #1 |
| suggestion oral cryotherapy | #1 |
| complete response authors | #1 |
| induced cipn | #1 |
| baseline neuropathic pain | #1 |
| sham acupuncture participants | #1 |
| cipn agents | #1 |
| olanzapine projects vomiting | #1 |
| items uncertain gbu | #1 |
| acute symptoms cycle | #1 |
| flashes stellate | #1 |
| tpn longterm survival | #1 |
| lymphedema prevention education | #1 |
| education lymphedema education | #1 |
| nonestrogenic management | #1 |
| flashes androgen | #1 |
| n08c3 | #1 |
| numbness tingling | #1 |
| hot flashes women | #1 |
| data hot | #1 |
| nonhormonal therapies paroxetine | #1 |
| ncctg n08c3 | #1 |
| treatment cipn | #1 |
| flaxseed bar lignans | #1 |
| inadequate control antidepressant | #1 |
| neuropathy randomized | #1 |
| cipnmethodspatients | #1 |
| anthracycline data | #1 |
| initiation tpn | #1 |
| inadequate hot | #1 |
| cryotherapy hands | #1 |
| patients highdose interferon | #1 |
| toxicity ocular | #1 |
| n00cb | #1 |
| treatment hot flashes | #1 |
| pilot trials efficacy | #1 |
| ncctg trial n06ca | #1 |
| ulabtka | #1 |
| flashes patients | #1 |
| rs9657362 | #1 |
| receiving fluorouracil | #1 |
| antiserotonergic drug | #1 |
| nonhormonal agents | #1 |
| gabapentin antidepressant | #1 |
| extreme phenotyping | #1 |
| suggestion toxicity | #1 |
| prominent clinical problem | #1 |
| positive indication prognosis | #1 |
| alliance study a221102 | #1 |
| male megestrol megestrol | #1 |
| alliance n08ca | #1 |
| anecdotal observations | #1 |
| intervention leap | #1 |
| placebo drowsiness | #1 |
| baseline week gabapentin | #1 |
| nonfluid bodyweights | #1 |
| control hot flashes | #1 |
| management genital symptoms | #1 |
| attribution percentage | #1 |
| efficacy gabapentin | #1 |
| underdescribers | #1 |
| testosterone improvements | #1 |
| preliminary promising data | #1 |
| 95 neuropathic pain | #1 |
| weight megestrol acetate | #1 |
| patients hot flashes | #1 |
| lenolidamide | #1 |
| cipn paps | #1 |
| institutional guidelines patients | #1 |
| resected cutaneous melanomas | #1 |
| trial n00cb | #1 |
| qol reported difficulty | #1 |
| tools oncologists | #1 |
| compliance institutional guideline | #1 |
| flaxseed bar | #1 |
| natural postural instability | #1 |
| patientcompleted questionnaires | #1 |
| acetate hot | #1 |
| patients 25 micrograms | #1 |
| prtmethodsdata | #1 |
| placebo oral mucositis | #1 |
| effects cipn | #1 |
| sae δ − | #1 |
| hot flashes patients | #1 |
| patients subcutaneous testosterone | #1 |
| flashes women | #1 |
| adjuvant numeracy calculators | #1 |
| decrease hot | #1 |
| doxepin mouthwash placebo | #1 |
| acetate doses | #1 |
| doxepin mouthwash | #1 |
| 1year survival trials | #1 |
| established cipn | #1 |
| aimss life | #1 |
| cachexia cyproheptadine | #1 |
| ctcae grade | #1 |
| ulabtka hfs | #1 |
| subcutaneous testosterone improvements | #1 |
| flashes prospective | #1 |
| small cell continuity | #1 |
| physical consequences cipn | #1 |
| tpn female services | #1 |
| 8week observation period | #1 |
| active nonhormonal | #1 |
| 1 month appetite | #1 |
| historical placebo response | #1 |
| vaginal dehydroepiandrosterone | #1 |
| difficulty neuropathic pain | #1 |
| pharmacological targeting oct2 | #1 |
| drug humans interferons | #1 |
| dronabinol megestrol acetate | #1 |
| patients underdescribers | #1 |
| methylphenidate cancer patients | #1 |
| 5 weeks device | #1 |
| pharmacologic therapeutics | #1 |
| postural instability chemotherapy | #1 |
| favor placebo | #1 |
| cipn clinical trial | #1 |
| treating institution intervention | #1 |
| mouthwash placebo | #1 |
| pain chemotherapy | #1 |
| polyneuropathy allelic variability | #1 |
| aminobutyric acid adt | #1 |
| based chemotherapy isae | #1 |
| acetate versus | #1 |
| hot flash scores | #1 |
| cipn postural control | #1 |
| flashes objective | #1 |
| single snv rs9657362 | #1 |
| points doxepin | #1 |
| ambulatory patients opioids | #1 |
| dronabinol combination | #1 |
| auc cryotherapy | #1 |
| baseline prognosis values | #1 |
| longitudinal continuation | #1 |
| anecdotal observations gabapentin | #1 |
| paclitaxel acute | #1 |
| placebos pregabalin quality | #1 |
| lymphedema hrqol outcomes | #1 |
| acetate anorexia | #1 |
| paps fatigue | #1 |
| chemotherapy response rates | #1 |
| metastatic disease initiation | #1 |
| authors 115 patients | #1 |
| patients dosing guidelines | #1 |
| gabapentin aminobutyric acid | #1 |
| survivors genitourinary syndrome | #1 |
| pregabalin paclitaxel | #1 |
| gabapentin baseline week | #1 |
| appetite stimulation patients | #1 |
| prevent oxaliplatin | #1 |
| alleviate hot | #1 |
| oncologists competence | #1 |
| neuropathic pain difficulty | #1 |
| antidepressants gabapentin | #1 |
| neuropathy data | #1 |
| oestrogen survivors | #1 |
| duloxetine response patients | #1 |
| items positive indication | #1 |
| hfs trial | #1 |
| hormone deprivation cancer | #1 |
| vaginal cytology women | #1 |
| efficacy agent | #1 |
| hot flash control | #1 |
| hot flashes | #1 |
| individuals impaired balance | #1 |
| numeracy adjuvant | #1 |
| middle aged minocycline | #1 |
| ganglion surveys humans | #1 |
| diphenhydraminelidocaineantacid | #1 |
| 2 study arms | #1 |
| magnesium oxaliplatininduced neurotoxicity | #1 |
| patients physical examinations | #1 |
| underdescribing | #1 |
| n08ca patients | #1 |
| acceptability ssc device | #1 |
| chemotherapy regimen type | #1 |
| pregenplus | #1 |
| safety oestrogen | #1 |
| supportive cryotherapy | #1 |
| prognosis items | #1 |
| dfs predictions adjuvant | #1 |
| agents cipn | #1 |
| populations neurologic humans | #1 |
| glutathione cipn | #1 |
| residual hot flashes | #1 |
| flashes gabapentin | #1 |
| cachexia studies | #1 |
| patients placebo pellet | #1 |
| underdescribers weeks | #1 |
| gabapentin arm | #1 |
| benefit fluoxetine | #1 |
| cipn phase iii | #1 |
| cipn data | #1 |
| sensory subscale | #1 |
| nociceptors putative mechanism | #1 |
| combination chemotherapy hec | #1 |
| fosaprepitant isae | #1 |
| topical cannabinoids patients | #1 |
| cipn adult | #1 |
| lymphedemafree rates groups | #1 |
| oral cryotherapy prevention | #1 |
| placebo anecdotal observations | #1 |
| sensory neuropathy symptoms | #1 |
| ssc device prototype | #1 |
| newer antidepressants | #1 |
| antidepressant gabapentin | #1 |
| hours nighttime sleep | #1 |
| n08cb | #1 |
| 137 patients cycle | #1 |
| current trial | #1 |
| qolresultsfrom | #1 |
| lymphedema incidence intervention | #1 |
| deprivation therapy patients | #1 |
| a151408 study data | #1 |
| balance patientreported outcomes | #1 |
| agents humans clinicians | #1 |
| 30 points 95 | #1 |
| 81 patients patients | #1 |
| slight appetite stimulation | #1 |
| premenopause radiotherapy | #1 |
| flashes prostate | #1 |
| cachexia carcinoma life | #1 |
| treatments modalities | #1 |
| head therapeutic equivalency | #1 |
| peripheral neuropathy | #1 |
| rest psychostimulants | #1 |
| time publication attitude | #1 |
| nonfluid weight gain | #1 |
| week hot | #1 |
| relatedness treatment arms | #1 |
| megestrol acetate patients | #1 |
| points diphenhydramine | #1 |
| mascc isoo evidence | #1 |
| symptoms cipn | #1 |
| nonhormonal hot | #1 |
| 20 data patients | #1 |
| extensive animal data | #1 |
| numbness scores | #1 |
| vitamin cipn | #1 |
| adam vte trial | #1 |
| flash score | #1 |
| suggestion pregabalin | #1 |
| tingling numbness | #1 |
| trust oncologists competence | #1 |
| ncctg n08c1 | #1 |
| cipn20 questionnaire | #1 |
| leap rom | #1 |
| nonfluid weight | #1 |
| humans ganglion surveys | #1 |
| discrepancies clinicians assessment | #1 |
| rs9657362 previous study | #1 |
| nonfluid | #1 |
| randomized study lymphedema | #1 |
| compounded topical gel | #1 |
| bakplo | #1 |
| hot flash relief | #1 |
| venous toxicity fosaprepitant | #1 |
| patients megestrol acetate | #1 |
| topical keratolytic | #1 |
| female services tpn | #1 |
| leap lymphedema | #1 |
| hot flashes day | #1 |
| fractures infertility | #1 |
| uniscale qol baseline | #1 |
| routine feces sensitivity | #1 |
| placebo 15 points | #1 |
| baseline week followup | #1 |
| women inadequate control | #1 |
| revisitation doc | #1 |
| regional hypothermia burden | #1 |
| infliximab cancer | #1 |
| 43 oral complications | #1 |
| neuropathic symptoms breast | #1 |
| deprivation symptoms | #1 |
| neoplasm recurrence apixaban | #1 |
| alopecia ocular toxicity | #1 |
| cipn function | #1 |
| weeks hot | #1 |
| flash scores | #1 |
| backgrounddehydroepiandrosterone | #1 |
| prevention paps | #1 |
| increased difficulty patients | #1 |
| cinv neoplasms vomiting | #1 |
| rom leap | #1 |
| placebo mouthwash | #1 |
| oestrogen hot flashes | #1 |
| oral cryotherapy | #1 |
| day cisplatin therapy | #1 |
| magnesium camg | #1 |
| chemotherapy treatment chemotherapy | #1 |
| compliance institutional guidelines | #1 |
| hfs symptoms patients | #1 |
| dmc samples | #1 |
| patientreported nasal symptoms | #1 |
| progestational agents patients | #1 |
| illness neuropathic symptoms | #1 |
| antacid mouthwash | #1 |
| n06ca | #1 |
| hec cisplatin therapy | #1 |
| tpn initiation death | #1 |
| oral mucositis alopecia | #1 |
| cancerassociated anorexia cachexia | #1 |
| topical cannabinoids | #1 |
| placebo arms percentage | #1 |
| cipn methods | #1 |
| rs2294039 | #1 |
| cipn nervous diseases | #1 |
| flashes venlafaxine | #1 |
| pilot trials venlafaxine | #1 |
| postsurgical neuropathic pain | #1 |
| breakthrough nausea patients | #1 |
| treatment symptom intervention | #1 |
| 5fuinduced stomatitis | #1 |
| flash therapies | #1 |
| isae patients | #1 |
| chamomile mouthwash toxicity | #1 |
| lignans 6 weeks | #1 |
| baseline fsfi score | #1 |
| cyclohexanols female | #1 |
| cachexia trial | #1 |
| cipnsummarythere | #1 |
| treatment alteration | #1 |
| placebo arm gabapentin | #1 |
| antibiotic lozenge | #1 |
| phytotherapy vitamin | #1 |
| severe stomatitis | #1 |
| gsm fsfi | #1 |
| effects hot flashes | #1 |
| duloxetine response | #1 |
| n08cb alliance | #1 |
| myalgias arthralgias | #1 |
| toxicities opioids | #1 |
| alliance a151724 | #1 |
| tingling | #1 |
| recommended colorectal | #1 |
| rose geranium | #1 |
| isaes | #1 |
| patients gabapentin | #1 |
| tpn death | #1 |
| attribution treatment | #1 |
| iii double | #1 |
| megestrol acetate nausea | #1 |
| daily hot | #1 |
| ocular ice packs | #1 |
| pilot trials citalopram | #1 |
| patientreported outcomes balance | #1 |
| eortc cipn | #1 |
| cipn development severity | #1 |
| fsfi 95 | #1 |
| patients dfs predictions | #1 |
| guidelineendorsed treatment | #1 |
| agents cyclohexanecarboxylic | #1 |
| outcomes study points | #1 |
| cvte rivaroxaban | #1 |
| accru study ru221408i | #1 |
| conducted studies hrt | #1 |
| bupropion nicotine dependence | #1 |
| udi scores baseline | #1 |
| cipn topical gel | #1 |
| discrepancies women | #1 |
| suggested gabapentin | #1 |
| motor subscales | #1 |
| women 65 day | #1 |
| qolconclusionsthe | #1 |
| patient followup studies | #1 |
| n08ca association | #1 |
| numeracy benefit | #1 |
| hot flash activity | #1 |
| nsclc response rate | #1 |
| paclitaxel polyneuropathy | #1 |
| fluorouracilinduced stomatitis | #1 |
| acetate dexamethasone | #1 |
| preliminary evidence improvement | #1 |
| hot flashes gabapentin | #1 |
| overview crci | #1 |
| feet oxaliplatin | #1 |
| improvements hot flashes | #1 |
| 2007 guidelines guideline | #1 |
| diseases pilot | #1 |
| arthralgia breast life | #1 |
| difference cipn20 scores | #1 |
| hfs ulabtka | #1 |
| hot flash | #1 |
| taxane infusion | #1 |
| benefit 5fu | #1 |
| cancer hot | #1 |
| alliance trial | #1 |
| prominent toxicity | #1 |
| life study arms | #1 |
| therapeutic targets cipn | #1 |
| women male megestrol | #1 |
| altered sensory organization | #1 |
| pregabalin paps | #1 |
| baseline prognosis | #1 |
| taxane treatment development | #1 |
| patients spray product | #1 |
| male megestrol life | #1 |
| safety progestational agents | #1 |
| patients ulabtka | #1 |
| placebo 30 points | #1 |
| association arhgef10 | #1 |
| oncology providers crci | #1 |
| coasting phenomenon | #1 |
| enoxaparin cvte | #1 |
| reducing hot | #1 |
| cancer anorexia cachexia | #1 |
| ocular ice | #1 |
| recommendation prevention | #1 |
| eortc qlqcipn20 instrument | #1 |
| supportive cytotoxic chemotherapy | #1 |
| gabapentin hot flashes | #1 |
| centrally active agent | #1 |
| reduction hot | #1 |
| oncologists prognostic | #1 |
| hot flashes acceptability | #1 |
| cytotoxic chemotherapy supportive | #1 |
| or1 year patients | #1 |
| agents antihypertensive agents | #1 |
| oncologists competence 95ci | #1 |
| neoplasms double | #2 |
| dronabinoltreated patients | #2 |
| study arms | #2 |
| symptoms surveys | #2 |
| dexamethasone fluoxymesterone | #2 |
| humans postmenopause pregabalin | #2 |
| phytogenic female humans | #2 |
| cancerassociated anorexia | #2 |
| monthly intervals appetite | #2 |
| 3 months bupropion | #2 |
| advancedstage cancer | #2 |
| study arms tetracycline | #2 |
| 120 arm | #2 |
| experience hot flashes | #2 |
| patients chemotherapyassociated anemia | #2 |
| scrambler | #2 |
| average stomatitis sex | #2 |
| cycle folfox | #2 |
| egfr inhibitor tetracycline | #2 |
| cpmp scrambler therapy | #2 |
| evaluating venlafaxine | #2 |
| venlafaxine control | #2 |
| prevent paclitaxel | #2 |
| patients difluoromethylornithine | #2 |
| citalopram cyclohexanols humans | #2 |
| 135±19 | #2 |
| aprepitan | #2 |
| scrambler therapy tens | #2 |
| humans citalopram cyclohexanols | #2 |
| women hot flashes | #2 |
| 46 screenrelevant neoplasms | #2 |
| placebo hf frequency | #2 |
| cipn | #2 |
| physicians kps | #2 |
| dronabinol combination therapy | #2 |
| tetracycline rash incidence | #2 |
| sdt2 hemoccult | #2 |
| npy anorexia cholecystokinin | #2 |
| anthraquinones agents breast | #2 |
| oxaliplatin hands | #2 |
| patients olanzapine arm | #2 |
| treatment target doses | #2 |
| 108±11 | #2 |
| depomedroxyprogesterone | #2 |
| standard arm rate | #2 |
| pa outcomes pros | #2 |
| target doses placebo | #2 |
| versus megestrol | #2 |
| nutrition scores physicians | #2 |
| cisplatin polymerase inhibitors | #2 |
| appetite dissent disputes | #2 |
| ctcae pruritus | #2 |
| weekly hf score | #2 |
| 5fuinduced mucositis | #2 |
| autonomic scales | #2 |
| descriptive manner | #2 |
| disagreement increased risk | #2 |
| oxybutynin doses placebo | #2 |
| randomized study mometasone | #2 |
| illness tetracycline egfr | #2 |
| sensitivity cold items | #2 |
| anabolic corticosteroid treatment | #2 |
| time ncctg alliance | #2 |
| 432 smokers treatment | #2 |
| time toxt approach | #2 |
| life aimss | #2 |
| symptomatic cipn | #2 |
| hot flash trials | #2 |
| lmwh arms | #2 |
| chronic chemotherapy | #2 |
| advanced cancer anorexia | #2 |
| venlafaxine treatment 75 | #2 |
| hot flash quality | #2 |
| hemoccultsensa sdt2 | #2 |
| symptoms skin toxicity | #2 |
| patient‐physician disagreement | #2 |
| acknowledged loss | #2 |
| 75 49 venlafaxine | #2 |
| cachexia decision | #2 |
| nonestrogenic therapies | #2 |
| participants 3 stools | #2 |
| paclitaxel chronic neuropathy | #2 |
| patients daily mmf | #2 |
| receive parenteral | #2 |
| evaluating gabapentin | #2 |
| outcome measures ctcae | #2 |
| longitudinal studies postmenopause | #2 |
| week breast cancer | #2 |
| screenrelevant neoplasms 16 | #2 |
| anorexia antineoplastic | #2 |
| mometasone time | #2 |
| 16 hemoccult | #2 |
| hemoccultsensa sensitivity | #2 |
| cipn primary outcomes | #2 |
| ≤ moderate correlations | #2 |
| hot flashes humans | #2 |
| cohosh treatment | #2 |
| life 4week intervention | #2 |
| trials suggested | #2 |
| smokers nicotine inhaler | #2 |
| 14 hot flashes | #2 |
| life treatment weeks | #2 |
| “use vitamin | #2 |
| neuropathy paclitaxel | #2 |
| data relative benefits | #2 |
| lamotrigine neuropathic symptoms | #2 |
| subject global impression | #2 |
| infliximab docetaxel | #2 |
| duloxetine hydrochloride humans | #2 |
| placebo bar | #2 |
| poor qol 95 | #2 |
| hemoccultsensa detection | #2 |
| management genitourinary symptoms | #2 |
| anemia caa | #2 |
| flash diary | #2 |
| cachexia pentoxifylline | #2 |
| weight concerns 26 | #2 |
| life venlafaxine | #2 |
| positive doseresponse | #2 |
| hot flashes pregabalin | #2 |
| shark cartilage placebo | #2 |
| pilocarpine vaginal | #2 |
| postchemotherapy rheumatism | #2 |
| 120k arm patients | #2 |
| sdt2 sdt1 | #2 |
| suggested agents | #2 |
| scrambler therapy management | #2 |
| treatment alterations | #2 |
| declining qol | #2 |
| n01c4 | #2 |
| glutamine placebo preparation | #2 |
| placebo oxybutynin doses | #2 |
| cancerassociated wasting | #2 |
| colonoscopically normal patients | #2 |
| incidence severity stomatitis | #2 |
| ductal mometasone furoate | #2 |
| chemotherapyassociated anemia caa | #2 |
| nonestrogenic hot | #2 |
| nutrition score disagreement | #2 |
| vte recurrence dalteparin | #2 |
| mucositis 5fubased chemotherapy | #2 |
| tamoxifen percentage reduction | #2 |
| hot flashes bupropion | #2 |
| global impression life | #2 |
| aprepitant 4 weeks | #2 |
| pilocarpine vaginal dryness | #2 |
| peripheral neuropathy cipn | #2 |
| folfox auc p0·0001 | #2 |
| appetite dissent | #2 |
| oxybutynin women | #2 |
| leucovorin women | #2 |
| previous hot flashes | #2 |
| reduce hot | #2 |
| cipn clinical | #2 |
| folfox symptoms | #2 |
| local antineoplastic agents | #2 |
| real patients treatment | #2 |
| 1 oral megestrol | #2 |
| cipn cases | #2 |
| mometasone surveys | #2 |
| levetiracetam 4 weeks | #2 |
| control arms rate | #2 |
| dronabinol versus | #2 |
| 800 liquid suspension | #2 |
| 16 sdt2 | #2 |
| oxaliplatin doses trends | #2 |
| trial acetate doses | #2 |
| feet 18 months | #2 |
| rash incidence severity | #2 |
| time randomized study | #2 |
| postural instability individuals | #2 |
| reducing chemotherapy | #2 |
| questionnaires antineoplastic agents | #2 |
| iii randomized | #2 |
| 95 indirect estimates | #2 |
| 49 venlafaxine | #2 |
| cipn cancer survivors | #2 |
| neuropathy cipn | #2 |
| decreasing stomatitis | #2 |
| original report time | #2 |
| treatment cycles cycle | #2 |
| n0993 | #2 |
| dna markers participants | #2 |
| established chemotherapy | #2 |
| life venlafaxine hydrochloride | #2 |
| 01 mmf | #2 |
| cck8 anorexia severity | #2 |
| increased risk cipn | #2 |
| study arms conclusions | #2 |
| scrambler therapy treatment | #2 |
| 5fubased chemotherapy mucositis | #2 |
| hot flash studies | #2 |
| placebo vaginal dryness | #2 |
| lvef 1000 | #2 |
| provider assessed | #2 |
| starting tamoxifen women | #2 |
| 40k arm 120000 | #2 |
| patients cipn | #2 |
| life scrambler therapy | #2 |
| venlafaxine gabapentin | #2 |
| central cancer | #2 |
| cipn paclitaxel | #2 |
| disagreement patients | #2 |
| day study week | #2 |
| surveys repeated measures | #2 |
| 150 groups patients | #2 |
| appetite improvement | #2 |
| cipn20 factor analysis | #2 |
| glutathione prevention | #2 |
| acttionconsortium | #2 |
| desipramine hot flashes | #2 |
| 15 points 95 | #2 |
| older age bupropion | #2 |
| survival 3915 patients | #2 |
| tamoxifen medications | #2 |
| megestrol acetate dexamethasone | #2 |
| study arms quality | #2 |
| females cessation treatment | #2 |
| alliance folfox | #2 |
| 40000 40k arm | #2 |
| anorexia severity | #2 |
| stomatitis women | #2 |
| topical aged antimetabolites | #2 |
| tingling patients | #2 |
| sensitivity screenrelevant neoplasms | #2 |
| single snv | #2 |
| mmf itching | #2 |
| type chemotherapy drug | #2 |
| women rom | #2 |
| 46 adenomas 1 | #2 |
| intervention 18 months | #2 |
| tamoxifenassociated hot flashes | #2 |
| anthrapyrazoles piroxantrone | #2 |
| rcts preventive therapies | #2 |
| 7 control arms | #2 |
| treatment smoking abstinence | #2 |
| patients receiving fluorouracil | #2 |
| bupropion nicotine inhaler | #2 |
| oral iron 46 | #2 |
| patients oxybutynin doses | #2 |
| differences mometasone | #2 |
| skindex16 itching | #2 |
| circulating concentrations npy | #2 |
| cycle chronic neurotoxicity | #2 |
| patients black cohosh | #2 |
| stat itching | #2 |
| coumarin placebo | #2 |
| treatment aprepitant | #2 |
| flashes citalopram | #2 |
| fsfi score baseline | #2 |
| neuropathy caused | #2 |
| original report mometasone | #2 |
| breast cancer venlafaxine | #2 |
| gabapentin symptoms | #2 |
| clinical trials n9741 | #2 |
| induced peripheral | #2 |
| hemoccultsensa sdt1 | #2 |
| day average pain | #2 |
| lmwh arms 7 | #2 |
| numeracy prognosis | #2 |
| coriat | #2 |
| ferric gluconate darbepoetin | #2 |
| patients 120k arm | #2 |
| postmenopausal women previous | #2 |
| sdt2 | #2 |
| eortc qlqcipn20 | #2 |
| study treatment citalopram | #2 |
| hot flashes citalopram | #2 |
| paclitaxel induced | #2 |
| trials newer antidepressants | #2 |
| flash studies | #2 |
| n06c4 | #2 |
| failure prior chemotherapy | #2 |
| sunscreen arms | #2 |
| patients shark cartilage | #2 |
| kps nutrition score | #2 |
| docetaxel serum concentrations | #2 |
| venlafaxine oxaliplatin neurotoxicity | #2 |
| hf frequency placebo | #2 |
| induced peripheral neuropathy | #2 |
| newer antidepressants trials | #2 |
| tens global impression | #2 |
| guidelines recommendation | #2 |
| treatment baseline week | #2 |
| substantial hot flashes | #2 |
| magnesium oxaliplatin | #2 |
| therapy hot flashes | #2 |
| placebo breast radiotherapy | #2 |
| hot flash diary | #2 |
| cipn prevention trials | #2 |
| methylphenidate cancer | #2 |
| women stomatitis | #2 |
| mometasone cream | #2 |
| detection dna markers | #2 |
| tens 2 weeks | #2 |
| treatment breakthrough cinv | #2 |
| topic estrogen | #2 |
| prevent radiation | #2 |
| intermediate term efficacy | #2 |
| skindex16 ctcae | #2 |
| prevalence weight concerns | #2 |
| pregabalin hot flashes | #2 |
| appearing pilot data | #2 |
| vte recurrence doacs | #2 |
| trial suggestion | #2 |
| pilocarpine arms | #2 |
| placebo combination therapy | #2 |
| placebo situ carcinoma | #2 |
| detection screenrelevant neoplasms | #2 |
| time toxt analysis | #2 |
| day baseline week | #2 |
| antidepressants hot | #2 |
| stat erythema | #2 |
| 95 oral placebo | #2 |
| 120k arm | #2 |
| screenrelevant neoplasms | #2 |
| gabapentin 4 weeks | #2 |
| ncctg trial | #2 |
| shark cartilage patients | #2 |
| stomatitis sex | #2 |
| cipn peripheral neuropathy | #2 |
| nonhormonal management | #2 |
| ncctg n10c1 | #2 |
| pruritus pros | #2 |
| qol hb increment | #2 |
| hot flash frequencies | #2 |
| supplementary n03cb | #2 |
| flashes placebo | #2 |
| treatment minority smokers | #2 |
| irox folfox auc | #2 |
| nutrition scores 95 | #2 |
| infertility ovarian failure | #2 |
| treatment week placebo | #2 |
| shark cartilage product | #2 |
| pain ≥4 10 | #2 |
| scrambler therapy | #2 |
| allopurinol mouthwash | #2 |
| natural paps | #2 |
| treatment arm mmf | #2 |
| inadequate benefit | #2 |
| induced arthralgias | #2 |
| epoetin alfa 40000 | #2 |
| 34—vitamin | #2 |
| ecog nutrition score | #2 |
| evaluate weight | #2 |
| hot flash management | #2 |
| 120000 epoetin alfa | #2 |
| vitamin hot | #2 |
| placebo arms women | #2 |
| anabolic corticosteroid | #2 |
| fluoxymesterone treatment | #2 |
| fosaprepitant patients | #2 |
| 979254 | #2 |
| antidepressant hot flashes | #2 |
| cdf score | #2 |
| conceppt | #2 |
| cipn20 scores | #2 |
| daily mmf radiotherapy | #2 |
| patients monthly intervals | #2 |
| pregabalin arms | #2 |
| folfox alliance | #2 |
| kps nutrition scores | #2 |
| guaninemethyltransferase | #2 |
| hot flashes data | #2 |
| adjuvant 5fu models | #2 |
| alternative treatment regimen | #2 |
| dhea vaginal symptoms | #2 |
| placebo pregabalin treatments | #2 |
| improvement hot flashes | #2 |
| thiophenes treatment life | #2 |
| indirect comparison apixaban | #2 |
| qol crc | #2 |
| worse survivorship | #2 |
| locoregional event | #2 |
| gabapentin venlafaxine hydrochloride | #2 |
| study n08cb alliance | #2 |
| subsequent mucositis | #2 |
| folfox auc analysis | #2 |
| vitamin hot flashes | #2 |
| cachexia acetate | #2 |
| dhea 4 weeks | #2 |
| months randomized | #2 |
| trial baseline week | #2 |
| life illness tetracycline | #2 |
| historic controls npy | #2 |
| arms conclusions | #2 |
| patients 40k arm | #2 |
| preventive therapies cipn | #2 |
| hemoccultsensa hemoccult | #2 |
| conclusions sunscreen | #2 |
| fatigue improvement methylphenidate | #2 |
| hot flashes efficacy | #2 |
| sdt1 hemoccult | #2 |
| lessons cipn | #2 |
| doses megestrol | #2 |
| hot flashes aprepitant | #2 |
| breakthrough cinv | #2 |
| 4 treatment weeks | #2 |
| dermatitis symptom evolution | #2 |
| cipn antineoplastic agents | #2 |
| receiving megestrol | #2 |
| dosing zoledronic | #2 |
| n03cb | #2 |
| weekly epoetin | #2 |
| cipn cohort | #2 |
| palliative communications | #2 |
| week baseline week | #2 |
| 40k arm | #2 |
| infliximab 5 day | #2 |
| week black cohosh | #2 |
| design considerations recommendations | #2 |
| ctcae differences | #2 |
| predictors disagreement | #2 |
| nicotine inhaler bupropion | #2 |
| citalopram hot flashes | #2 |
| starting tamoxifen | #2 |
| hot flashes dehydroepiandrosterone | #2 |
| woman quality | #2 |
| moderate correlations ≤ | #2 |
| dalteparin lowest risk | #2 |
| 80 anorexia | #2 |
| real real patients | #2 |
| stage disease 5fu | #2 |
| baseline week day | #2 |
| cipn interventions | #2 |
| anabolic corticosteroid appetite | #2 |
| data gabapentin | #2 |
| appetite cachexia | #2 |
| efficacy scrambler therapy | #2 |
| npy levels groups | #2 |
| singleagent megestrol acetate | #2 |
| sulfate prevent | #2 |
| tingling shooting | #2 |
| injections hot flashes | #2 |
| tamoxifen metabolism evidence | #2 |
| cipn cancer treatment | #2 |
| randomized receive | #2 |
| pregabalin treatments placebo | #2 |
| cold items 71 | #2 |
| toxicity profiles time | #2 |
| treating chemotherapy | #2 |
| pilot citalopram | #2 |
| product hot flashes | #2 |
| manuscript “use | #2 |
| life cancerrelated fatigue | #2 |
| middle aged survivors | #2 |
| oxaliplatin induced neurotoxicity | #2 |
| life cipn20 | #2 |
| improvement hot | #2 |
| chemotherapy peripheral neuropathy | #2 |
| patients adjuvant 5fu | #2 |
| oral megestrol | #2 |
| clinically deficient fatigue | #2 |
| piroxantrone women | #2 |
| conclusions original report | #2 |
| usual breathing | #2 |
| patients treating institution | #2 |
| chemotherapy increases | #3 |
| patients upfront arm | #3 |
| epoetin alfa hgb | #3 |
| 51 female age | #3 |
| ctcae grading arms | #3 |
| thirdline hormonal therapy | #3 |
| oxaliplatin cipn | #3 |
| drug toxicity patients | #3 |
| carboplatin gwas | #3 |
| pros differences | #3 |
| traditional ctcae | #3 |
| combinationtreated arms | #3 |
| acetate treated | #3 |
| egfr inhibitor patients | #3 |
| cvte | #3 |
| incurable cancers | #3 |
| trials n9741 | #3 |
| survival cancerassociated wasting | #3 |
| average severity | #3 |
| 95 udi | #3 |
| canada collaborative effort | #3 |
| general subscale mfsisf | #3 |
| life antineoplastic agents | #3 |
| hands burning pain | #3 |
| neoplasms vomiting | #3 |
| cancer patients drugs | #3 |
| trial bmd | #3 |
| hgb rbc transfusions | #3 |
| etanercept current trial | #3 |
| shooting burning pain | #3 |
| thromboembolism secondary | #3 |
| cipn ctpm | #3 |
| pilot evaluation gabapentin | #3 |
| topical ceramides | #3 |
| survival epa | #3 |
| cipn n08cx population | #3 |
| interventions cancerrelated fatigue | #3 |
| stomatitis sucralfate | #3 |
| snv cmtassociated genes | #3 |
| baseline hot | #3 |
| paps scores | #3 |
| toxicities selfreport | #3 |
| mfsisf 4 weeks | #3 |
| methodologic lessons | #3 |
| n08ca n08cb study | #3 |
| data ginseng | #3 |
| flutamide hgpin | #3 |
| starting letrozole | #3 |
| cmt genes oxaliplatin | #3 |
| cumulative neurotoxicity oxaliplatin | #3 |
| physiologic pilot | #3 |
| relationship response rate | #3 |
| tamoxifen fluoxetine | #3 |
| controls singleton snv | #3 |
| paps scores dose | #3 |
| cipn evidence | #3 |
| gabapentin management | #3 |
| 10 weeks therapy | #3 |
| iii evaluation | #3 |
| vitamin prevention | #3 |
| genetic predictors paclitaxel | #3 |
| ssc device | #3 |
| treatment bother | #3 |
| sham acupuncture week | #3 |
| hot flashes trial | #3 |
| epa combinationtreated arms | #3 |
| chlorhexidine mouthwash | #3 |
| hgpin chemoprevention trial | #3 |
| depression somnolence | #3 |
| dalteparin vte | #3 |
| cipn cmtassociated genes | #3 |
| chemotherapyassociated anemia | #3 |
| patients baseline week | #3 |
| feet 15 | #3 |
| corticosteroid medications | #3 |
| radiation‐induced mucositis | #3 |
| acute neuropathy | #3 |
| ginseng crf | #3 |
| completed diaries | #3 |
| patients paps scores | #3 |
| dhea hot flashes | #3 |
| evidence prostate adenocarcinoma | #3 |
| topic mayo clinic | #3 |
| life eortc qlq | #3 |
| pilot trial pregabalin | #3 |
| qlqcipn20 scores | #3 |
| patient completed | #3 |
| patients scrambler therapy | #3 |
| centrally active agents | #3 |
| controlled double | #3 |
| clonidine randomized trials | #3 |
| oxaliplatininduced neuropathy | #3 |
| patients lidocaine patch | #3 |
| prophylactic tetracycline | #3 |
| n08cx | #3 |
| asco guideline management | #3 |
| asco surveillance | #3 |
| qol placebotreated patients | #3 |
| bit hands | #3 |
| advanced cancer standard | #3 |
| median δ | #3 |
| intravenous calcium magnesium | #3 |
| fasting chemotherapy | #3 |
| 3 weeks 80k | #3 |
| 95 40 points | #3 |
| ≤−20 | #3 |
| upfront arm | #3 |
| placebo preparation | #3 |
| minocycline prevention | #3 |
| epoetintreated patients incidence | #3 |
| crossover methodology | #3 |
| numeracy patients | #3 |
| 40000 units | #3 |
| cartilage shark | #3 |
| toxicity agents | #3 |
| survivors gsm | #3 |
| methylphenidate patients | #3 |
| epoetintreated patients | #3 |
| weekly arm differences | #3 |
| patients chemotherapy cycle | #3 |
| genetic factors patients | #3 |
| study antidepressive agents | #3 |
| ctcae grades patients | #3 |
| delayed zoledronic | #3 |
| experts cipn | #3 |
| week chemotherapy dose | #3 |
| rash symptoms | #3 |
| cipn mcbdr population | #3 |
| frequency hot | #3 |
| genetic predictors cipn | #3 |
| placebo prostate adenocarcinoma | #3 |
| repeated measures analyses | #3 |
| mpa single dose | #3 |
| longitudinal adverse | #3 |
| qlqcipn20 traditional ctcae | #3 |
| mcbdr primary endpoint | #3 |
| trials newer | #3 |
| iii controlled | #3 |
| management cancer cachexia | #3 |
| eventual sensory patients | #3 |
| mastectomy rates | #3 |
| cachexia decision humans | #3 |
| patients cancerassociated wasting | #3 |
| osteoporosis osteopenia letrozole | #3 |
| “use | #3 |
| prevent epidermal | #3 |
| cmt gene | #3 |
| 1 month cytokines | #3 |
| alfa compared | #3 |
| hemoccultsensa | #3 |
| chronic neuropathy patients | #3 |
| patients antiemetic | #3 |
| blind trial | #3 |
| life dronabinol | #3 |
| egfr inhibitorinduced rash | #3 |
| oral megestrol acetate | #3 |
| months bupropion | #3 |
| apixaban lowest risk | #3 |
| primary endpoint gwas | #3 |
| n03cc | #3 |
| baseline treatment day | #3 |
| additional 4 weeks | #3 |
| neurotoxic chemotherapy cipn | #3 |
| middle aged pilot | #3 |
| mouthwash patients | #3 |
| cipn biological targets | #3 |
| patients cyproheptadine | #3 |
| cmtassociated genes | #3 |
| upfront treatment arm | #3 |
| rash study arms | #3 |
| questionnaires syndrome paclitaxel | #3 |
| centric decision | #3 |
| real day | #3 |
| hormonal ablation | #3 |
| mucositis scores | #3 |
| fluoxetine arm | #3 |
| preventing peripheral | #3 |
| cyclohexanecarboxylic acids | #3 |
| oxaliplatinbased therapy | #3 |
| reported rash | #3 |
| ctcae pros | #3 |
| chemotherapy induced | #3 |
| ctpm experts | #3 |
| cyproheptadine patients | #3 |
| hot flashes placebo | #3 |
| neuropathy chemotherapy | #3 |
| receive placebo | #3 |
| data pilot trials | #3 |
| n08ca paclitaxel | #3 |
| follow fsfi | #3 |
| bacterial agents life | #3 |
| aminobutyric acid gabapentin | #3 |
| combinationtreated arms survival | #3 |
| purposefosaprepitant | #3 |
| neuropathy trials | #3 |
| placebo breast | #3 |
| qol hgb | #3 |
| selfreport ctcae grading | #3 |
| recommendations dietary counseling | #3 |
| oncology colorectal | #3 |
| female gabapentin | #3 |
| neurotoxic chemotherapies | #3 |
| study population mcbdr | #3 |
| gwas mayo clinic | #3 |
| tingling burning pain | #3 |
| qlqcipn20 | #3 |
| life hospice patients | #3 |
| eightyone randomized women | #3 |
| undergoing androgen ablation | #3 |
| subcutaneous weekly | #3 |
| purposeoxaliplatin | #3 |
| chemotherapy‐associated anemia | #3 |
| rash conclusions | #3 |
| hemoccult hemoccultsensa | #3 |
| ” numbness | #3 |
| rash prevention | #3 |
| week venlafaxine therapy | #3 |
| classic sums | #3 |
| projects prospective | #3 |
| cipn snv | #3 |
| vaginal dhea | #3 |
| relationship numbness | #3 |
| oxaliplatin primary endpoint | #3 |
| inhibitorinduced rash | #3 |
| pts stage iii | #3 |
| mcbdr | #3 |
| 20 calories | #3 |
| chemotherapy gabapentin | #3 |
| experience greater | #3 |
| epoetintreated patients study | #3 |
| anorexia anorexia appetite | #3 |
| baseline general subscale | #3 |
| bivariate construct | #3 |
| male megestrol | #3 |
| cold items | #3 |
| snv charcotmarietooth disease | #3 |
| ginseng arm | #3 |
| measures peripheral | #3 |
| paps dose | #3 |
| n05c4 | #3 |
| delayed treatment arm | #3 |
| burning pain patients | #3 |
| bupropion 3 | #4 |
| appetite stimulation | #4 |
| based chemotherapy severity | #4 |
| therapy oncologists | #4 |
| cancer acute vte | #4 |
| 95 oral iron | #4 |
| qol baseline fatigue | #4 |
| prominent problem | #4 |
| flash frequency | #4 |
| oral cryotherapy mucositis | #4 |
| hec cisplatin | #4 |
| surgery lymphedema | #4 |
| aged mouthwashes | #4 |
| day paroxetine | #4 |
| fluorouracilbased chemotherapy | #4 |
| control hot | #4 |
| symptoms individual patients | #4 |
| toxt analysis | #4 |
| odx ctx | #4 |
| bupropion 3 months | #4 |
| severe stomatitis leukopenia | #4 |
| hemoccult | #4 |
| 3915 patients | #4 |
| backgroundhistorically | #4 |
| apr dex | #4 |
| ctx odx | #4 |
| calgb 70305 | #4 |
| 40000 | #4 |
| egfr inhibitor rash | #4 |
| secondary vte prevention | #4 |
| loss syndrome | #4 |
| colorectal cancer asco | #4 |
| based chemotherapy women | #4 |
| major doselimiting toxicity | #4 |
| placebo hot | #4 |
| to100 | #4 |
| cachexia purpose | #4 |
| treatment ncctg | #4 |
| additional meta analysis | #4 |
| controls imbalance | #4 |
| trpa1 cisplatin | #4 |
| cipn20 ctcae | #4 |
| appetite quality | #4 |
| risk reduction therapy | #4 |
| baseline fatigue survival | #4 |
| arm breast neoplasms | #4 |
| cco guideline followup | #4 |
| hot flashes therapy | #4 |
| qol performance score | #4 |
| predictors duloxetine response | #4 |
| outcomes olanzapine | #4 |
| therapy aimss | #4 |
| hgpin antineoplastic agents | #4 |
| parenteral iron | #4 |
| chronic neuropathy | #4 |
| weekly toxicity | #4 |
| single dose venlafaxine | #4 |
| oral cavity mucosa | #4 |
| rash incidence | #4 |
| nsclc trials | #4 |
| numbness toes | #4 |
| women greater toxicity | #4 |
| flaxseed placebo | #4 |
| measurable metastatic disease | #4 |
| endorsed treatment | #4 |
| anorectic cancer patients | #4 |
| rash study | #4 |
| guidelines oral | #4 |
| 900 dose | #4 |
| followup surveillance protocol | #4 |
| tpn initiation | #4 |
| anorexia cholecystokinin | #4 |
| or1 year | #4 |
| survivors hot | #4 |
| 1093 women | #4 |
| cutaneous electrostimulation | #4 |
| doac dalteparin | #4 |
| topic survivors | #4 |
| nonestrogenic | #4 |
| placebo arms | #4 |
| publication antiemetics humans | #4 |
| recommended endorsement | #4 |
| oxybutynin placebo | #4 |
| odc activity mice | #4 |
| iron arm | #4 |
| odc odc activity | #4 |
| dietician | #4 |
| addition letrozole | #4 |
| intrapatient difference | #4 |
| treatment cancer anorexia | #4 |
| chemotherapy‐induced peripheral | #4 |
| paced breathing | #4 |
| aimss | #4 |
| nonabsorbable antibiotic | #4 |
| achievements ncctg | #4 |
| mastectomy rates patients | #4 |
| logistic regression incidence | #4 |
| ais biomarkers | #4 |
| severity sexes | #4 |
| gabapentin day | #4 |
| anorexia weight | #4 |
| receive oral | #4 |
| vaginal assessment scale | #4 |
| administration parp inhibitor | #4 |
| breast medical oncologists | #4 |
| inhibitor induced | #4 |
| hfs quality | #4 |
| suggested efficacy | #4 |
| weight loss syndrome | #4 |
| general subscale | #4 |
| 6 months bupropion | #4 |
| recommendation ctx | #4 |
| doxepin female head | #4 |
| daily baseline | #4 |
| benefits adjuvant | #4 |
| doubleblind manner | #4 |
| hot flashes week | #4 |
| rectal cancer surveillance | #5 |
| neuropathy acute | #5 |
| discontinuation aimss | #5 |
| olanzapine arm | #5 |
| crc cancers | #5 |
| fiftynine percent | #5 |
| study dmc | #5 |
| induced stomatitis | #5 |
| questionnaires pregabalin | #5 |
| cindices ajcc | #5 |
| physicianreported | #5 |
| treating postmenopausal | #5 |
| reported hot | #5 |
| mucositis allopurinol | #5 |
| physicians predictive ttr | #5 |
| fosaprepitant prevention | #5 |
| fluoxymesterone patients | #5 |
| death communication humans | #5 |
| grade model estimates | #5 |
| cipn effects | #5 |
| gabapentin trial | #5 |
| patient outcomes numeracy | #5 |
| cumulative neurotoxicity | #5 |
| cyclohexanecarboxylic | #5 |
| cachexia anorexia | #5 |
| acetate neoplasms | #5 |
| kps ecog | #5 |
| life lmwh | #5 |
| cipn participants | #5 |
| libido | #5 |
| patients lmwh injections | #5 |
| higher drug doses | #5 |
| pain scores dose | #5 |
| ttr cindices | #5 |
| trials cytotoxic chemotherapy | #5 |
| sham real | #5 |
| combination electroacupuncture | #5 |
| 5fu trials | #5 |
| life epa | #5 |
| numeracy online clinical | #5 |
| cancerrelated fatigue patients | #5 |
| bone loss osteopenia | #5 |
| aapro | #5 |
| vasomotor hot flashes | #5 |
| impaired postural | #5 |
| women 5fu | #5 |
| trial gabapentin | #5 |
| iron oral | #5 |
| numeracy tools | #5 |
| neoplasms compared | #5 |
| placebo exposed | #5 |
| neoplasm diagnostic tests | #5 |
| trial hot | #5 |
| ttr ajcc | #5 |
| cancer survivors symptoms | #5 |
| odx | #5 |
| treatment benefits sex | #5 |
| editor manuscript | #5 |
| trials lessons | #5 |
| cisplatin ganglia | #5 |
| intravenous calcium | #5 |
| disputes female humans | #5 |
| tools numeracy | #5 |
| reduce chemotherapy | #5 |
| trial developed | #5 |
| postsurgical neuropathic | #5 |
| ajcc version staging | #5 |
| gabapentin patients | #5 |
| agents basis | #5 |
| ongoing clinical trial | #5 |
| nodal status stage | #5 |
| acetate neoplasms quality | #5 |
| ajcc tools | #5 |
| major outcome measure | #5 |
| subsets treatment benefits | #5 |
| neuropeptide leptin | #5 |
| digital melt | #5 |
| epa supplement | #5 |
| medical oncology outpatients | #5 |
| 3 patients 4 | #5 |
| additional 8 weeks | #5 |
| colorectal cancer society | #5 |
| genetic quality life | #5 |
| colorectal cancer surveillance | #5 |
| difference control arm | #5 |
| cancer anorexia | #5 |
| ttr variables | #5 |
| receiving paclitaxel | #5 |
| progestational agent | #5 |
| models ttr | #5 |
| 3 stools | #5 |
| nutrition scores | #5 |
| neuropathic pain qol | #5 |
| acetate placebo | #5 |
| hb increment | #5 |
| crc cancer types | #5 |
| centrally active | #5 |
| current trial patients | #5 |
| appetite enhancement | #5 |
| mucositis caused | #5 |
| cipnrelated symptoms | #5 |
| race ttr | #5 |
| oxantrazole | #5 |
| cipn numbness | #5 |
| nodal status grade | #5 |
| groups leptin concentrations | #5 |
| flashes data | #5 |
| ajcc external validation | #5 |
| 5fu folfox | #6 |
| life toxicity | #6 |
| data supporting | #6 |
| apixaban cancer patients | #6 |
| hrqol breast neoplasms | #6 |
| nci ctcae | #6 |
| sadenosyllmethionine treatment | #6 |
| intervention lymphedema | #6 |
| staging patient outcomes | #6 |
| predictive illness surveys | #6 |
| pharmaceutic aged aged | #6 |
| smoking abstinence rates | #6 |
| north central | #6 |
| medical acupuncture | #6 |
| alliance clinical | #6 |
| imidazoles letrozole | #6 |
| background chemotherapy | #6 |
| her2directed therapy | #6 |
| cipn treatment | #6 |
| flashes humans | #6 |
| paclitaxel peripheral neuropathy | #6 |
| inhaler bupropion | #6 |
| severity data | #6 |
| severity neuropathic symptoms | #6 |
| 500 mcg | #6 |
| loe guidelines | #6 |
| sensory scale | #6 |
| fatigue pilot study | #6 |
| selective poly | #6 |
| 71 sensitivity | #6 |
| hospitalized oncology patients | #6 |
| placebo hot flashes | #6 |
| bf qol | #6 |
| methylo | #6 |
| rs11572080 | #6 |
| neurological safety | #6 |
| induced sensory | #6 |
| participants sham acupuncture | #6 |
| studies vomiting | #6 |
| cancerrelated fatigue life | #6 |
| mri trends | #6 |
| 4week intervention | #6 |
| highly emetogenic chemotherapy | #6 |
| placebo hfs | #6 |
| olanzapine prevention | #6 |
| breakthrough nausea | #6 |
| longacting methylphenidate | #6 |
| proportion aes | #6 |
| wisconsin ginseng | #6 |
| megestrol | #6 |
| agents breast | #6 |
| depomedroxyprogesterone acetate | #6 |
| versus combination | #6 |
| daily diary questionnaires | #6 |
| nicotine inhaler | #6 |
| therapy 10 weeks | #6 |
| death kps | #6 |
| active malignancy | #6 |
| nonanthracycline chemotherapy | #6 |
| placebo arm patients | #6 |
| 5fubased chemotherapy | #6 |
| bupropion relapse | #7 |
| intervention lymphedema status | #7 |
| accru | #7 |
| 5fu based chemotherapy | #7 |
| fuinduced | #7 |
| paclitaxel peripheral | #7 |
| patient anthracycline | #7 |
| sensitivity fecal | #7 |
| cream versus | #7 |
| letrozole differences | #7 |
| hemoquant | #7 |
| transdermal clonidine | #7 |
| lymphedema education | #7 |
| uniscale qol | #7 |
| induced neuropathy | #7 |
| cryotherapy arm | #7 |
| toxic polyneuropathy | #7 |
| venlafaxine day | #7 |
| blind study | #7 |
| nutrition score | #7 |
| weight concerns smokers | #7 |
| uniscale | #7 |
| study drug trial | #7 |
| 12 treatment arms | #7 |
| odx score | #7 |
| venlafaxine versus | #7 |
| menopause hot | #7 |
| cyclophosphamidedoxorubicin | #7 |
| smoking 3 | #7 |
| cancer patients anorexia | #7 |
| skindex16 | #7 |
| illness antimetabolites | #7 |
| venlafaxine therapy | #7 |
| rs10509681 | #7 |
| pain cipn | #7 |
| model estimates survival | #7 |
| adjuvant interferon patients | #7 |
| follow year | #7 |
| patients hb response | #7 |
| neuropathy oxaliplatin | #7 |
| minority smokers | #7 |
| stage nodal status | #7 |
| induced rash | #7 |
| hemoccult hemoquant | #7 |
| placebocontrolled trial | #7 |
| citalopram cyclohexanols | #7 |
| intermediate odx | #7 |
| pregabalin prevention | #7 |
| mucositis placebo | #7 |
| incidence rbc transfusion | #7 |
| lower extremity symptoms | #7 |
| week followup | #7 |
| throat discomfort | #7 |
| cmt genes | #7 |
| fluoxetine clinical trials | #7 |
| nausea cancer patients | #7 |
| appetites | #7 |
| study arms difference | #7 |
| prevalence moderatetosevere | #7 |
| weekly epoetin alfa | #7 |
| 20 percent placebo | #7 |
| vte recurrence doac | #7 |
| patients oral cryotherapy | #7 |
| scheduled receive | #7 |
| patients product | #7 |
| serum concentrations cytokines | #7 |
| mpa arm | #7 |
| outcomes primary outcomes | #7 |
| chronic postmastectomy pain | #7 |
| 1week baseline period | #7 |
| symptom subscale | #7 |
| agents newer | #8 |
| factors cipn | #8 |
| smokers weight concerns | #8 |
| neuropathy pain | #8 |
| women hfs | #8 |
| direct oral factor | #8 |
| symptoms neuropathy | #8 |
| topic antineoplastic | #8 |
| venous toxicity | #8 |
| 1355 | #8 |
| placebo pilot study | #8 |
| antidepressant patients | #8 |
| 18 months symptoms | #8 |
| cycle capecitabine | #8 |
| neuropathy scale | #8 |
| series clinical trials | #8 |
| efficacy newer antidepressants | #8 |
| raw data trials | #8 |
| libido women | #8 |
| prior chemotherapy exposure | #8 |
| progestational | #8 |
| fecal blood | #8 |
| stomatitis patients | #8 |
| paclitaxel severity | #8 |
| opioids moderate pain | #8 |
| chronic neurotoxicity | #8 |
| flutamide placebo | #8 |
| cpmp | #8 |
| nonhormonal treatments | #8 |
| induced painful | #8 |
| greater toxicity | #8 |
| paclitaxel pain | #8 |
| oral iron placebo | #8 |
| treatment cinv | #8 |
| evidence pharmacologic interventions | #8 |
| mouth sores | #8 |
| oxaliplatin paclitaxel | #8 |
| cancer survivors cipn | #8 |
| epa survival | #8 |
| severe hot flashes | #8 |
| placebo suggestion | #8 |
| tamoxifeninduced hot flashes | #8 |
| oxaliplatin neuropathy | #8 |
| life antibodies | #8 |
| sdt1 | #8 |
| venlafaxine hot flashes | #8 |
| odx risk | #8 |
| pros aes | #8 |
| folfox dfs | #8 |
| neuropathic symptoms | #8 |
| recurrence colon cancer | #8 |
| administered systemically | #8 |
| 70305 | #8 |
| oral placebo | #8 |
| anecdotal | #8 |
| cancer patients cipn | #9 |
| fosaprepitant | #9 |
| trial paroxetine | #9 |
| acid amines | #9 |
| patients provided | #9 |
| dose dfmo | #9 |
| radiationinduced esophagitis | #9 |
| 5 nausea | #9 |
| patients hot | #9 |
| incurable disease | #9 |
| flashes hot | #9 |
| disease recurrence recurrence | #9 |
| disease receive | #9 |
| skindex16 scores | #9 |
| letrozole day | #9 |
| lamotrigine pain | #9 |
| genistein tumor growth | #9 |
| cipn patients | #9 |
| oxaliplatin placebo | #9 |
| prevention vomiting | #9 |
| surgical year | #9 |
| baseline week week | #9 |
| hot flashes tamoxifen | #9 |
| lmwh injections | #9 |
| cutaneous aged anesthetics | #9 |
| flash control | #9 |
| lymphedema prevention | #9 |
| medications evidence | #9 |
| neuropathic symptoms patients | #9 |
| numbness fingers | #9 |
| lymphedema hrqol | #9 |
| topical antimetabolites | #9 |
| follow tests | #9 |
| fatigue methylphenidate | #9 |
| apixaban lower rate | #9 |
| study treatment arm | #9 |
| incidence colorectal adenomas | #9 |
| antiemetic properties | #9 |
| appetite weight | #9 |
| aged pilot | #9 |
| ambulatory analgesics | #9 |
| 43 trials | #9 |
| questionnaires syndrome | #9 |
| sensory axonopathy | #9 |
| relapse relapse prevention | #9 |
| mucositis pain | #9 |
| vitality subscale | #9 |
| mometasone furoate placebo | #9 |
| combination therapy relapse | #10 |
| life topic reproducibility | #10 |
| shark cartilage | #10 |
| flash data | #10 |
| antineoplastic agents humans | #10 |
| 40 arm | #10 |
| aprepitant treatment | #10 |
| megestrol acetate quality | #10 |
| gabapentin | #10 |
| asco guideline | #10 |
| venlafaxine arm | #10 |
| differences 5 years | #10 |
| humans megestrol | #10 |
| controlled randomized | #10 |
| inhibit cyp2d6 | #10 |
| trials demonstrated | #10 |
| nonhormonal therapies | #10 |
| factes | #10 |
| adult cancers | #10 |
| randomized placebo | #10 |
| physical consequences | #10 |
| ecog kps | #10 |
| symptomatic malignant ascites | #10 |
| neoplasms neuralgia | #10 |
| doses citalopram | #10 |
| recommendations general population | #10 |
| patients neurotoxic chemotherapy | #10 |
| frequency hot flashes | #10 |
| cancerrelated fatigue fatigue | #10 |
| chemotherapy‐induced | #10 |
| data relatedness | #10 |
| pain medications patients | #10 |
| scrambler therapy patients | #10 |
| ctcae grades | #10 |
| phase iii | #10 |
| folfox 5fu | #10 |
| vaginal dryness | #10 |
| incidence stomatitis | #10 |
| advanced cancer life | #10 |
| minocycline reduction | #10 |
| qol total | #10 |
| oxaliplatin peripheral | #10 |
| qol anemia | #10 |
| nonhormonal treatment | #10 |
| cognitive chemotherapy | #10 |
| cancerassociated anemia | #10 |
| sensitivity cancer | #10 |
| anorexia cachexia | #10 |
| patients treatment period | #10 |
| life dietary supplements | #10 |
| δ − | #10 |
| oxaliplatin trpa1 | #10 |
| dalteparin major bleeding | #11 |
| hydrazine sulfate | #11 |
| promising data | #11 |
| institutional guideline | #11 |
| differences study arms | #11 |
| diphenhydramine lidocaine | #11 |
| difficulty patients | #11 |
| olanzapine chemotherapy | #11 |
| sensory neurotoxicity | #11 |
| melt curve | #11 |
| anastrozole 10 | #11 |
| prevalence neuropathic pain | #11 |
| fsfi female | #11 |
| ativan | #11 |
| nicotine patch therapy | #11 |
| erythropoietic response | #11 |
| curve assay | #11 |
| reported incidences | #11 |
| cancer undergoing | #11 |
| vomiting cancer patients | #11 |
| efficacy black cohosh | #11 |
| antiemetic guidelines | #11 |
| combination treated | #11 |
| translational component | #11 |
| physicians increased risk | #11 |
| ginseng placebo | #11 |
| flashes | #11 |
| qol uniscale | #11 |
| gbu | #11 |
| electroanalgesia | #11 |
| cipn development | #12 |
| cachexia clinical trials | #12 |
| venlafaxine hydrochloride | #12 |
| valerian placebo | #12 |
| completed daily | #12 |
| reported peripheral | #12 |
| oxaliplatin induced | #12 |
| hot flashes 95 | #12 |
| capsaicin cream | #12 |
| −307 | #12 |
| apixaban dalteparin | #12 |
| pilot trial levetiracetam | #12 |
| leptin cck8 | #12 |
| gait testing | #12 |
| breast cancer letrozole | #12 |
| ctpm | #12 |
| cycles drugs | #12 |
| toxicities groups | #12 |
| neurotoxic chemotherapy | #12 |
| recurrence comparisons | #12 |
| venlafaxine women | #12 |
| patients cipn symptoms | #12 |
| hb response | #12 |
| toxicity 4 weeks | #12 |
| irox folfox | #12 |
| decreased libido | #12 |
| adjuvant communication decision | #12 |
| individuals advanced adenomas | #12 |
| probability prospective studies | #12 |
| rash quality | #12 |
| pluronic lecithin organogel | #12 |
| 2000 update | #13 |
| andropause | #13 |
| therapy benefits | #13 |
| acute treatment vte | #13 |
| weight cachexia | #13 |
| median hb | #13 |
| bmd 1 year | #13 |
| rs3213619 | #13 |
| patients breakthrough cinv | #13 |
| patients advancedstage cancer | #13 |
| troublesome symptoms | #13 |
| adenomas aspirin | #13 |
| incident exposure | #13 |
| newer antidepressants placebo | #13 |
| anemia life | #13 |
| adjuvant benefit | #13 |
| abh gel | #13 |
| treatment advanced cancer | #13 |
| neuropathic pain surgery | #13 |
| venlafaxine life | #13 |
| adjuvant colon cancer | #13 |
| patients diphenhydramine | #13 |
| neuropathy outcome | #13 |
| flashes day | #13 |
| estimates prognosis | #13 |
| oral anesthetics | #13 |
| improve cancer | #13 |
| life investigation | #13 |
| 10 range | #13 |
| ais women | #13 |
| valerian sleep | #13 |
| troubling | #13 |
| major bleeding doac | #13 |
| common toxicity | #13 |
| autonomic scale | #13 |
| life neoplasm recurrence | #13 |
| trial support | #13 |
| nausea patients | #13 |
| months smoking | #13 |
| ncctg | #13 |
| initial 3 months | #13 |
| education clinical practice | #13 |
| severity hot flashes | #13 |
| venlafaxine paroxetine | #13 |
| paroxetine hot flashes | #13 |
| hot flashes baseline | #13 |
| 40 points 95 | #13 |
| megestrol acetate therapy | #13 |
| 5fu surgery | #14 |
| provided data | #14 |
| benefit toxicity | #14 |
| phase 3 months | #14 |
| biomarkers bone formation | #14 |
| patients pain scores | #14 |
| fluoxymesterone | #14 |
| oral iron | #14 |
| recurrences patients | #14 |
| marked toxicity | #14 |
| diagnosis localized disease | #14 |
| genital symptoms | #14 |
| based topical | #14 |
| flash activity | #14 |
| life anemia | #14 |
| palliate | #14 |
| stool dna | #14 |
| oxaliplatin vivo | #14 |
| smokers placebo | #14 |
| prophylactic agent | #14 |
| oxaliplatininduced neurotoxicity | #15 |
| triazoles zoledronic | #15 |
| lidocaine patch | #15 |
| bfq | #15 |
| acute diarrhea patients | #15 |
| taste alterations | #15 |
| week darbepoetin | #15 |
| sternal skin conductance | #15 |
| syndromes peripheral | #15 |
| treatment weeks patients | #15 |
| androgen ablation therapy | #15 |
| academic oncologists | #15 |
| acceptability device | #15 |
| grade age | #15 |
| trials gabapentin | #15 |
| highly emetogenic | #15 |
| life life survivors | #15 |
| 16–28 | #15 |
| week baseline | #15 |
| clinician perception | #15 |
| aes treatment | #15 |
| therapy nicotine | #15 |
| agents life | #15 |
| evidence treatment options | #15 |
| adjuvant aromatase | #15 |
| vaginal dryness dyspareunia | #15 |
| persistent incisional pain | #15 |
| mastectomy irradiation | #15 |
| folfox irox | #15 |
| prognosis quality life | #15 |
| monoclonal carcinoma antibodies | #15 |
| suggestion guideline | #15 |
| advanced cancer methods | #15 |
| duloxetine cipn | #15 |
| advanced malignant disease | #15 |
| premenopausal women chemotherapy | #16 |
| endpoints baseline | #16 |
| measurable evaluable disease | #16 |
| patients venlafaxine | #16 |
| loss appetite | #16 |
| venlafaxine patients | #16 |
| treatment cancer vte | #16 |
| advancedstage cancer patients | #16 |
| findings education | #16 |
| stool dna test | #16 |
| paclitaxel oxaliplatin | #16 |
| rash pruritus | #16 |
| tingling pain | #16 |
| patch therapy | #16 |
| mfsi | #16 |
| diarrhoea time | #16 |
| antiemetic agent | #16 |
| product time | #16 |
| female cancer survivors | #16 |
| breast gynecologic cancer | #16 |
| dalteparin 95 | #16 |
| randomized trial aspirin | #16 |
| symptoms numbness | #16 |
| vte apixaban | #16 |
| induced hot | #16 |
| leap study | #17 |
| study tetracycline | #17 |
| 786 patients | #17 |
| screen detection | #17 |
| vaginal symptoms | #17 |
| flashes tamoxifen | #17 |
| oxaliplatin doses | #17 |
| arthralgias | #17 |
| venlafaxine | #17 |
| 18 months women | #17 |
| arhgef10 | #17 |
| oxaliplatin treated | #17 |
| breast cancer oestrogen | #17 |
| women metastatic | #17 |
| adenomas 1 | #17 |
| institute common | #17 |
| reduction fatigue | #17 |
| recommendation suggestion | #17 |
| fractional co2 | #17 |
| inadequate control | #17 |
| cancer menopause | #17 |
| leptin concentrations groups | #17 |
| device women | #17 |
| dfs folfox | #17 |
| rs11849538 | #17 |
| crc patients patients | #17 |
| placebo 04 | #18 |
| oral dronabinol | #18 |
| severity cipn | #18 |
| symptoms hormone | #18 |
| sternal skin | #18 |
| intervention guidelines | #18 |
| data followup | #18 |
| patients overview | #18 |
| secondary endpoint analysis | #18 |
| postmenopausal women letrozole | #18 |
| subsets age | #18 |
| patients irox | #18 |
| randomized trials women | #18 |
| treatment osteopenia | #18 |
| prophylactic antiemetic therapy | #18 |
| flash frequencies | #18 |
| patients hb | #18 |
| standard prognostic | #18 |
| sigmoidoscopy tomography | #18 |
| 5 adjuvant | #18 |
| 120000 | #18 |
| severity hot | #18 |
| menopausal problems | #18 |
| baseline 4 | #18 |
| mri mastectomy | #18 |
| patients informed decisions | #18 |
| receiving head | #18 |
| oncology providers patients | #18 |
| rs7349683 | #19 |
| patients based chemotherapy | #19 |
| oxaliplatin carboplatin | #19 |
| physician reported | #19 |
| bmd neoplasms chemotherapy | #19 |
| 7 outcomes | #19 |
| double blinded | #19 |
| flash reduction | #19 |
| groups infliximab | #19 |
| mastectomy methotrexate | #19 |
| neoplasms peripheral | #19 |
| minimal adverse effects | #19 |
| n6 n5 | #19 |
| previous colorectal | #19 |
| folfox fluorouracil | #19 |
| 95 46 | #19 |
| life gabapentin | #19 |
| ncdf | #19 |
| treatment mastectomy | #19 |
| unpleasant taste | #19 |
| evidence status | #19 |
| induced mucositis | #19 |
| oxaliplatin neurotoxicity | #19 |
| acute cancer | #19 |
| panax quinquefolius | #19 |
| placebo smokers | #20 |
| advanced cancer study | #20 |
| cancer cancer therapy | #20 |
| diseases randomized | #20 |
| emetogenic chemotherapy | #20 |
| progestational agents | #20 |
| numbness | #20 |
| palliating | #20 |
| pilot trials | #20 |
| appetite nutritional status | #20 |
| study ginseng | #20 |
| life skindex16 | #20 |
| therapeutic options treatment | #20 |
| reducing pain | #20 |
| revisitation | #20 |
| moderate pain patients | #20 |
| receiving pelvic | #20 |
| fatigue 4 | #20 |
| major bleeding treatment | #20 |
| surveillance protocol | #20 |
| fecal occult | #20 |
| placebo cream | #20 |
| baseline week | #20 |
| trial 12 months | #21 |
| cipn symptoms | #21 |
| therapy adverse effects | #21 |
| refractory cachexia | #21 |
| studies methylphenidate | #21 |
| substantial problem | #21 |
| cancer starting | #21 |
| female menopause | #21 |
| acetate patients | #21 |
| treatment options women | #21 |
| radiationinduced dermatitis | #21 |
| oral mucositis pain | #21 |
| receptorpositive breast cancer | #21 |
| chemotherapy agents | #21 |
| metastatic breast carcinoma | #21 |
| management cachexia | #21 |
| routine test | #21 |
| crossover analysis | #21 |
| severity adverse events | #22 |
| candidate single | #22 |
| gain patients | #22 |
| asco panel | #22 |
| median time initiation | #22 |
| projects quality | #22 |
| subcutaneous testosterone | #22 |
| scores ≤ | #22 |
| doc time | #22 |
| n9741 | #22 |
| guideline intervention | #22 |
| crossover phase | #22 |
| npy leptin | #22 |
| location stage | #22 |
| patients testosterone | #22 |
| pharmacokinetics infliximab | #22 |
| 150 groups | #22 |
| patients 5 weeks | #22 |
| emetogenic | #22 |
| optumlabs | #22 |
| decision adjuvant | #23 |
| fsdsr | #23 |
| followup tests | #23 |
| versus delayed | #23 |
| detecting recurrence | #23 |
| 5 pounds | #23 |
| mcf7 cells genistein | #23 |
| aes qol | #23 |
| life ascites | #23 |
| acetate middle | #23 |
| acupuncture hot | #23 |
| stool dna testing | #23 |
| mascc isoo | #23 |
| sucralfate patients | #23 |
| potential toxicities | #23 |
| design rcts | #24 |
| n56 | #24 |
| apixaban treatment | #24 |
| weeks primary | #24 |
| aged amines | #24 |
| pilot clinical | #24 |
| ortho biotech | #24 |
| female hot | #24 |
| adjuvant decision making | #24 |
| replacement testosterone | #24 |
| randomized 1 | #24 |
| day chemotherapy | #24 |
| every3 | #24 |
| mirtazapine patients | #24 |
| hrt survival | #24 |
| prevention chemotherapy | #24 |
| tamoxifen octreotide | #24 |
| abstract5fluorouracil | #24 |
| topic design severity | #24 |
| aged anorexia | #24 |
| criteria adverse | #25 |
| women adjuvant tamoxifen | #25 |
| neoplasia screening | #25 |
| lymphedema incidence | #25 |
| institutional guidelines | #25 |
| qol tools | #25 |
| prevention nausea | #25 |
| vte trial | #25 |
| mmf placebo | #25 |
| bpisf | #25 |
| severe nausea vomiting | #25 |
| doses schedules | #25 |
| placebo arm treatment | #25 |
| cco guideline | #25 |
| recommendations basis | #25 |
| trial pilot | #25 |
| nausea olanzapine | #25 |
| antiepileptic agent | #25 |
| cancerassociated weight loss | #25 |
| 2005 update | #26 |
| receiving oxaliplatin | #26 |
| agents prevention | #26 |
| combination weight loss | #26 |
| syndrome menopause | #26 |
| neoplasms estrogens | #26 |
| mfsisf | #26 |
| oncology journals | #26 |
| trial evaluate | #26 |
| joints muscles | #26 |
| prior week | #26 |
| undergoing adjuvant | #26 |
| cachexia carcinoma | #26 |
| irradiation mastectomy | #26 |
| nci ctc | #26 |
| aiinduced | #26 |
| colorectal adenomas patients | #26 |
| dose gabapentin | #26 |
| treatment arms | #26 |
| regional breast | #26 |
| induced musculoskeletal | #26 |
| clinical trials chemotherapy | #26 |
| prophylactic antiemetic | #27 |
| series trials | #27 |
| hot flashes hf | #27 |
| valerian | #27 |
| antiemetic | #27 |
| fubased | #27 |
| nurse survey | #27 |
| lmwh survival | #27 |
| adjuvant 5fu | #27 |
| smoking bupropion | #27 |
| events ctcae | #27 |
| lymphedema arm | #27 |
| patients short term | #27 |
| neuropathy symptoms | #27 |
| recommendations trials | #27 |
| fluoxetine citalopram | #28 |
| lidocaine patches | #28 |
| definitively | #28 |
| matched general population | #28 |
| alliance | #28 |
| describers | #28 |
| mastectomy rate | #28 |
| primary endpoint proportion | #28 |
| standard prognostic factors | #28 |
| intractable palliative | #28 |
| muscles joints | #28 |
| treatment hot flushes | #28 |
| gynecologic cancer survivors | #28 |
| newer | #28 |
| prevent colorectal adenomas | #28 |
| chest rays | #28 |
| taxanebased chemotherapy | #29 |
| mucositis study | #29 |
| patients paclitaxel | #29 |
| statistical controversies | #29 |
| points study | #29 |
| difluoromethylornithine dfmo | #29 |
| feet hands | #29 |
| citalopram placebo | #29 |
| biological predictors | #29 |
| smokers bupropion | #29 |
| survival arms | #29 |
| paclitaxel cipn | #29 |
| pain cancer survivors | #29 |
| placebo arm | #29 |
| vitamin incidence | #29 |
| blood screening | #29 |
| asco guideline update | #29 |
| efficacy venlafaxine | #29 |
| chemotherapy cipn | #29 |
| middle aged postmenopause | #30 |
| phase iii comparison | #30 |
| anthrapyrazoles | #30 |
| twoyear followup | #30 |
| benadryl | #30 |
| alfa darbepoetin | #30 |
| cipn pain | #30 |
| development cipn | #30 |
| mild nausea | #30 |
| postmenopause predictive | #30 |
| loss postmenopausal | #30 |
| small pilot | #30 |
| management oral mucositis | #30 |
| month duration | #30 |
| diseases peripheral | #30 |
| contralateral axillary | #30 |
| usual oncology | #30 |
| pain oral | #30 |
| patients races | #31 |
| ixabepilone patients | #31 |
| sixtysix patients | #31 |
| mastectomy mri | #31 |
| efficacy methylphenidate | #31 |
| treatment acute vte | #31 |
| management menopausal symptoms | #31 |
| benefit dfs | #31 |
| prevention oral mucositis | #31 |
| patients secondary analysis | #31 |
| symptomatic ascites | #31 |
| pain quality life | #31 |
| treatment paclitaxel | #31 |
| calcium magnesium | #31 |
| term rectal | #31 |
| middle aged perimenopause | #31 |
| arms placebo | #31 |
| receiving highly | #32 |
| women lymphedema | #32 |
| guideline endorsement | #32 |
| camg | #32 |
| doubleblind trial | #32 |
| breast cancer symptoms | #32 |
| evidencebased guidance | #32 |
| vera gel | #32 |
| oncologist patients | #32 |
| female services | #32 |
| delayed chemotherapy | #32 |
| rash severity | #32 |
| smokers randomized | #33 |
| 4week followup | #33 |
| toxicity breast | #33 |
| aloe vera gel | #33 |
| pursuant | #33 |
| painful cipn | #33 |
| instruments life | #33 |
| acupuncture hot flashes | #33 |
| dose megestrol | #33 |
| sensitivity polyps | #33 |
| survival advanced cancer | #33 |
| neuropathy patients | #33 |
| chemotherapeutic regimens | #33 |
| patients taxol | #33 |
| hands feet | #33 |
| fingers hands | #33 |
| blind manner | #33 |
| patients cinv | #33 |
| increased difficulty | #33 |
| week treatment | #33 |
| breast neoplasms life | #33 |
| questionnaires total | #33 |
| therapy bupropion | #33 |
| isoo | #33 |
| neoplasms carboplatin | #33 |
| patients nausea | #34 |
| patients acitretin | #34 |
| chemotherapy hec | #34 |
| continuation study | #34 |
| toxicity fluorouracil | #34 |
| patients tools | #35 |
| formal consensus process | #35 |
| 4 week | #35 |
| inhibitors venlafaxine | #35 |
| carcinoembryonic antigen levels | #35 |
| trial designed | #35 |
| united states hrqol | #35 |
| major bleeding lmwh | #35 |
| moderatetosevere patients | #35 |
| cipn severity | #35 |
| prevention chemotherapyinduced nausea | #35 |
| primary outcomes trials | #35 |
| levels week | #35 |
| stomatitis | #35 |
| treating cancer | #35 |
| dawley statistics | #35 |
| cancer international society | #35 |
| tnfα study | #36 |
| pyrexia patients | #36 |
| myalgias | #36 |
| cohosh | #36 |
| lymphedema treatment | #36 |
| mometasone placebo | #36 |
| stages colorectal cancer | #36 |
| pain pilot | #36 |
| doxepin | #36 |
| head neck radiotherapy | #36 |
| secondary prevention measures | #36 |
| nk1ras | #36 |
| mc5 | #37 |
| global impression | #37 |
| ctcae | #37 |
| p00052 | #37 |
| alleviation | #37 |
| topic humans life | #37 |
| early integrated | #37 |
| survival supportive | #37 |
| planned sample size | #37 |
| symptoms cancer | #37 |
| study intravenous | #37 |
| chronic nausea | #37 |
| topic stomatitis | #37 |
| nausea neoplasms | #37 |
| cancerrelated fatigue | #37 |
| fluorouracil based | #38 |
| sensitization nociceptors | #38 |
| trial conducted | #38 |
| tests controlled trials | #38 |
| patients taxanes | #38 |
| oncology providers | #38 |
| patients highdose melphalan | #38 |
| 5ht3ras | #38 |
| relationships populations | #38 |
| illness purpose | #38 |
| individual item | #38 |
| women metastatic disease | #38 |
| crushed ice | #39 |
| grade 2 toxicity | #39 |
| 3 agents | #39 |
| menopause gsm | #39 |
| qol clinical trials | #39 |
| trials oncology | #39 |
| blind crossover | #39 |
| european organisation cancer | #39 |
| chi2 tests | #39 |
| cohort type | #39 |
| arm placebo | #39 |
| arm difference | #39 |
| acids drug | #39 |
| treatment breakthrough | #39 |
| study double | #39 |
| method fatigue | #40 |
| terminology criteria | #40 |
| mastectomy chemotherapy | #40 |
| difluoromethylornithine | #40 |
| topic reproducibility surveys | #40 |
| arthralgia breast | #40 |
| treatment analyses | #40 |
| cachexia clinical | #40 |
| single dose placebo | #40 |
| patients lamotrigine | #40 |
| initial mastectomy | #40 |
| appetite patients | #40 |
| prevent colorectal | #40 |
| symptoms 12 months | #41 |
| smokers weight | #41 |
| bupropion smokers | #41 |
| trial performed | #41 |
| relapse 3 months | #41 |
| gabapentin placebo | #41 |
| united states guidelines | #41 |
| drug evaluation studies | #41 |
| treatment period | #41 |
| cure recurrence | #41 |
| zoledronic acid bmd | #41 |
| undergoing androgen | #41 |
| appetite body | #42 |
| oral gabapentin | #42 |
| neuronal protection | #42 |
| patients incurable | #42 |
| chemotherapy day | #42 |
| nortriptyline placebo | #42 |
| transdermal gel | #42 |
| location age | #42 |
| randomized doubleblind trial | #42 |
| treating institution | #42 |
| placebo venlafaxine | #42 |
| patients completed | #42 |
| desipramine patients | #43 |
| median weight | #43 |
| sex location | #43 |
| dietary supplements life | #43 |
| postsurgical | #43 |
| baseline fatigue | #43 |
| 5 induced | #43 |
| preliminary insights | #43 |
| highdose interferon | #43 |
| surveillance united states | #44 |
| trial benefit | #44 |
| nonpain | #44 |
| risk cipn | #44 |
| outcome gamma | #44 |
| sensory symptoms | #44 |
| weeks efficacy | #44 |
| vaginal moisturizer | #44 |
| collaborative effort | #44 |
| bupropion placebo | #44 |
| chemotherapyinduced nausea vomiting | #44 |
| pain reduction patients | #44 |
| disagreement | #44 |
| survivors colorectal cancer | #45 |
| 5 years incidence | #45 |
| conclusion trial | #45 |
| objective tumor regression | #45 |
| humans peripheral | #45 |
| menogaril | #45 |
| ginseng panax quinquefolius | #45 |
| acute pain patients | #45 |
| historic controls | #45 |
| genitourinary syndrome menopause | #45 |
| piroxantrone | #45 |
| rash grade | #45 |
| fisher tests | #45 |
| chemotherapy antineoplastic | #46 |
| current manuscript | #46 |
| iii colon cancer | #46 |
| study gaba | #46 |
| radiationinduced oral mucositis | #46 |
| patients advanced adenomas | #46 |
| item measures | #46 |
| factor prognostic | #46 |
| megestrol acetate treatment | #46 |
| epoetin alfa placebo | #46 |
| longitudinal methods | #46 |
| nonpharmacological therapy | #46 |
| acute skin toxicity | #46 |
| adverse symptoms | #46 |
| vaccines melanoma | #46 |
| putative mechanism | #46 |
| radiotherapy randomized | #46 |
| cisplatin neuropathy | #46 |
| phase iii life | #46 |
| randomized comparison | #46 |
| clinical problem | #46 |
| middle aged patient | #46 |
| differences pros | #47 |
| twopart | #47 |
| cachexia female | #47 |
| genetic predictors | #47 |
| bipn | #47 |
| neoplasms parenteral nutrition | #47 |
| aged mometasone | #47 |
| darbepoetin alfa patients | #47 |
| screening setting | #47 |
| dose paclitaxel | #47 |
| mascc | #47 |
| average pain | #47 |
| neck radiotherapy | #48 |
| placebo gabapentin | #48 |
| genitourinary symptoms | #48 |
| oxybutynin | #48 |
| nausea day | #48 |
| physical examinations | #48 |
| qol female humans | #48 |
| menopause life | #48 |
| stratification factor | #48 |
| female cancer | #49 |
| chemotherapy nausea | #49 |
| flie | #49 |
| patientclinician communication | #49 |
| sham arm | #49 |
| hot flashes hfs | #50 |
| mastectomy pain | #50 |
| receiving androgen | #50 |
| cachexia | #50 |
| cancer survivors fatigue | #50 |
| antiserotonergic | #50 |
| time conclusions | #50 |
| placebos randomized | #50 |
| replens | #50 |
| models stage | #50 |
| pain numbness | #50 |
| cisplatin humans | #51 |
| patients cancer pain | #51 |
| vomiting chemotherapy | #51 |
| effective treating | #51 |
| transdermal testosterone | #51 |
| patients 8 weeks | #51 |
| genitourinary syndrome | #51 |
| blinded placebo | #51 |
| regional hypothermia | #51 |
| management chemotherapy | #52 |
| treatment adt | #52 |
| 80k | #52 |
| black cohosh | #52 |
| differences treatment arms | #52 |
| metaanalysis incidence | #52 |
| risk bone loss | #52 |
| aged orchiectomy | #52 |
| trastuzumab orr | #52 |
| control nausea | #53 |
| purposepatients | #53 |
| receiving radiotherapy | #53 |
| potential adjuvant | #53 |
| cancer venous | #53 |
| tamoxifen antineoplastic agents | #53 |
| toxicity time | #53 |
| nervous peripheral | #53 |
| life topic humans | #54 |
| double‐blind trial | #54 |
| antiemetics antineoplastic | #54 |
| severe hot | #54 |
| recurrent disease | #54 |
| levetiracetam treatment | #54 |
| standard placebo | #54 |
| treatment months | #54 |
| pilot trial | #54 |
| 20 data | #54 |
| blood testing | #54 |
| treatment tobacco dependence | #55 |
| acupuncture cancer | #55 |
| cancerdirected therapy | #55 |
| cachexia therapy | #55 |
| scalp cooling | #55 |
| symptoms therapy | #55 |
| fatigue inventory | #55 |
| serial levels | #55 |
| bupropion treatment | #55 |
| carboplatin female humans | #56 |
| adjuvant endocrine treatment | #56 |
| diseases antineoplastic | #56 |
| undergoing chemotherapy | #56 |
| symptoms hot | #56 |
| xaliproden | #56 |
| time placebo | #56 |
| common terminology | #57 |
| 12 courses | #57 |
| benefit scale | #57 |
| recurrence symptoms | #57 |
| adjuvant colon | #57 |
| placebo solution | #57 |
| completion adjuvant chemotherapy | #58 |
| major bleeding enoxaparin | #58 |
| ferric gluconate | #58 |
| cachexia weight loss | #58 |
| undergoing treatment | #58 |
| limited degree | #58 |
| topical gel | #58 |
| quality life questionnaire | #58 |
| pain peripheral | #58 |
| skin dermatitis | #58 |
| points placebo | #58 |
| compared oral | #58 |
| safety rivaroxaban | #59 |
| weight appetite | #59 |
| osteopaenia | #59 |
| coprescription | #59 |
| chemotherapy cognitive | #59 |
| patients hec | #59 |
| data understanding | #59 |
| chemotherapyinduced nausea | #59 |
| ocular irritation | #59 |
| placebo citalopram | #59 |
| hb baseline | #60 |
| colonoscopically | #60 |
| anticonvulsants antidepressive | #60 |
| serotonergic effects | #60 |
| patients mirtazapine | #60 |
| study medication | #60 |
| 1 week treatment | #61 |
| caregivers pain | #61 |
| doubleblind | #61 |
| bleomycin patients | #61 |
| tamoxifen metabolism | #61 |
| 3 randomized | #61 |
| cancer patients study | #61 |
| paroxetine fluoxetine | #61 |
| topic surveys life | #61 |
| lymphedema women | #61 |
| pipn | #61 |
| sensitivity individuals | #61 |
| emla cream | #61 |
| standard dosing | #61 |
| recurrent disease patients | #62 |
| venlafaxine placebo | #62 |
| fluorouracil induced | #62 |
| efficacy fluoxetine | #62 |
| induced taste | #62 |
| ocular toxicity | #62 |
| dermatological toxicities | #62 |
| alpha weight | #62 |
| chemotherapy dose | #62 |
| pain bleeding | #62 |
| antibodies monoclonal carcinoma | #63 |
| lessen | #63 |
| prior chemotherapy regimen | #63 |
| aged placebos | #63 |
| anorexia patients | #63 |
| 105 months | #63 |
| integrative oncology | #63 |
| ncictc | #63 |
| patients disease recurrence | #63 |
| bupropion nicotine | #64 |
| alleviate | #64 |
| incidence rash | #64 |
| carboplatin oxaliplatin | #64 |
| improvement sexual function | #64 |
| patients cancer types | #64 |
| painful peripheral neuropathy | #64 |
| allelic variability | #64 |
| cyproheptadine | #64 |
| rivaroxaban enoxaparin | #64 |
| versus placebo | #64 |
| aged nausea | #64 |
| cyclohexanols | #64 |
| treatment chemotherapy | #64 |
| agents double | #65 |
| dalteparin treatment | #65 |
| efficacy toxicity | #65 |
| 75 daily | #65 |
| validated patient | #65 |
| 4 weeks week | #65 |
| administration paclitaxel | #65 |
| appetite weight loss | #65 |
| patients comparisons | #65 |
| patients minocycline | #65 |
| survivorship issues | #65 |
| nicotine nasal | #66 |
| study gabapentin | #66 |
| diseases neoplasms | #66 |
| oncology clinical | #66 |
| acetate therapy | #66 |
| food intake patients | #66 |
| placebo months | #66 |
| estrogen suppression | #67 |
| life topic | #67 |
| target doses | #67 |
| qol fatigue | #67 |
| clinician training | #67 |
| induced dermatitis | #68 |
| hec | #68 |
| subcutaneous dalteparin | #68 |
| patients randomized | #68 |
| hormonal therapies | #68 |
| 46 95 | #68 |
| cachexia weight | #68 |
| baseline study | #68 |
| prevention smoking | #68 |
| pilocarpine treatment | #68 |
| debilitating | #69 |
| ongoing loss | #69 |
| vasomotor symptoms women | #69 |
| fsfi score | #69 |
| gained weight | #69 |
| skin surveys | #69 |
| chemotherapy anemia | #70 |
| item score | #70 |
| women ais | #70 |
| multifactorial syndrome | #70 |
| development severity | #70 |
| induced ovarian | #70 |
| nonsignificant trends | #70 |
| surgery cancer | #70 |
| life referral | #71 |
| weight compared | #71 |
| infliximab combination | #71 |
| incidence severity | #71 |
| major bleeding apixaban | #71 |
| anthrapyrazole | #71 |
| week percentage | #71 |
| effects ginseng | #72 |
| patients pilot | #72 |
| cisplatin treated | #72 |
| systemic retinoids | #72 |
| humans lignans | #72 |
| oral drug administration | #72 |
| placebo patches | #72 |
| trials planning | #72 |
| ginseng treatment | #73 |
| chemoprevention trial | #73 |
| chemotherapy supportive | #73 |
| prospective pilot trial | #73 |
| ergotamines | #73 |
| placebo | #73 |
| stage primary | #73 |
| weeks placebo | #73 |
| anemia antineoplastic | #74 |
| trial evaluating | #74 |
| qli | #74 |
| rcts systematic reviews | #74 |
| women estrogen therapy | #74 |
| dronabinol | #74 |
| fractional co2 laser | #74 |
| rash | #74 |
| receiving chemotherapy | #74 |
| nervous diseases | #75 |
| cancerrelated fatigue crf | #75 |
| acid supplement | #75 |
| prevention | #75 |
| 353 patients | #75 |
| cycles cycle | #76 |
| acute skin | #76 |
| blind clinical | #76 |
| inhibitors tamoxifen | #76 |
| weekly arm | #76 |
| tamoxifen postmenopausal | #77 |
| cancer randomized | #77 |
| alliance patients | #77 |
| anorexia weight loss | #77 |
| breast cancer paclitaxel | #77 |
| dose 90 | #77 |
| 95 01 | #77 |
| week p005 | #77 |
| anemia darbepoetin | #77 |
| hospice staff | #77 |
| female humans insurance | #78 |
| 3 arm | #78 |
| tamoxifen postmenopausal women | #78 |
| patients zoledronic acid | #78 |
| values data | #78 |
| surgery year | #79 |
| vte recurrence | #79 |
| patients darbepoetin alfa | #79 |
| week schedule | #79 |
| efficacy lamotrigine | #79 |
| pain syndrome | #79 |
| symptoms sensitivity | #79 |
| therapy antineoplastic | #79 |
| serum concentrations infliximab | #79 |
| foot syndrome | #80 |
| life phase iii | #80 |
| time mastectomy | #80 |
| vomiting antiemetics | #80 |
| isoflavone supplements | #80 |
| zoledronic acid treatment | #80 |
| week 4 | #80 |
| lowmolecular weight heparin | #81 |
| oral oncology | #81 |
| period crossover | #81 |
| patient qol | #81 |
| patients treatment arms | #81 |
| study march | #81 |
| guideline recommendation | #81 |
| backgroundchemotherapy | #82 |
| greater weight gain | #82 |
| paroxetine patients | #82 |
| standard clinical | #82 |
| bupropion smoking | #82 |
| suggestion | #82 |
| trpv1 trpa1 | #83 |
| day weeks | #83 |
| orbital stability | #83 |
| patients participating | #83 |
| recommendations article | #83 |
| cinv patients | #84 |
| trpm8 trpa1 | #84 |
| method female | #84 |
| zinc sulfate | #84 |
| neoplasm metastasis neoplasms | #85 |
| systematic reviews rcts | #85 |
| ice pack | #85 |
| cancer weight | #85 |
| cryotherapy patients | #86 |
| mayo clinic | #86 |
| receiving placebo | #86 |
| ttf survival | #86 |
| treatment nicotine dependence | #86 |
| nicotine nasal spray | #87 |
| methodspatients | #87 |
| life cachexia | #87 |
| baseline arms | #87 |
| primary symptom | #87 |
| week 5 | #87 |
| therapyinduced | #87 |
| frequency severity | #87 |
| incidence osteoporosis | #87 |
| serum hepcidin levels | #87 |
| pilot study safety | #87 |
| anecdotal reports | #88 |
| integrative therapies | #88 |
| acp documentation | #88 |
| treatment fatigue | #89 |
| iu daily | #89 |
| cancer vte | #89 |
| putative mediator | #89 |
| clinical oncology asco | #90 |
| morphine pharmacokinetics | #90 |
| male chemotherapy | #90 |
| outcome venlafaxine | #90 |
| endoxifen concentrations | #91 |
| ncorp | #91 |
| tolerated patients | #91 |
| symptoms including | #91 |
| iii efficacy | #91 |
| scores placebo | #91 |
| delayed cinv | #91 |
| arm treatment | #91 |
| nerve pain | #92 |
| patients paroxetine | #92 |
| completion chemotherapy | #92 |
| trials treatment | #92 |
| patients upfront | #92 |
| cisplatin oxaliplatin | #92 |
| ameliorating | #93 |
| questionnaires survival | #94 |
| 1 primary | #94 |
| arm 3 | #94 |
| neoplasms quality life | #94 |
| duloxetine hydrochloride | #94 |
| anemic patients | #94 |
| mometasone | #94 |
| apixaban dose | #94 |
| quiet stance | #94 |
| breast cancer survivors | #94 |
| alfa patients | #95 |
| patients appetite | #95 |
| common symptoms | #95 |
| cancerrelated pain | #95 |
| failure chemotherapy | #96 |
| hlaa2 patients | #96 |
| 0 10 | #96 |
| udi | #96 |
| patients completion | #96 |
| mayo clinic rochester | #96 |
| ccop | #96 |
| prevention management | #96 |
| paclitaxel patient | #97 |
| oral mucositis patients | #97 |
| acute vte | #97 |
| pyrexia | #97 |
| adjuvant therapy survival | #97 |
| painful area | #98 |
| alleviating | #98 |
| treatment tolerability | #98 |
| crnmb | #98 |
| text review | #98 |
| preliminary data | #98 |
| completed study | #98 |
| agents paclitaxel | #98 |
| 15 points | #98 |
| identical placebo | #98 |
| difference incidence | #99 |
| 5fu leucovorin | #99 |
| bcca | #99 |
| topic cyclophosphamide | #99 |
| fatigue insomnia | #99 |
| pregnadienediols | #99 |
| patient questionnaires | #99 |
| induced esophagitis | #99 |
| 4 weeks baseline | #99 |
| 5fluorouracil oxaliplatin | #99 |
| patient medical | #99 |
| qlq | #100 |
| male sex factors | #100 |
| oncology outpatients | #100 |
| survival nsclc | #100 |
| clinician communication | #100 |
| 10 doses | #100 |
| lidocaine lidocaine | #101 |
| antineoplastic agents life | #101 |
| postresection | #101 |
| oncology clinicians | #101 |
| nortriptyline | #101 |
| humans life | #101 |
| 275 patients | #101 |
| oncology asco | #101 |
| 5 based | #101 |
| lung cancer chemoprevention | #101 |
| placebo 1 year | #102 |
| methods trial | #102 |
| reported effects | #103 |
| variance clinical trials | #103 |
| purposeprevious | #104 |
| patients anorexia | #104 |
| 3106 | #104 |
| races ethnicities | #104 |
| quality life data | #104 |
| diseases treatment | #105 |
| patients 150 | #105 |
| leap | #105 |
| phytogenic clinical trials | #105 |
| 12 24 months | #105 |
| chemotherapy cycle | #105 |
| stool samples patients | #106 |
| compounds oxaliplatin | #106 |
| dfmo | #106 |
| infusion site | #106 |
| neuropathy | #106 |
| dalteparin patients | #106 |
| trial studies | #106 |
| nutritional determinants | #106 |
| months relapse | #106 |
| valeriana officinalis | #107 |
| anastrozole letrozole | #107 |
| cycle cycles | #107 |
| urogenital diseases | #107 |
| pain intensity ratings | #107 |
| versus dexamethasone | #107 |
| humans menopause | #107 |
| epoetin alfa patients | #107 |
| breast cancer tamoxifen | #108 |
| life topic severity | #108 |
| women experience | #108 |
| week study | #108 |
| time toxicity | #108 |
| relapse prevention | #108 |
| patients guideline | #109 |
| female urogenital | #109 |
| women vasomotor symptoms | #109 |
| levocarnitine | #109 |
| treatment cancer pain | #109 |
| mouthwash | #109 |
| strong prognostic factor | #109 |
| oxaliplatin therapy | #110 |
| life adverse events | #110 |
| combined paclitaxel | #110 |
| patients cancer treatment | #110 |
| clinic rochester | #110 |
| vomiting adult | #111 |
| prevention bone loss | #111 |
| cmf chemotherapy | #111 |
| egfr inhibitor | #111 |
| function suppression | #112 |
| insomnia pain | #112 |
| dosing schedules | #112 |
| reassess | #113 |
| colorectal neoplasia | #113 |
| patients arms | #113 |
| adverse events ctcae | #113 |
| visits patient | #113 |
| –iii | #113 |
| functional iron deficiency | #113 |
| vaginal diseases | #113 |
| vestibulitis | #113 |
| treatment arms patients | #113 |
| agents hormonal | #113 |
| single nucleotide variants | #114 |
| therapy induced | #114 |
| months 3 | #114 |
| acitretin | #114 |
| hfsd | #114 |
| cachexia humans | #114 |
| alopecia patients | #114 |
| patients olanzapine | #114 |
| diseases breast | #114 |
| dietary lignans | #114 |
| qol patient | #114 |
| studies randomized | #115 |
| letrozole tamoxifen | #115 |
| laser therapy lasers | #115 |
| crci | #115 |
| patients anthracycline | #115 |
| combination nicotine | #115 |
| rivaroxaban venous | #115 |
| treatment arm | #116 |
| placebo postmenopausal women | #116 |
| patients peripheral neuropathy | #117 |
| induction ornithine decarboxylase | #117 |
| nk1 receptor antagonist | #117 |
| oral factor | #117 |
| symptoms chemotherapy | #117 |
| 2007 guidelines | #117 |
| recurrence diagnosis | #118 |
| appetite stimulant | #118 |
| oral antineoplastic agents | #118 |
| trials conducted | #119 |
| patients weekly paclitaxel | #119 |
| trpa1 trpv1 | #119 |
| 3915 | #119 |
| diseases pain | #119 |
| preventive therapies | #119 |
| noradrenaline reuptake | #119 |
| participants arms | #120 |
| treatment weeks | #120 |
| resultswhile | #120 |
| clinical histories | #120 |
| original report | #120 |
| 750 day | #120 |
| olanzapine placebo | #120 |
| definition classification | #120 |
| hormonal agents | #121 |
| fullerton | #121 |
| postmenopausal postmenopause | #121 |
| induced ocular | #121 |
| placebo double | #121 |
| untoward | #121 |
| patients cancers | #121 |
| nervous agents | #122 |
| oxaliplatin folfox | #122 |
| cancer multiple | #122 |
| skin pain | #123 |
| objective review | #123 |
| surgery analysis | #123 |
| netupitant | #123 |
| rolapitant | #123 |
| acute oral | #123 |
| weeks 4 | #123 |
| cancer quality | #123 |
| stable dose | #123 |
| rivaroxaban compared | #124 |
| patients diploid tumors | #124 |
| treatment letrozole | #124 |
| pros baseline | #124 |
| neuropathic pain patients | #124 |
| survivors breast cancer | #124 |
| isoflavones genistein | #124 |
| 90 dose | #125 |
| week dose | #125 |
| 1 month patients | #125 |
| resultsfour | #126 |
| neurotoxic agents | #126 |
| factors odds | #126 |
| promising agents | #127 |
| fsfi | #127 |
| anorexia | #127 |
| diagnosis metastatic disease | #127 |
| patients physicians | #127 |
| genetic quality | #127 |
| recurrent adenomas | #127 |
| hormonal breast | #127 |
| uncommon variants | #128 |
| cancerassociated vte | #128 |
| alfa erythropoietin | #128 |
| belladonna | #128 |
| arms patients | #128 |
| weight concerns | #128 |
| clinical trial patients | #129 |
| 5 leucovorin | #129 |
| agents neoplasms | #129 |
| resultsforty | #129 |
| neoplasms quality | #129 |
| vomiting cinv | #129 |
| postural instability | #129 |
| problem patients | #130 |
| serum baseline | #130 |
| patientreported outcome | #130 |
| control arms | #130 |
| 150 iu | #131 |
| treatment toxicities | #131 |
| prognostic variables | #131 |
| bmd tscore | #131 |
| cancer fatigue | #131 |
| function fsfi | #131 |
| onycholysis | #132 |
| neurotoxicity syndromes | #132 |
| efficacy vitamin | #132 |
| relapse smoking | #132 |
| cancerrelated symptoms | #132 |
| pilot data | #132 |
| topical treatment | #133 |
| assessable | #133 |
| cachexia patients | #133 |
| progress report | #133 |
| symptom control | #134 |
| endodermal sinus tumor | #134 |
| ginseng panax | #134 |
| 5 placebo | #134 |
| ganglion block | #134 |
| chemotherapy 5 | #135 |
| common adverse effects | #135 |
| 150 women | #135 |
| cancers patients | #135 |
| cold hyperalgesia | #135 |
| toxt | #135 |
| bmd postmenopausal women | #135 |
| agents generation | #135 |
| weekly therapy | #136 |
| patientlevel pooled analysis | #136 |
| symptomatic benefit | #136 |
| painful neuropathy | #136 |
| bothersome | #136 |
| npy levels | #136 |
| life physical function | #137 |
| stage cancer | #137 |
| study trials | #137 |
| severe fatigue | #137 |
| poor qol | #137 |
| percentage reduction | #137 |
| intrapatient | #137 |
| substantial benefit | #137 |
| agents bortezomib | #137 |
| zoledronic | #138 |
| grade stage | #138 |
| accrued | #138 |
| hfs patients | #138 |
| incurable cancer | #139 |
| underwent mastectomy | #139 |
| advanced lung | #139 |
| therapy breast | #139 |
| chemoprevention studies | #139 |
| factbr | #139 |
| liquid suspension | #140 |
| patients advanced cancer | #140 |
| breast chest wall | #140 |
| patients placebo | #141 |
| paclitaxel weekly | #141 |
| oxaliplatin chemotherapy | #141 |
| disclose | #142 |
| patients levetiracetam | #142 |
| tamoxifen placebo | #142 |
| financial concerns | #142 |
| medicine clinical | #143 |
| protocols breast | #143 |
| fluorouracil 5 | #143 |
| allopurinol placebo | #144 |
| snv | #144 |
| european organisation | #144 |
| preoperative magnetic | #144 |
| eortc qlq | #145 |
| fluorouracil humans | #145 |
| agents bone | #145 |
| vaginal cytology | #145 |
| debilitating condition | #145 |
| evidence loe | #145 |
| eligible women | #146 |
| surgery type | #146 |
| backgroundwomen | #148 |
| volatile plants | #148 |
| oral olanzapine | #148 |
| dietary counselling | #148 |
| numeracy | #149 |
| desipramine treatment | #149 |
| adjuvant systemic | #150 |
| n201 | #150 |
| venlafaxine treatment | #150 |
| predict recurrence | #150 |
| intravenous access | #151 |
| response rate survival | #151 |
| daily diaries | #151 |
| prior chemotherapy regimens | #151 |
| multinational association | #151 |
| women estrogen | #151 |
| patients receive | #151 |
| methodologic | #151 |
| oral mucositis | #152 |
| 14 week | #152 |
| caa patients | #152 |
| balance impairments | #152 |
| tumor recurrence patients | #152 |
| ovarian function suppression | #152 |
| groups symptoms | #152 |
| cramping | #153 |
| 80 dose | #154 |
| carboplatin trastuzumab | #154 |
| adjuvant systemic therapy | #155 |
| dermatomes | #155 |
| cindices | #155 |
| fsds | #156 |
| infliximab 5 | #156 |
| mangafodipir | #156 |
| vinblastine bleomycin | #156 |
| methods randomized | #156 |
| integrated palliative | #156 |
| combination chemotherapy cisplatin | #156 |
| life randomized | #156 |
| hyperalimentation | #156 |
| breast cancer trastuzumab | #157 |
| women breast carcinoma | #157 |
| common terminology criteria | #157 |
| gait stability | #157 |
| racially diverse | #157 |
| vomiting nausea | #158 |
| oncology study | #158 |
| study initiation | #158 |
| arm versus | #158 |
| physicians patients | #159 |
| weekly doses | #159 |
| induced nausea | #159 |
| iii clinical | #159 |
| chemotherapy breast cancer | #159 |
| survivors colorectal | #159 |
| chemotherapy quality | #160 |
| stellate ganglion | #160 |
| european organisation treatment | #160 |
| cancer pain patients | #160 |
| treatment postmenopausal women | #160 |
| paclitaxel taxol | #160 |
| major problem | #160 |
| women hormone therapy | #161 |
| validity life | #161 |
| estrogen depletion | #161 |
| risk infertility | #161 |
| data efficacy | #163 |
| neoplasms pain | #164 |
| efficacy women | #164 |
| mometasone furoate | #165 |
| cisplatin vinblastine | #165 |
| current project | #165 |
| patients 1 month | #166 |
| skeletal events | #166 |
| pharmacokinetic analyses | #166 |
| illness surveys questionnaires | #167 |
| osteoporosis prevention | #167 |
| life topic surveys | #167 |
| chemotherapy‐induced nausea | #168 |
| anthracycline | #168 |
| direct inhibitors | #168 |
| chemotherapy groups | #168 |
| patients adenomas | #169 |
| patients data | #169 |
| 432 patients | #169 |
| menopause symptoms | #169 |
| dosing patients | #169 |
| ixabepilone | #170 |
| management chronic pain | #170 |
| disease cmt | #171 |
| rochester | #171 |
| prospective clinical trials | #171 |
| daily placebo | #171 |
| global quality | #171 |
| prestudy | #172 |
| chemotherapy completion | #172 |
| judicious | #173 |
| lamotrigine placebo | #173 |
| label pilot | #173 |
| 1 year therapy | #173 |
| hot flushes | #173 |
| impaired balance | #173 |
| placebos | #173 |
| prospective evaluation | #174 |
| phase iii trial | #174 |
| methylphenidate placebo | #174 |
| diarrhoea patients | #174 |
| pilot feasibility study | #174 |
| decreased quality | #175 |
| arthralgia | #175 |
| male breast cancer | #175 |
| cancer cancer treatment | #175 |
| physician order | #175 |
| baseline weight | #176 |
| treatment 14 | #177 |
| life assessments | #177 |
| weeks women | #177 |
| bodyweights | #178 |
| thirty percent | #178 |
| expected benefits | #179 |
| bothered | #179 |
| treatmentrelated toxicity | #179 |
| bolus fluorouracil | #179 |
| life baseline | #179 |
| sufferer | #180 |
| phase evaluation | #181 |
| darbepoetin | #182 |
| gain weight | #182 |
| oxaliplatin 5fluorouracil | #182 |
| escalations | #182 |
| ginseng | #182 |
| organisation treatment | #183 |
| toxicity criteria | #183 |
| peri postmenopausal women | #183 |
| prognostic criteria | #184 |
| infliximab antibodies | #184 |
| effects chemotherapy | #184 |
| acute pain | #184 |
| white smokers | #184 |
| tube primary | #184 |
| acetyll | #184 |
| received oral | #184 |
| biostatisticians | #184 |
| outcome measures life | #185 |
| additional chemotherapy | #185 |
| reported sexual | #185 |
| arm volume | #186 |
| delayed nausea | #187 |
| patients drug | #187 |
| cinv | #187 |
| treatment 4 weeks | #187 |
| treating | #187 |
| tamoxifen letrozole | #188 |
| strong prognostic | #188 |
| reduction therapy | #188 |
| lessened | #188 |
| management breast cancer | #188 |
| week follow | #188 |
| adjuvant decision | #188 |
| troublesome | #188 |
| neoplasia female humans | #189 |
| oxaliplatin dose | #189 |
| aching | #189 |
| aged nitriles | #190 |
| protocol therapy | #190 |
| placebo study | #190 |
| week 1 | #190 |
| survivors breast | #190 |
| antiemetic regimens | #190 |
| twentyfive patients | #191 |
| cancer cancer survivors | #191 |
| completed baseline | #191 |
| fortysix patients | #192 |
| patients increases | #192 |
| aches | #192 |
| chronic lymphedema | #192 |
| toxicity patients | #192 |
| treatment cancer patients | #192 |
| aspirin incidence | #192 |
| manuscript | #192 |
| cimicifuga racemosa | #193 |
| humans isoflavones | #193 |
| assigned receive | #193 |
| effective agents | #194 |
| weekly trastuzumab | #194 |
| 25 women | #194 |
| 3 fatty | #195 |
| weight loss patients | #195 |
| pain breast | #195 |
| ornithine decarboxylase activity | #195 |
| resultsdata | #196 |
| acids double | #196 |
| palonosetron dexamethasone | #197 |
| pituitaryadrenal axis | #197 |
| trial designs | #197 |
| resultstwo | #198 |
| toxicity profiles | #198 |
| surveillance strategy | #198 |
| postmenopausal patients | #198 |
| accent | #199 |
| patients letrozole | #199 |
| culminates | #199 |
| organization treatment | #199 |
| nicotine patch | #199 |
| delayed emesis | #199 |
| women menopause | #199 |
| adjuvant interferon | #200 |
| percent reduction | #200 |
| menopause premature | #201 |
| oral glutamine | #201 |
| primary goal | #202 |
| greater 5 | #202 |
| treatment week | #202 |
| item responses | #202 |
| treatment bmd | #202 |
| imiquimod | #202 |
| bmd postmenopausal | #203 |
| hormonal treatments | #203 |
| cancer anemia | #203 |
| composition cachexia | #204 |
| pelvic radiation therapy | #204 |
| plo | #204 |
| treated placebo | #204 |
| induced oral | #205 |
| unwilling | #206 |
| leucovorin patients | #206 |
| chemotherapy drugs | #206 |
| udi6 | #206 |
| dalteparin | #206 |
| placebo 8 | #206 |
| mice cisplatin | #207 |
| heat hyperalgesia | #207 |
| pharmacologic interventions | #207 |
| 4 8 weeks | #208 |
| humans leucovorin | #208 |
| incurable | #208 |
| reduced food intake | #208 |
| chemotherapy | #209 |
| hands patients | #209 |
| 5 daily | #209 |
| controlled evaluation | #210 |
| estrogen receptor modulators | #210 |
| lamotrigine | #210 |
| methotrexate 5 | #210 |
| gel application | #211 |
| methodsthis | #212 |
| vomiting patients | #212 |
| regionally advanced | #212 |
| diagnosis recurrence | #212 |
| initials | #212 |
| docetaxel cyclophosphamide | #213 |
| trial vitamin | #213 |
| charcotmarietooth disease | #213 |
| dexamethasone control | #214 |
| oncology practices | #214 |
| placebo 6 weeks | #214 |
| patient weight | #214 |
| antiemetic therapy | #215 |
| december patients | #215 |
| 15 minutes | #215 |
| olanzapine 5 | #215 |
| oxaliplatin | #215 |
| neoplasms cross | #216 |
| prostate cancer survivors | #216 |
| gabapentin humans | #217 |
| tamoxifen users | #217 |
| patients duloxetine | #217 |
| women tamoxifen | #217 |
| women breast cancer | #217 |
| purposethe purpose | #218 |
| placebo weeks | #218 |
| hot | #218 |
| current management | #218 |
| aprepitant | #218 |
| nonmajor | #218 |
| —reply | #218 |
| 10 daily | #218 |
| life humans | #219 |
| palliative oncology | #219 |
| nmscs | #219 |
| transdermal fentanyl | #219 |
| sexual symptoms | #220 |
| nonabsorbable | #220 |
| sublingual administration | #220 |
| society clinical oncology | #221 |
| painful peripheral | #221 |
| pregabalin patients | #221 |
| moderate pain | #221 |
| ornithine decarboxylase odc | #221 |
| relieving | #222 |
| treatment postmenopausal | #222 |
| ginkgo biloba egb | #222 |
| prospective study women | #222 |
| methylphenidate modafinil | #222 |
| neoplasms palliative | #222 |
| primary breast cancer | #222 |
| lymphedema patients | #222 |
| furoate | #223 |
| randomized doubleblind study | #223 |
| prevention patients | #224 |
| computerized physician | #225 |
| 99 months | #225 |
| quinquefolius | #225 |
| agent patients | #226 |
| vaginal estrogen | #226 |
| partial mastectomy | #226 |
| turmoil | #227 |
| bupropion | #227 |
| pain presence | #227 |
| trial | #228 |
| clinical situation | #228 |
| secondary endpoint | #229 |
| 200 iu | #229 |
| nondiploid | #229 |
| editorials | #230 |
| hospice patients | #230 |
| antidepressive | #230 |
| akt inhibitor | #230 |
| physicians quality | #230 |
| placebo 10 | #230 |
| anthracycline cardiotoxicity | #230 |
| eating disorders humans | #230 |
| cancer recommendations | #230 |
| rashes | #231 |
| vitamin effects | #231 |
| based adjuvant | #231 |
| time study | #232 |
| conclusionsthe | #232 |
| lightheadedness | #232 |
| handfoot syndrome | #232 |
| cachexia cytokines | #232 |
| fluoxetine paroxetine | #233 |
| nonpharmacologic | #233 |
| acute symptoms | #234 |
| treatment vte | #234 |
| 4 doses | #234 |
| women hot | #234 |
| thirty women | #234 |
| tamoxifen neoplasms chemotherapy | #235 |
| 375 day | #235 |
| day response | #235 |
| relieve | #235 |
| arm 95 | #235 |
| sucralfate | #235 |
| effective treatments | #236 |
| premenopausal patients | #237 |
| placebo gel | #237 |
| flash | #238 |
| survivors treatment | #238 |
| antiemetics | #238 |
| incidence grade | #238 |
| postoperative monitoring | #238 |
| letrozole patients | #238 |
| overexpressing metastatic | #239 |
| improved bioavailability | #239 |
| menopause middle | #239 |
| chemotherapy placebo | #239 |
| nonpharmacologic interventions | #239 |
| adjuvant 5 | #239 |
| methodswomen | #239 |
| oncology clinic | #239 |
| oral complications | #240 |
| treatment breast cancer | #240 |
| neoadjuvant therapy surgery | #240 |
| cachexia syndrome | #240 |
| independent tests | #241 |
| participants randomized | #242 |
| stinging | #242 |
| aged paclitaxel | #243 |
| small doses | #243 |
| tetracycline | #244 |
| epoetin alfa | #245 |
| 3 arms | #245 |
| common practice | #246 |
| adjuvant oxaliplatin | #246 |
| appetite stimulants | #246 |
| efficacy placebo | #247 |
| cachexia cancer | #248 |
| mouthwashes | #248 |
| dysgeusia | #249 |
| 800 iu | #249 |
| survivors adult | #250 |
| randomized sham | #250 |
| item scores | #250 |
| loss bmd | #250 |
| 689 | #251 |
| major problems | #251 |
| patients physical | #251 |
| topic vitamin | #252 |
| menopause women | #252 |
| coasting | #252 |
| randomised studies | #253 |
| armodafinil | #253 |
| primary point | #253 |
| average intensity | #254 |
| nasal spray | #254 |
| moderate degree | #254 |
| chemotherapy breast | #255 |
| recurrence registries | #255 |
| longitudinal followup | #256 |
| prospective clinical | #256 |
| antidepressant | #257 |
| cancer treatment | #257 |
| neoplasms randomized | #257 |
| therapy women | #257 |
| women treated | #258 |
| pretreatment levels | #258 |
| new therapeutic approaches | #258 |
| dyspareunia | #258 |
| rigors | #259 |
| hydrochloride | #259 |
| opioid doseresponse relationship | #260 |
| tube cancer | #260 |
| inhibitors treatment | #260 |
| patients cancer | #261 |
| common problem | #261 |
| 1 baseline | #261 |
| repeated measures | #261 |
| patients ovarian cancer | #262 |
| citalopram treatment | #262 |
| chronic post | #262 |
| management options | #263 |
| months treatment | #263 |
| decision framework | #263 |
| dosage levels | #263 |
| phytogenic | #264 |
| hematinics | #264 |
| duloxetine placebo | #264 |
| treatment oxaliplatin | #264 |
| recommendations quality | #265 |
| outcome administration | #265 |
| preoperative mri | #266 |
| treatmentrelated deaths | #266 |
| surgery adjuvant | #267 |
| placebo 8 weeks | #267 |
| paresthesia | #267 |
| substantiation | #267 |
| individual items | #267 |
| treatment cancer | #267 |
| impact quality | #268 |
| adult cancer survivors | #268 |
| 208 patients | #269 |
| nausea | #270 |
| signaled | #270 |
| ginkgo biloba | #270 |
| patients rash | #270 |
| patients octreotide | #271 |
| moderate correlations | #271 |
| estrogen antagonists | #271 |
| 80 90 | #271 |
| distressing | #272 |
| control trials | #272 |
| weekly | #272 |
| treatment 95 | #272 |
| bridged ring | #272 |
| dna test | #272 |
| score baseline | #272 |
| performance status patients | #272 |
| placebo‐controlled trial | #273 |
| abstinence rates | #273 |
| dryness | #274 |
| sham treatment | #274 |
| oncology clinical trials | #274 |
| induced cisplatin | #275 |
| valeriana | #275 |
| gross disease | #275 |
| patients caa | #276 |
| chemoprevention trials | #277 |
| perspiration | #278 |
| treatment breast | #278 |
| prominent | #279 |
| biomarkers disease humans | #279 |
| cimicifuga | #279 |
| patients hospice | #279 |
| patients symptoms | #279 |
| therapeutic options | #279 |
| cartilage patients | #280 |
| patients frequency | #280 |
| individual patient | #280 |
| breast cancer outcomes | #280 |
| cholinergic antagonists | #280 |
| zoledronic acid patients | #281 |
| doxorubicin cyclophosphamide | #281 |
| psychometric testing | #281 |
| stage colon | #282 |
| antidepressive agents | #282 |
| chamomile | #282 |
| completed questionnaires | #284 |
| women effects | #284 |
| greater severity | #284 |
| smoking abstinence | #285 |
| gabapentin treatment | #285 |
| fatigue crf | #286 |
| early discontinuation | #286 |
| female hormone | #287 |
| acid adult | #287 |
| colorectal lung | #287 |
| weeks patients | #287 |
| function quality | #287 |
| paps | #287 |
| symptoms function | #287 |
| aromatase inhibitor therapy | #288 |
| hot flush | #288 |
| life survival | #290 |
| eligible patients | #291 |
| common symptom | #292 |
| qualitative approach | #292 |
| clinical trial participation | #292 |
| treatment target | #292 |
| discouraged | #292 |
| mucositis oral | #293 |
| weight gain patients | #294 |
| cbdca | #294 |
| 1636 | #294 |
| pain symptoms | #294 |
| monographs | #295 |
| vinca alkaloids | #295 |
| citalopram | #295 |
| testosterone supplementation | #295 |
| bone loss patients | #295 |
| toxicity evaluation | #296 |
| primary peritoneal cancer | #297 |
| aspirin placebo | #298 |
| patients entered | #298 |
| questionnaires treatment | #298 |
| feet | #299 |
| peripheral nervous | #299 |
| neoplasms cyclophosphamide | #299 |
| hypothetical scenarios | #300 |
| radiation dermatitis | #300 |
| inhibitors ais | #300 |
| treated combination | #301 |
| shooting | #301 |
| survival trials | #302 |
| octreotide | #302 |
| nogalamycin | #302 |
| acute neurotoxicity | #303 |
| treatment serum | #303 |
| stage grade | #303 |
| symptoms pain | #304 |
| subscale scores | #304 |
| nausea vomiting | #304 |
| prime time | #305 |
| placebo groups | #305 |
| complementary therapies | #305 |
| schedule female | #305 |
| prospective clinical trial | #305 |
| global quality life | #306 |
| factg | #306 |
| inflammatory breast cancer | #307 |
| aromatase inhibitor | #307 |
| shortread | #307 |
| placebo treatment | #307 |
| prochlorperazine | #307 |
| drug embryo | #308 |
| apixaban | #308 |
| neoplasms chemotherapy | #308 |
| aged cancer | #308 |
| darbepoetin alfa | #309 |
| studies double | #310 |
| zoledronic acid | #310 |
| lung docetaxel | #311 |
| riskstratification | #311 |
| cancer receiving | #311 |
| advanced cancer | #311 |
| individual subject | #311 |
| placebo‐controlled | #312 |
| epoetin | #312 |
| testosterone placebo | #312 |
| patients cycle | #313 |
| musculoskeletal symptoms | #313 |
| syndrome aps | #314 |
| cancer adjuvant | #314 |
| or10 | #314 |
| operative chemotherapy | #315 |
| new primary | #315 |
| article evidence | #316 |
| organoplatinum | #316 |
| blinded | #317 |
| bfi | #317 |
| ambulatory patients | #317 |
| sesame oil | #317 |
| symptoms breast | #317 |
| double‐blind | #317 |
| rivaroxaban patients | #318 |
| efficacy treatment | #319 |
| irox | #319 |
| informed decisions | #321 |
| life differences | #322 |
| dietary counseling | #322 |
| thromboembolism anticoagulants | #323 |
| smokers nicotine | #324 |
| monthly intervals | #324 |
| glutamine humans | #324 |
| preventing | #325 |
| nsclc chemotherapy | #326 |
| breast radiotherapy | #326 |
| compared baseline | #327 |
| titrate | #327 |
| patients ductal carcinoma | #327 |
| continuation phase | #328 |
| oral nutritional supplements | #329 |
| antagonists female | #329 |
| patients resected | #329 |
| lymphedema | #329 |
| treatment 1 year | #329 |
| conducted evaluate | #329 |
| vte cancer patients | #329 |
| arms | #330 |
| patients nasal | #330 |
| potential efficacy | #330 |
| future clinical trials | #330 |
| controlled clinical | #330 |
| polymerase inhibitor | #331 |
| lozenge | #332 |
| cancer ontario | #332 |
| diagnosed primary | #332 |
| placebo patients | #334 |
| 80 anemia | #334 |
| patients daily | #334 |
| time disease | #335 |
| 128 patients | #336 |
| relative benefits | #336 |
| ongoing clinical | #336 |
| paclitaxel therapy | #336 |
| pain scale | #336 |
| sublingual | #337 |
| 5 fluorouracil | #337 |
| adjuvant letrozole | #337 |
| survival 5 years | #338 |
| surveillance guidelines | #338 |
| discernible | #339 |
| order entry | #340 |
| flutamide | #340 |
| treatment proportion | #341 |
| patients 4 weeks | #341 |
| mastectomy radiotherapy | #341 |
| eligible participants | #341 |
| cancer cachexia | #342 |
| fallopian tube cancer | #342 |
| osteopenia osteoporosis | #342 |
| society clinical | #343 |
| tooth disease | #343 |
| diseases quality | #343 |
| pilot randomized | #344 |
| clinicians patients | #345 |
| epha5 | #345 |
| skeletal neoplasms | #345 |
| accruing | #346 |
| mk2206 | #346 |
| clinical problems | #346 |
| coumarin | #347 |
| therapy pain | #347 |
| adverse events groups | #347 |
| mucositis patients | #348 |
| sham acupuncture | #349 |
| antineoplastic therapy | #349 |
| induced acute | #350 |
| vast majority | #350 |
| baseline quality | #350 |
| adjuvant folfox | #350 |
| dose schedule | #351 |
| dehydroepiandrosterone dhea | #351 |
| treatment citalopram | #351 |
| study therapy | #352 |
| response letter | #353 |
| paclitaxel | #353 |
| patientreported outcomes | #353 |
| endodermal sinus | #353 |
| letrozole | #355 |
| risedronate | #355 |
| cancer life | #355 |
| pain baseline | #356 |
| adjuvant colonic | #359 |
| skin toxicities | #359 |
| vomiting | #359 |
| clin oncol | #360 |
| cryotherapy | #360 |
| potential benefit | #360 |
| wellknown | #360 |
| ductal situ carcinoma | #360 |
| diaries | #361 |
| began | #361 |
| direct oral | #362 |
| pelvic radiation | #362 |
| ovarian suppression | #363 |
| cancer surveillance | #363 |
| flaxseed | #363 |
| pain measures | #363 |
| calculators | #363 |
| nonpharmacological | #363 |
| cddp | #365 |
| local prognosis receptor | #365 |
| docetaxel paclitaxel | #365 |
| completing | #365 |
| ovarian fallopian | #365 |
| bioavailable testosterone | #366 |
| management cancer | #366 |
| patients delayed | #366 |
| optimal frequency | #366 |
| pain cancer | #366 |
| scalp | #367 |
| weeks study | #368 |
| 5‐year | #368 |
| scale 0 | #368 |
| aged neoplasms | #369 |
| scheduled | #369 |
| hrt risk | #370 |
| cancer received | #371 |
| skeletalrelated events | #371 |
| orally daily | #372 |
| gamma aminobutyric acid | #372 |
| 5fluorouracil 5fu | #373 |
| skin toxicity | #373 |
| symptoms patients | #373 |
| resected stage | #374 |
| irreversible damage | #374 |
| clinical oncology | #374 |
| ovarian failure | #374 |
| ecogps | #374 |
| paclitaxel dose | #374 |
| −005 | #375 |
| decreasing | #376 |
| women breast | #376 |
| therapy based | #376 |
| blood test | #377 |
| medroxyprogesterone acetate | #377 |
| week patients | #378 |
| assessable patients | #378 |
| polyneuropathy | #378 |
| humans specificity | #378 |
| drowsiness | #378 |
| nociceptors | #379 |
| national cancer institute | #380 |
| loss skeletal | #381 |
| fura | #381 |
| telerehabilitation | #381 |
| 4 treatment | #382 |
| leucovorin | #383 |
| unacceptable toxicity | #383 |
| organoplatinum compounds | #383 |
| 402 | #384 |
| disputes | #384 |
| trials involving | #384 |
| adverse event | #384 |
| patients capecitabine | #384 |
| target dose | #384 |
| function pain | #384 |
| conservation agents | #385 |
| 5fluorouracil leucovorin | #385 |
| leptin patients | #385 |
| fourths | #386 |
| density conservation | #386 |
| 2 treatment | #388 |
| androgendeprivation therapy | #389 |
| treatment women | #390 |
| glutathione gsh | #390 |
| advanced adenomas | #391 |
| aromatase inhibitors ais | #392 |
| sexual desire | #392 |
| dying patients | #394 |
| adjuvant trials | #394 |
| 4 weeks | #394 |
| early palliative | #395 |
| discontinuation rates | #396 |
| life breast | #396 |
| humans mastectomy | #397 |
| cytotoxics | #397 |
| olanzapine | #397 |
| performance score | #397 |
| ring compounds | #397 |
| paired tests | #398 |
| patients randomly | #398 |
| 1280 | #398 |
| life data | #399 |
| intramuscular | #400 |
| chemotherapy colorectal | #400 |
| fatty acid supplementation | #400 |
| questionnaires treatment outcome | #400 |
| withdrew | #400 |
| peripheral neurotoxicity | #400 |
| estrogen receptors biomarkers | #401 |
| 3 cohorts | #401 |
| 8090 | #401 |
| assigned | #401 |
| evidencebased | #402 |
| entered | #402 |
| loe | #402 |
| sadenosyllmethionine | #403 |
| female humans life | #403 |
| acid female | #403 |
| 5 weeks | #405 |
| female fluorouracil | #406 |
| baseline demographics | #406 |
| responding patients | #408 |
| cisplatin induced | #409 |
| keratolytic | #410 |
| life aged | #411 |
| patients 5fu | #411 |
| topic neoplasms | #412 |
| female hemorrhage humans | #412 |
| regimens patients | #414 |
| ornithine decarboxylase | #414 |
| based chemotherapy | #415 |
| pain qol | #415 |
| oxaliplatin based | #415 |
| placebo 2 | #415 |
| acetate | #415 |
| carboplatin patients | #416 |
| oncology neoplasms | #416 |
| patient factors | #416 |
| delayed | #417 |
| platinum agents | #417 |
| prospective pilot | #417 |
| gabapentinoids | #417 |
| receiving | #418 |
| nighttime sleep | #419 |
| metastatic breast cancer | #419 |
| 0 4 | #419 |
| case series patients | #419 |
| adjuvant hormonal therapy | #419 |
| antiemetic prophylaxis | #420 |
| cancer purpose | #421 |
| controlled pilot | #421 |
| tcl1a | #421 |
| tamoxifen women | #421 |
| study entry | #421 |
| fourth week | #422 |
| selfreported symptoms | #422 |
| directed therapy | #422 |
| severities | #422 |
| arm 2 | #423 |
| pyridones | #423 |
| 5 trials | #423 |
| adequately | #423 |
| neurophysiologic | #424 |
| tamoxifen | #425 |
| androgen ablation | #425 |
| anastrozole | #425 |
| ongoing clinical trials | #426 |
| complementary alternative | #426 |
| prevention vte | #427 |
| baseline 6 weeks | #427 |
| gain adult | #428 |
| treating patients | #428 |
| primary peritoneal | #428 |
| creatine | #429 |
| greater percentage | #429 |
| adjectives | #430 |
| desipramine | #430 |
| fatigue humans | #431 |
| methodsa | #431 |
| glycitein | #431 |
| detection colorectal | #431 |
| hgb | #431 |
| contraindicated | #431 |
| laser therapy | #431 |
| symptom management | #432 |
| diploid tumors | #432 |
| sunscreen | #433 |
| antiseizure | #433 |
| joint symptoms | #433 |
| 115 patients | #434 |
| resultsone | #434 |
| cancer tamoxifen | #434 |
| purpose objectives | #434 |
| oral calcium | #435 |
| nutrition cancer | #436 |
| topic treatment | #436 |
| pains | #436 |
| 1157 | #436 |
| olanzapine treatment | #436 |
| anthracyclinebased chemotherapy | #438 |
| clinical cancer | #438 |
| absolute terms | #438 |
| nodenegative breast cancer | #439 |
| administration cutaneous | #440 |
| postoperative follow | #440 |
| neoplasms cancer | #441 |
| expected survival | #441 |
| diminish | #441 |
| vasomotor | #442 |
| yoga | #442 |
| hgpin | #444 |
| baseline 1 month | #444 |
| loss aged | #445 |
| preoperative breast | #445 |
| screening colorectal | #445 |
| receive | #445 |
| life efficacy | #445 |
| doxorubicin drug administration | #445 |
| agents antineoplastic | #446 |
| marie | #446 |
| day dexamethasone | #447 |
| treatment regimen | #447 |
| acid aged | #447 |
| 2 months | #448 |
| european organization | #448 |
| patients qol | #448 |
| patients weight | #448 |
| climacteric | #449 |
| estrogen therapy | #449 |
| baseline patient | #450 |
| premature discontinuation | #451 |
| baseline 4 weeks | #452 |
| cancer symptoms | #452 |
| outline | #453 |
| study feasibility | #453 |
| nodepositive breast cancer | #454 |
| arms arm | #454 |
| dhea | #455 |
| postmenopause | #455 |
| geranium | #456 |
| 5fu patients | #456 |
| axillary metastases | #457 |
| diphenhydramine | #458 |
| evaluate efficacy | #459 |
| mucositis | #460 |
| patients venous thromboembolism | #461 |
| questionnaires terminology | #461 |
| enforced | #461 |
| helpful | #462 |
| cytokines patients | #462 |
| 6 weeks | #462 |
| patients baseline | #462 |
| increased weight | #463 |
| potential interventions | #463 |
| therapy stage | #464 |
| asco | #468 |
| cancer institute | #468 |
| clin | #468 |
| referral centers | #469 |
| radiation enteritis | #469 |
| lung humans | #469 |
| consensus guideline | #470 |
| sexual distress | #470 |
| treatment options patients | #471 |
| esophagitis patients | #471 |
| purposethis | #471 |
| chemotherapy regimens | #472 |
| new treatment | #473 |
| subscale | #474 |
| 432 | #474 |
| pilocarpine | #474 |
| hormonal replacement therapy | #475 |
| symptoms menopause | #475 |
| groups 6 months | #475 |
| uncertain | #476 |
| appears | #477 |
| preliminary studies | #477 |
| single item | #477 |
| clinical decision making | #478 |
| placebo 24 weeks | #478 |
| iii colon | #479 |
| onco | #479 |
| variables age | #479 |
| doubleblind study | #479 |
| 95 placebo | #479 |
| vitamin placebo | #480 |
| enrollment patients | #480 |
| alopecia | #480 |
| osteoporosis osteopenia | #481 |
| crc 95 | #482 |
| moderatetosevere | #482 |
| higher dose | #483 |
| adjuvant therapy | #484 |
| reluctance | #484 |
| neurotoxicity patients | #485 |
| endpoints included | #485 |
| tpn | #485 |
| locoregional disease | #485 |
| cure | #486 |
| 655 | #486 |
| blind | #488 |
| taqman pcr | #488 |
| induced neuropathic | #489 |
| pain scores | #491 |
| estrogen deprivation | #491 |
| doselimiting toxicity | #491 |
| cancer cardiovascular disease | #492 |
| combined modality treatment | #493 |
| plant preparations | #493 |
| primary breast | #493 |
| narcotics | #494 |
| patients stage disease | #495 |
| decarboxylase activity | #498 |
| dropout rates | #499 |
| patients breast cancer | #500 |
| fentanyl humans | #500 |
| received placebo | #501 |
| “ ” | #501 |
| placebo‐controlled study | #502 |
| pilot studies | #502 |
| life questionnaires survivors | #502 |
| kps | #502 |
| metastatic cancer | #503 |
| loss patients | #504 |
| mesonephroma | #504 |
| chest ray | #505 |
| awaited | #506 |
| survival chemotherapy | #509 |
| pain inventory | #510 |
| placebo trial | #511 |
| smoking nicotine | #511 |
| preventative | #512 |
| breast diseases | #513 |
| therapy aged | #513 |
| trials data | #513 |
| advance planning acp | #514 |
| flic | #514 |
| nonmetastatic breast cancer | #514 |
| evidencebased interventions | #515 |
| women receiving | #516 |
| premature menopause | #516 |
| letrozole treatment | #516 |
| outcome antineoplastic | #517 |
| serum albumin levels | #517 |
| acute diarrhea | #519 |
| pain medications | #520 |
| achievements | #520 |
| eflornithine | #521 |
| cbcs | #521 |
| pharmaceutic | #522 |
| gamma aminobutyric | #522 |
| poorer quality life | #523 |
| symptoms fatigue | #525 |
| mastectomy middle | #525 |
| chills | #525 |
| resultsto | #527 |
| controlled crossover | #528 |
| prophylactic therapy | #528 |
| adverse events placebo | #528 |
| patients clinical trial | #529 |
| phytogenic area | #529 |
| abt888 | #529 |
| cmf | #529 |
| therapy prostate | #530 |
| centrally | #531 |
| oncologists | #531 |
| radiodermatitis | #531 |
| pregabalin | #531 |
| patients vitamin | #532 |
| iii trial | #533 |
| 30 minutes | #534 |
| genitourinary | #535 |
| patients evaluated | #536 |
| medications treatment | #536 |
| antineoplastic agents | #537 |
| study week | #538 |
| weeks therapy | #538 |
| superficial bladder | #538 |
| agents chemotherapy | #538 |
| patients clinical trials | #539 |
| terminally | #540 |
| patients assigned | #541 |
| pharmacologic | #542 |
| topic severity | #543 |
| dehydroepiandrosterone | #543 |
| pain patients | #543 |
| risedronic | #544 |
| week 6 | #544 |
| pain score | #544 |
| 329 | #545 |
| 592 | #546 |
| peripheral | #548 |
| patients scheduled | #548 |
| unable | #549 |
| bmd baseline | #550 |
| receiving adjuvant | #550 |
| differences study | #551 |
| 3 95 | #552 |
| dabrafenib trametinib | #552 |
| axonal transport | #553 |
| hypesthesia | #553 |
| adenomas patients | #554 |
| leucovorin oxaliplatin | #555 |
| neoplasms drug | #556 |
| evaluable | #556 |
| dysplastic lesions | #556 |
| regular aspirin | #556 |
| co2 laser | #556 |
| 300 day | #557 |
| abh | #557 |
| vasomotor symptoms | #559 |
| rbc transfusions | #560 |
| reported outcomes | #560 |
| emesis | #560 |
| 80000 | #560 |
| day treatment | #561 |
| methylphenidate | #561 |
| moisturizer | #561 |
| mesna | #562 |
| hands | #564 |
| lmwh patients | #564 |
| induced cold | #565 |
| method drug | #565 |
| time detection | #565 |
| treatment periods | #566 |
| trial data | #566 |
| 4 8 | #567 |
| supportive cancer | #567 |
| survival stage | #567 |
| 11 months | #568 |
| scientifically | #569 |
| therapy primary | #569 |
| adjuvant clinical trials | #569 |
| calgb | #569 |
| decarboxylase odc | #571 |
| lower dose | #571 |
| topic treatment outcome | #571 |
| bibliometric analysis | #572 |
| paclitaxel patients | #573 |
| topical capsaicin | #578 |
| fluorouracil oxaliplatin | #578 |
| refute | #580 |
| patients candidates | #580 |
| methods systematic review | #580 |
| hwe | #581 |
| treatment phase | #581 |
| breakthrough pain | #583 |
| paced | #583 |
| life questionnaire | #584 |
| paracentesis | #584 |
| moderate correlation | #585 |
| desvenlafaxine | #585 |
| drug toxicity | #587 |
| neoplasms nutritional | #587 |
| paclitaxel carboplatin | #588 |
| muscle cramps | #589 |
| aged occult | #589 |
| emotional functioning | #589 |
| oxaliplatin patients | #589 |
| multiple cancers | #589 |
| limited efficacy | #589 |
| osteopenia | #590 |
| aminobutyric | #590 |
| taxane chemotherapy | #590 |
| acrin | #591 |
| median time progression | #592 |
| crossover trial | #592 |
| ablation therapy | #592 |
| platinum drugs | #593 |
| chemotherapy benefit | #595 |
| pentoxifylline | #596 |
| compounded | #596 |
| radiotherapy breast | #597 |
| exanthema | #597 |
| sst2 | #597 |
| fatigue female | #597 |
| topic depressive disorder | #598 |
| multisite | #598 |
| initial surgery | #599 |
| patients mastectomy | #599 |
| publication administration | #599 |
| thromboembolism vte | #600 |
| effects breast | #600 |
| patients etanercept | #600 |
| statistically differences | #601 |
| health providers | #601 |
| 1093 | #601 |
| discretion | #601 |
| oral solution | #601 |
| patient decision | #601 |
| prevention measures | #602 |
| vte cancer | #602 |
| cfibers | #603 |
| cancer survivors | #604 |
| exposed patients | #604 |
| anthracycline based | #604 |
| toxicity profile | #605 |
| endoxifen | #607 |
| 16 women | #608 |
| toes | #608 |
| chemotherapy administration | #608 |
| agents antidepressive | #609 |
| iron supplementation | #609 |
| management symptoms | #609 |
| agents tricyclic | #611 |
| topic reproducibility | #612 |
| pilot | #613 |
| 2 95 | #613 |
| updated analysis | #614 |
| montanide | #615 |
| animal data | #616 |
| qol baseline | #616 |
| humans quality | #617 |
| 118 patients | #617 |
| commonly | #618 |
| appetite | #620 |
| antacid | #620 |
| aic | #621 |
| persistent symptoms | #621 |
| urinary frequency | #621 |
| follow median | #622 |
| itching | #625 |
| gangliosides humans | #626 |
| analyzable | #626 |
| cisplatin etoposide | #627 |
| life quality | #630 |
| 1 month | #631 |
| iii patients | #632 |
| authors knowledge | #633 |
| biological targets | #634 |
| mistletoe | #634 |
| month patients | #637 |
| female sexual function | #638 |
| assessment cancer | #640 |
| serum hepcidin | #640 |
| dose placebo | #640 |
| eligible | #641 |
| poorer quality | #642 |
| hormonal aromatase | #643 |
| inhibitors breast | #643 |
| prostatic intraepithelial | #644 |
| placebo time | #645 |
| multiple studies | #646 |
| palliative quality | #647 |
| nasal symptoms | #647 |
| malignant melanomas | #648 |
| 300 patients | #648 |
| syndrome acute | #649 |
| symptoms | #649 |
| sores | #651 |
| doses patients | #651 |
| flushes | #651 |
| method humans | #651 |
| appeared | #652 |
| opioid analgesic | #653 |
| limiting toxicity | #653 |
| dose limiting | #653 |
| patients 16 | #655 |
| poms | #657 |
| prior chemotherapy | #658 |
| complete response patients | #659 |
| grade glioma | #660 |
| twentysix patients | #661 |
| colorectal adenocarcinoma | #662 |
| patients chemotherapy | #662 |
| 62 months | #663 |
| 95 − | #665 |
| alternative treatments | #666 |
| neoplasms patient | #666 |
| cancer prospective | #666 |
| active agent | #666 |
| life radiotherapy | #667 |
| nonparametric surveys | #667 |
| levetiracetam | #668 |
| cancer treatments | #668 |
| treatment trials | #669 |
| women chemotherapy | #670 |
| paclitaxel docetaxel | #671 |
| marie tooth | #671 |
| p00004 | #674 |
| 1822 | #674 |
| axonopathy | #674 |
| pain adult | #674 |
| maintenance disorders | #675 |
| pharmacologic management | #675 |
| racially | #676 |
| induced cognitive | #676 |
| patients standard | #678 |
| 5 consecutive | #678 |
| controlled study | #679 |
| routine follow | #680 |
| reported outcome | #681 |
| diethylstilbestrol | #681 |
| purpose report | #682 |
| study samples | #684 |
| highdose melphalan | #685 |
| popularly | #685 |
| oncology practice | #685 |
| deprivation therapy | #686 |
| therapy cancer | #687 |
| fluorouracil leucovorin | #687 |
| charcot marie | #688 |
| practice settings | #688 |
| sulindac | #688 |
| neurologic injury | #688 |
| life survivors | #692 |
| pharmacological targeting | #692 |
| guideline update | #693 |
| rescue medication | #693 |
| administration schedule | #694 |
| phlebitis | #694 |
| randomized treatment | #695 |
| based testing | #698 |
| desmethyl | #699 |
| potential benefits | #699 |
| descriptive statistics | #700 |
| versa | #701 |
| appearing | #702 |
| postmenopausal | #704 |
| chemopreventive agent | #704 |
| v30 | #705 |
| medical oncologists | #706 |
| effective interventions | #707 |
| tens | #709 |
| locoregionally advanced | #710 |
| capecitabine patients | #711 |
| 160 | #712 |
| randomized studies | #712 |
| erythropoiesis stimulating | #712 |
| tube neoplasms | #714 |
| newer agents | #714 |
| prevention cancer | #715 |
| breast magnetic | #716 |
| lowmolecularweight heparin | #717 |
| inflammatory breast | #717 |
| convened | #719 |
| endorsement | #719 |
| ameliorate | #720 |
| data baseline | #722 |
| erythropoietin female | #722 |
| palliative medicine | #725 |
| cyclophosphamide methotrexate | #725 |
| 6 months 95 | #725 |
| humans neoplasms | #725 |
| therapeutic equivalency | #727 |
| 4 hours | #728 |
| physicians predictive | #728 |
| joint pain | #729 |
| patients radiation therapy | #730 |
| study treatment | #731 |
| induced human | #731 |
| odc activity | #731 |
| charcotmarietooth | #732 |
| women undergoing | #733 |
| nucleotide variants | #734 |
| medroxyprogesterone | #735 |
| vinca | #735 |
| adjuvant clinical | #736 |
| secondary prevention | #737 |
| chemotherapy women | #738 |
| induced neurotoxicity | #738 |
| opd | #739 |
| mirtazapine | #741 |
| prescribing practices | #742 |
| locoregional therapy | #742 |
| 4 weeks patients | #742 |
| fist | #744 |
| armamentarium | #745 |
| baseline 1 year | #745 |
| women placebo | #745 |
| patients breast | #747 |
| ecog | #748 |
| bone loss | #748 |
| trials patients | #749 |
| chemotherapy initiation | #749 |
| 271 | #750 |
| psychostimulant | #750 |
| superficial bladder cancer | #750 |
| alfa | #750 |
| rand | #752 |
| cervical dysplasia | #752 |
| compared placebo | #753 |
| complementary medicine | #753 |
| 4·2 | #754 |
| oct2 | #754 |
| antigen levels | #754 |
| radiation skin | #754 |
| 46 | #755 |
| trouble | #755 |
| secondary points | #755 |
| paclitaxel chemotherapy | #755 |
| patients insomnia | #756 |
| metastatic breast | #757 |
| hepcidin levels | #758 |
| local anesthetics | #759 |
| reduction pain | #759 |
| rifngamma | #759 |
| sulfasalazine | #760 |
| prostate adenocarcinoma | #760 |
| additional data | #762 |
| pain quality | #763 |
| ambulatory setting | #765 |
| seventy patients | #766 |
| 81 patients | #766 |
| occult blood | #766 |
| acid 4 | #768 |
| neoplasms prospective | #768 |
| medroxyprogesterone acetate mpa | #768 |
| humans imidazoles | #769 |
| baseline pain | #769 |
| actual | #770 |
| activity breast | #770 |
| sensory neuropathy | #771 |
| breast carcinoma ductal | #772 |
| modified radical mastectomy | #772 |
| sweating | #772 |
| relatedness | #772 |
| premenopausal women | #773 |
| primary endpoint | #773 |
| women enrolled | #773 |
| keratinocyte growth factor | #773 |
| emla | #774 |
| 10 day | #774 |
| patients colon | #774 |
| neoplasms breast | #774 |
| fifty patients | #774 |
| aged peripheral | #775 |
| acupuncture therapy | #776 |
| octreotide treatment | #776 |
| oral administration | #777 |
| 257 | #777 |
| charcot | #778 |
| p00002 | #778 |
| gsm | #778 |
| 137 patients | #781 |
| severity patients | #782 |
| menopausal symptoms | #783 |
| agents phytogenic | #784 |
| benefits patients | #785 |
| cutaneous administration | #785 |
| skin conductance | #785 |
| prognostic survival | #787 |
| enoxaparin | #788 |
| management | #788 |
| symptom experience | #791 |
| anesthetics local | #792 |
| subsequent cycles | #793 |
| women reported | #793 |
| colon rectal cancer | #796 |
| baseline period | #797 |
| estrogen levels | #798 |
| potential treatments | #798 |
| clinical questions | #801 |
| life outcomes | #801 |
| neuralgia pain | #801 |
| osteoporosis women | #802 |
| erythropoiesisstimulating agents | #802 |
| day 3 | #804 |
| randomized phase trial | #804 |
| lack efficacy | #804 |
| primary points | #805 |
| glutathione | #805 |
| effects patients | #806 |
| double | #806 |
| 894 | #807 |
| opioid analgesia | #807 |
| 80 antineoplastic | #808 |
| placebotreated patients | #808 |
| etoposide cisplatin | #808 |
| 3 day | #808 |
| continue | #808 |
| 0025 | #809 |
| complete response | #811 |
| abrogate | #812 |
| odc | #812 |
| previous reports | #816 |
| mild symptoms | #817 |
| disease genes | #818 |
| lorazepam | #819 |
| eastern cooperative | #820 |
| agents clinical | #820 |
| etoposide patients | #823 |
| randomly | #824 |
| statisticians | #826 |
| tolerated | #826 |
| 148 patients | #827 |
| cancer control | #828 |
| rasch model | #828 |
| administration oral | #830 |
| placebo 6 months | #830 |
| suggestive | #830 |
| cancer phase | #830 |
| dabrafenib | #832 |
| neoplasms bone | #832 |
| humans medical | #833 |
| subset analysis | #833 |
| similarities differences | #835 |
| advanced malignancies | #836 |
| 366 | #836 |
| mandelic | #837 |
| prognosis quality | #837 |
| numeric | #838 |
| eventual | #844 |
| breast neoplasms | #845 |
| herbal products | #846 |
| adverse events aes | #846 |
| p006 | #847 |
| global qol | #848 |
| 142 patients | #848 |
| detection rates | #849 |
| eortc | #850 |
| toxicities | #850 |
| taxol | #851 |
| prostate cancer patients | #852 |
| oncotype | #853 |
| stage ovarian | #853 |
| n55 | #853 |
| palliative services | #855 |
| daily dosing | #858 |
| taxoids | #859 |
| vaginal bleeding | #859 |
| assessment management | #859 |
| published data | #860 |
| stratification patients | #860 |
| strongest | #864 |
| etidronic | #866 |
| unacceptable | #868 |
| patients trial | #868 |
| placebo baseline | #868 |
| jellies | #873 |
| efficacious | #873 |
| peritoneal cancer | #874 |
| treatment completion | #875 |
| timepoints | #878 |
| 5ht3 | #879 |
| symptomatic women | #880 |
| phytogenic carcinoma | #880 |
| nonpharmacological interventions | #880 |
| midlife women | #881 |
| antineoplastic | #883 |
| study placebo | #883 |
| 450 | #883 |
| monoclonal antineoplastic agents | #885 |
| mitigates | #889 |
| neurotoxic | #889 |
| topic female | #890 |
| monoclonal female humans | #891 |
| data article | #892 |
| concomitant chemotherapy | #893 |
| cancer guidelines | #894 |
| caa | #894 |
| control arm | #896 |
| completed | #900 |
| neoplasms hormone | #901 |
| oxy | #901 |
| women hormone | #902 |
| nodal status | #903 |
| percent | #903 |
| inconvenience | #903 |
| nmsc | #904 |
| chemotherapy response | #905 |
| provided | #905 |
| 00006 | #905 |
| survival surgery | #905 |
| hospices | #909 |
| increased risk death | #910 |
| chemotherapeutic | #910 |
| cancer studies | #913 |
| weight maintenance | #914 |
| national cancer | #914 |
| norepinephrine reuptake | #915 |
| life cancer patients | #916 |
| paroxetine | #916 |
| gynecomastia | #918 |
| prospective pilot study | #919 |
| cycle chemotherapy | #920 |
| advanced cancer patients | #921 |
| mouth mucosa | #921 |
| evidence practice | #923 |
| population cohort | #924 |
| manuscripts | #924 |
| illness female humans | #925 |
| primary objectives | #926 |
| chemotherapy study | #927 |
| oral dosing | #929 |
| upper extremities | #929 |
| lasa | #930 |
| oncol | #931 |
| starting | #932 |
| fluoxetine | #933 |
| minocycline | #935 |
| cytotoxic therapy | #937 |
| day placebo | #938 |
| serotonin uptake | #939 |
| electronic health record | #939 |
| visual analogue | #940 |
| treatment symptoms | #940 |
| 138 patients | #942 |
| advanced adenoma | #943 |
| uptake inhibitors | #943 |
| high‐risk | #943 |
| letter editor | #944 |
| patient population | #944 |
| colorectal adenomas | #944 |
| beckman | #945 |
| iii topic | #945 |
| gp100 | #945 |
| 1year survival | #946 |
| fluorouracil | #948 |
| arm patients | #949 |
| natural menopause | #951 |
| recurrence score | #952 |
| compare | #953 |
| jci | #954 |
| orally | #954 |
| evaluating | #955 |
| participating centers | #955 |
| cooperative oncology | #957 |
| adjuvant therapies | #958 |
| rheumatologic | #958 |
| aloe vera | #958 |
| hfs | #958 |
| erythropoietic | #959 |
| leukopenia | #959 |
| moderately | #961 |
| monoclonal carcinoma | #962 |
| pjnk | #963 |
| trpm8 | #963 |
| received adjuvant | #964 |
| serum cytokine | #966 |
| menopause | #968 |
| 1160 | #969 |
| mart1 | #970 |
| earlystage disease | #972 |
| table | #972 |
| randomized pilot | #973 |
| gluconate | #976 |
| olmsted county | #977 |
| restarted | #977 |
| 1 10 | #978 |
| hypercalcemia | #978 |
| mechanical allodynia | #980 |
| 1month | #980 |
| 2700 | #982 |
| antidotes | #984 |
| 1 week | #984 |
| 150 | #984 |
| threequarters | #989 |
| patients venous | #989 |
| adjuvant | #992 |
| pain reduction | #993 |
| multiple logistic regression | #997 |
| analyses data | #998 |
| bother | #1003 |
| mayo | #1003 |
| cancer chemoprevention | #1005 |
| publication analgesics | #1007 |
| 71 | #1010 |
| continued | #1014 |
| patients metastatic disease | #1015 |
| organ systems | #1016 |
| neurocutaneous | #1018 |
| anthraquinones | #1019 |
| patients mri | #1020 |
| reported pain | #1021 |
| life symptoms | #1023 |
| trial participation | #1026 |
| 145 patients | #1027 |
| fatigue patients | #1028 |
| enteritis | #1028 |
| urogenital | #1030 |
| alternative treatment | #1031 |
| delayed treatment | #1031 |
| evidence treatment | #1037 |
| pill | #1037 |
| ” “ | #1038 |
| androgen deprivation therapy | #1042 |
| validity responsiveness | #1043 |
| postural control | #1044 |
| prx | #1044 |
| randomized trial patients | #1046 |
| patients safety | #1047 |
| colorectal tumor | #1047 |
| prevention intervention | #1047 |
| substantial | #1050 |
| frey | #1051 |
| nutritional supplementation | #1051 |
| 30 40 | #1053 |
| life | #1053 |
| postchemotherapy | #1056 |
| doxorubicin female humans | #1056 |
| minority | #1057 |
| osteoporosis treatment | #1059 |
| primary analysis | #1059 |
| feeding eating | #1059 |
| 10 weeks | #1060 |
| day study | #1061 |
| tricyclic | #1061 |
| prospective validation | #1063 |
| oncologist | #1063 |
| fruitful | #1063 |
| 347 | #1064 |
| endocrine resistance | #1064 |
| ongoing studies | #1066 |
| loss weight | #1066 |
| therapy | #1069 |
| disappointing | #1069 |
| suggested | #1069 |
| metastatic lung | #1070 |
| practical guidance | #1070 |
| descriptive | #1073 |
| tobacco dependence | #1075 |
| concurrent chemotherapy | #1078 |
| monoclonal humans | #1078 |
| nccn | #1078 |
| women treatment | #1079 |
| placebo day | #1080 |
| patients bone metastases | #1081 |
| women received | #1083 |
| advance planning | #1084 |
| placebo participants | #1085 |
| prompted | #1089 |
| breast cancer recurrence | #1089 |
| duloxetine | #1089 |
| patients adjuvant therapy | #1090 |
| low intermediate | #1091 |
| prospective multicenter study | #1092 |
| progestogens | #1094 |
| postoperative surveillance | #1095 |
| palonosetron | #1095 |
| adult breast | #1097 |
| 25 day | #1098 |
| favor | #1099 |
| intravenous iron | #1099 |
| agents treatment | #1100 |
| previous chemotherapy | #1100 |
| functional ability | #1100 |
| phytoestrogens | #1103 |
| 54 | #1103 |
| prospective trial | #1106 |
| peripheral neuropathies | #1108 |
| acknowledged | #1110 |
| 3 6 months | #1112 |
| transdermal | #1114 |
| randomized | #1115 |
| 1 year treatment | #1116 |
| prevention trials | #1119 |
| treatment life | #1121 |
| life death | #1122 |
| inhaler | #1124 |
| cancer trials | #1126 |
| interprofessional relations | #1126 |
| prilocaine | #1127 |
| unpleasant | #1127 |
| dmc | #1127 |
| based evidence | #1128 |
| mexiletine | #1129 |
| participants received | #1131 |
| patients versus | #1133 |
| clinician | #1133 |
| sunscreening | #1136 |
| lecithins | #1137 |
| 25 micrograms | #1139 |
| opioid therapy | #1139 |
| practice guideline | #1140 |
| hormonal therapy | #1140 |
| cancer | #1141 |
| inhibit | #1144 |
| purposeto | #1144 |
| randomized crossover | #1146 |
| cancer pain | #1146 |
| egb | #1146 |
| locoregionally | #1147 |
| illness surveys | #1148 |
| taste disorders | #1149 |
| premature ovarian failure | #1150 |
| shark | #1150 |
| purpose determine | #1150 |
| nervousness | #1153 |
| 730 | #1153 |
| detrimental | #1154 |
| hormonal | #1154 |
| smoking prevention | #1154 |
| flecainide | #1157 |
| 325 | #1159 |
| 481 | #1161 |
| rinse | #1162 |
| 22 | #1162 |
| doac | #1163 |
| educate | #1164 |
| toxicity assessment | #1167 |
| purposethis study | #1167 |
| comparative efficacy | #1172 |
| ceramides | #1173 |
| therapy estrogens | #1174 |
| painful | #1174 |
| intervention trials | #1175 |
| receptor modulators | #1176 |
| patients syndrome | #1177 |
| clinical trial | #1178 |
| inadequately | #1179 |
| projects | #1180 |
| lowest risk | #1181 |
| chemotherapy regimen | #1182 |
| chose | #1184 |
| aged prostatic | #1185 |
| growing population | #1186 |
| physician patient | #1187 |
| electrostimulation | #1188 |
| international consensus | #1189 |
| prior treatment | #1189 |
| mastectomy breast | #1190 |
| acetate treatment | #1190 |
| usage | #1193 |
| gained | #1196 |
| diary | #1197 |
| estrogen replacement therapy | #1197 |
| olmsted | #1197 |
| experiencing | #1198 |
| alternative therapies | #1200 |
| caregivers patients | #1202 |
| partial responses | #1204 |
| 552 | #1204 |
| male smokers | #1204 |
| panax | #1205 |
| clinical trials patients | #1207 |
| magnesium | #1208 |
| satisfied | #1212 |
| breast cancer | #1212 |
| induced skin | #1213 |
| patients pts | #1215 |
| 611 | #1215 |
| communication skills | #1215 |
| likert | #1217 |
| adjuvant endocrine | #1218 |
| sexuality | #1219 |
| precludes | #1219 |
| secondary endpoints | #1219 |
| 8 week | #1221 |
| phase clinical trial | #1223 |
| higher numbers | #1223 |
| limiting | #1224 |
| editor | #1227 |
| thighs | #1227 |
| participants reported | #1229 |
| organogel | #1230 |
| 8 weeks | #1232 |
| primary melanomas | #1232 |
| 52 | #1233 |
| n54 | #1234 |
| randomized phase | #1235 |
| discontinue | #1235 |
| tricyclic antidepressants | #1241 |
| clinical syndrome | #1241 |
| baseline values | #1245 |
| day 2 | #1248 |
| review data | #1248 |
| symptoms diagnosis | #1248 |
| decided | #1249 |
| female sexual | #1250 |
| etiologies | #1250 |
| bedtime | #1252 |
| postmenopausal women | #1252 |
| il1β tnfα | #1253 |
| estrogens female | #1255 |
| diarrhea patients | #1257 |
| diphosphonates | #1258 |
| thromboembolism patients | #1258 |
| combination docetaxel | #1258 |
| patients 4 | #1259 |
| hypochromic | #1259 |
| trametinib | #1259 |
| kidney dysfunction | #1260 |
| rasch | #1260 |
| pain medication | #1261 |
| doubts | #1263 |
| neurologic humans | #1263 |
| tumor promotion | #1265 |
| dna ploidy | #1265 |
| sae | #1266 |
| esophagitis | #1266 |
| protocols chemotherapy | #1268 |
| magnesium oxide | #1270 |
| phytotherapy | #1271 |
| qol scores | #1272 |
| drug double | #1272 |
| short form36 | #1273 |
| situ carcinoma ductal | #1273 |
| patients families | #1274 |
| preoperative chemotherapy | #1274 |
| preclude | #1276 |
| cutaneous melanomas | #1278 |
| tamoxifen patients | #1279 |
| taxanes | #1279 |
| median ttp | #1280 |
| dosing interval | #1281 |
| heparin lmwh | #1282 |
| label trial | #1284 |
| male medication adherence | #1285 |
| medical oncology | #1286 |
| adjuvant tamoxifen | #1287 |
| opposed | #1289 |
| cyclophosphamide doxorubicin | #1289 |
| adjuvant therapy patients | #1289 |
| folfox | #1291 |
| 109 patients | #1292 |
| cochran | #1294 |
| acupuncture treatment | #1294 |
| prevalence severity | #1296 |
| data clinical | #1296 |
| antimetabolites antineoplastic | #1297 |
| neurosensory | #1298 |
| neoplasms disease | #1300 |
| emetic | #1301 |
| women cancer | #1303 |
| 8 cycles | #1307 |
| abstinent | #1307 |
| stimulating agents | #1309 |
| survival 5 | #1310 |
| motion rom | #1310 |
| critical review | #1312 |
| sportdiscus | #1313 |
| gynecologic cancers | #1314 |
| gsh | #1315 |
| melanoma antigen | #1315 |
| biotech | #1315 |
| breast biopsy | #1317 |
| contacted | #1318 |
| durations | #1318 |
| etanercept | #1320 |
| health‐related quality | #1320 |
| oncology patients | #1321 |
| investigative | #1321 |
| controlled | #1321 |
| chemotherapeutic agents | #1321 |
| pain interference | #1322 |
| primary outcome measure | #1322 |
| patients quality | #1322 |
| ointments | #1323 |
| nerve damage | #1326 |
| appetite loss | #1327 |
| life scores | #1328 |
| patient physician | #1328 |
| agents colorectal | #1329 |
| cardiac toxicity | #1329 |
| life surveys | #1337 |
| adjuvant breast | #1339 |
| 375 | #1340 |
| published reports | #1341 |
| evenly | #1342 |
| 2 week | #1345 |
| ambulatory monitoring | #1346 |
| platinum compounds | #1347 |
| breast cancer women | #1347 |
| colonoscopic | #1350 |
| experienced | #1350 |
| tibolone | #1351 |
| karnofsky | #1352 |
| cancer experience | #1353 |
| benefit patients | #1353 |
| malignant ascites | #1354 |
| carcinoembryonic | #1356 |
| period patients | #1358 |
| eligibility criteria | #1359 |
| wks | #1360 |
| agents cancer | #1367 |
| effects treatment | #1368 |
| attribution | #1369 |
| postural balance | #1372 |
| continues | #1376 |
| combination female humans | #1377 |
| hopes | #1379 |
| titrated | #1381 |
| n29 | #1382 |
| patients colon cancer | #1382 |
| n32 | #1382 |
| duplicates | #1386 |
| mastectomy | #1387 |
| hydrazines | #1387 |
| snvs | #1388 |
| patients 40 | #1391 |
| femoral neck bmd | #1396 |
| medical literature | #1397 |
| ajcc | #1399 |
| cancer adult | #1400 |
| cancer therapies | #1403 |
| pain neuropathic | #1404 |
| somnolence | #1406 |
| rifn | #1407 |
| polyneuropathies | #1407 |
| replete | #1408 |
| physical activity level | #1410 |
| treats | #1411 |
| integrative medicine | #1412 |
| fisher test | #1415 |
| viscum | #1416 |
| wilcoxon | #1416 |
| combination chemotherapy | #1417 |
| cessation treatment | #1418 |
| quality life | #1420 |
| treatment recommendations | #1423 |
| sleep initiation | #1424 |
| subjective symptoms | #1424 |
| noncompliance | #1424 |
| biloba | #1425 |
| methodsdata | #1426 |
| therapy initiation | #1426 |
| prevent | #1427 |
| cancer quality life | #1427 |
| cytotoxic chemotherapy | #1428 |
| aromatase | #1431 |
| hormonal treatment | #1431 |
| and or | #1432 |
| weight heparin | #1433 |
| 5fu | #1433 |
| statistically difference | #1434 |
| radiation injuries | #1434 |
| daily intake | #1435 |
| primary objective | #1437 |
| caloric intake | #1439 |
| adults cancer | #1440 |
| female humans illness | #1442 |
| proctitis | #1445 |
| goserelin | #1445 |
| aminobutyric acid | #1446 |
| ehrs | #1447 |
| postacute | #1447 |
| cancer clinical trials | #1449 |
| incidences | #1449 |
| assigning | #1450 |
| coulter | #1453 |
| patients ovarian | #1454 |
| treatment pain | #1454 |
| nccn guidelines | #1454 |
| infliximab | #1455 |
| cognitive testing | #1456 |
| bruising | #1457 |
| hrqol | #1458 |
| 63 | #1459 |
| effective management | #1461 |
| dna testing | #1461 |
| individual patients | #1461 |
| adjuvant treatment | #1463 |
| life cancer | #1466 |
| aged quality | #1466 |
| network meta | #1467 |
| haloperidol humans | #1467 |
| discrepancies | #1467 |
| crossover | #1468 |
| nutritional support | #1469 |
| locally advanced head | #1469 |
| physical activity patients | #1470 |
| recurrent vte | #1475 |
| hormone dependent | #1477 |
| life treatment | #1477 |
| resultsa | #1479 |
| substantial proportion | #1479 |
| lower extremities | #1483 |
| tumor promoter | #1484 |
| oral aged | #1484 |
| pik3ca mutation | #1485 |
| aromatase inhibitors | #1492 |
| nrs | #1493 |
| cancer society | #1494 |
| ongoing | #1495 |
| systemic chemotherapy | #1498 |
| mood states | #1499 |
| planned | #1500 |
| resultsafter | #1501 |
| paclitaxel cisplatin | #1501 |
| mpa | #1509 |
| colon cancer patients | #1510 |
| anti anxiety | #1510 |
| gynecologic cancer | #1513 |
| perimenopause | #1513 |
| premalignant | #1514 |
| neuropeptide npy | #1518 |
| bowel function | #1520 |
| biweekly | #1523 |
| hair loss | #1523 |
| efficacy | #1523 |
| diagnosed cancer | #1525 |
| p0024 | #1525 |
| oncology | #1526 |
| root ganglion | #1526 |
| 3 weeks | #1528 |
| interfered | #1530 |
| balanced | #1532 |
| gastrointestinal toxicity | #1533 |
| cck8 | #1537 |
| cytotoxic agents | #1537 |
| survivors | #1538 |
| physical examination | #1542 |
| cycle patients | #1546 |
| warranted | #1548 |
| guideline recommendations | #1549 |
| tamoxifen treatment | #1550 |
| treatment induced | #1556 |
| adult cancer | #1560 |
| blind randomized | #1562 |
| male breast | #1562 |
| pounds | #1567 |
| transfusion requirements | #1568 |
| design considerations | #1569 |
| response rates | #1572 |
| or1 | #1574 |
| iii disease | #1576 |
| pharmacologic treatment | #1576 |
| 5 day | #1579 |
| bibliographies | #1580 |
| patients small | #1583 |
| rivaroxaban | #1583 |
| crushed | #1583 |
| rate survival | #1584 |
| vaginal | #1587 |
| prospective trials | #1588 |
| postmenopausal breast | #1589 |
| updates | #1590 |
| image body | #1593 |
| dissent | #1593 |
| phase iii study | #1595 |
| localized disease | #1599 |
| trpa1 | #1600 |
| stratification | #1600 |
| therapy cyclophosphamide | #1602 |
| completion | #1603 |
| aged cross | #1603 |
| advanced colorectal cancer | #1604 |
| disagreements | #1605 |
| modafinil | #1606 |
| allopurinol | #1608 |
| ≥70 | #1611 |
| bid | #1612 |
| dosing | #1619 |
| aged antineoplastic | #1620 |
| accrual | #1623 |
| oncology nursing | #1624 |
| 970 | #1624 |
| dna markers | #1626 |
| cream | #1627 |
| 176 | #1628 |
| prophylactic treatment | #1629 |
| tumor type | #1633 |
| 227 | #1634 |
| vte | #1636 |
| upfront | #1637 |
| potential channels | #1642 |
| respiratory depression | #1643 |
| combined modality therapy | #1649 |
| cardiovascular toxicity | #1650 |
| 49 | #1651 |
| controlled phase | #1652 |
| 2003 | #1652 |
| monthly | #1656 |
| cancer stage | #1660 |
| current treatment | #1661 |
| limited data | #1663 |
| pelvic radiotherapy | #1664 |
| referencing | #1666 |
| populationbased cohort | #1667 |
| breast cancer patients | #1667 |
| evaluation female | #1670 |
| treated breast | #1676 |
| patient preference | #1679 |
| therapy hrt | #1680 |
| ovid medline | #1682 |
| hb | #1683 |
| agents carcinoma | #1687 |
| blood tests | #1689 |
| publication attitude | #1691 |
| neoplasms practice | #1693 |
| anticancer therapy | #1693 |
| weight patients | #1694 |
| percent patients | #1695 |
| stopping | #1695 |
| ≤2 | #1696 |
| methyldopa | #1696 |
| patients bone | #1698 |
| nootropic | #1698 |
| randomization | #1698 |
| morpholines | #1700 |
| patients control | #1701 |
| symptom distress | #1701 |
| endpoint | #1703 |
| enrolled patients | #1705 |
| glutamine | #1705 |
| reported symptoms | #1706 |
| study groups | #1707 |
| chisquare | #1708 |
| chemotherapy patients | #1709 |
| 595 | #1709 |
| endocrine treatment | #1711 |
| incorrectly | #1714 |
| inhibitor therapy | #1715 |
| crossover study | #1716 |
| hyperalgesia male | #1717 |
| antineoplastic agents carcinoma | #1719 |
| interventions patients | #1720 |
| human epidermal | #1726 |
| effects cancer | #1726 |
| selective estrogen | #1728 |
| referral consultation | #1728 |
| testosterone treatment | #1729 |
| 652 | #1729 |
| nineteen | #1730 |
| orchiectomy | #1731 |
| neuropathic pain | #1731 |
| lmwh | #1738 |
| paucity | #1740 |
| life questionnaires | #1741 |
| topical | #1746 |
| p450 cyp2d6 | #1746 |
| oxcarbazepine | #1749 |
| ≥10 | #1749 |
| scores patients | #1751 |
| fifty | #1752 |
| recommendations patients | #1753 |
| neoplasms early | #1754 |
| unique challenges | #1754 |
| treatment data | #1762 |
| insufficient evidence | #1762 |
| greater reduction | #1762 |
| cramps | #1764 |
| fall risk | #1765 |
| massage | #1766 |
| grade 2 | #1766 |
| progression survival | #1770 |
| anticoagulants doacs | #1772 |
| urinary symptoms | #1775 |
| performance status | #1779 |
| clinical endpoints | #1781 |
| 95 0 | #1781 |
| fingers | #1784 |
| objective responses | #1784 |
| behavioral interventions | #1785 |
| lignans | #1785 |
| pros | #1787 |
| dizziness | #1789 |
| facts | #1790 |
| anorectic | #1791 |
| survival outcomes patients | #1791 |
| life assessment | #1791 |
| drug therapy | #1792 |
| rbc transfusion | #1794 |
| transient receptor | #1795 |
| alternative medicine | #1796 |
| primary therapy | #1796 |
| descriptive analysis | #1798 |
| decision aids | #1800 |
| investigator | #1802 |
| treatment cycles | #1803 |
| acetylcarnitine | #1803 |
| severe toxicity | #1804 |
| median survival time | #1804 |
| supporting | #1805 |
| premenopause | #1807 |
| adjunct | #1808 |
| analgesic efficacy | #1811 |
| topic | #1812 |
| agents female | #1813 |
| 16 patients | #1813 |
| breast surgery | #1816 |
| evidencebased recommendations | #1818 |
| trpm | #1818 |
| ql | #1821 |
| receptor potential | #1822 |
| cancer women | #1823 |
| 327 | #1823 |
| evaluable patients | #1825 |
| effective therapy | #1825 |
| anxiety agents | #1827 |
| humans neoplasm | #1831 |
| ganglion neurons | #1831 |
| longterm survival patients | #1835 |
| neoplasms prognosis | #1835 |
| suffering | #1836 |
| menopausal transition | #1837 |
| administration topical | #1849 |
| active cancer | #1850 |
| months 12 | #1851 |
| comprehensive cancer | #1851 |
| neuropathic | #1853 |
| 23 months | #1853 |
| patients prognosis | #1853 |
| dermatological | #1853 |
| providers patients | #1857 |
| cancer types | #1858 |
| aged postmenopause | #1858 |
| initial dose | #1858 |
| rationale design | #1863 |
| antimitotic | #1864 |
| univariate analyses | #1867 |
| antimetabolites | #1871 |
| humans pain | #1873 |
| europe female humans | #1873 |
| secondary objective | #1876 |
| continuing | #1877 |
| vice | #1878 |
| induced pain | #1879 |
| resultsa total | #1879 |
| musculoskeletal pain | #1881 |
| antigen colorectal | #1881 |
| analysis adult | #1881 |
| leucovorin male | #1886 |
| galvanic | #1887 |
| weeks | #1888 |
| 15 weeks | #1890 |
| keratinocyte | #1891 |
| schedules | #1891 |
| questionnaires time | #1891 |
| mainstay | #1892 |
| sexual functioning | #1893 |
| hospice | #1896 |
| triazoles | #1897 |
| sensory motor | #1898 |
| stellate | #1899 |
| problematic | #1899 |
| psqi | #1903 |
| topic surveys | #1910 |
| treatment modality | #1911 |
| neuropeptide | #1913 |
| evidence recommendations | #1918 |
| serum cortisol | #1922 |
| creams | #1924 |
| unwanted | #1928 |
| symptoms women | #1933 |
| pain | #1940 |
| health personnel attitude | #1946 |
| prematurely | #1946 |
| patients prostate cancer | #1949 |
| 5year followup | #1950 |
| treatment trial | #1951 |
| peritoneal neoplasms | #1952 |
| imidazoles | #1953 |
| cancer survivorship | #1955 |
| diagnosed breast | #1956 |
| cannabidiol | #1964 |
| signed | #1966 |
| nipple | #1969 |
| primary aim | #1971 |
| iii breast | #1971 |
| warrant | #1972 |
| surveillance colonoscopy | #1974 |
| articles | #1974 |
| initiating | #1975 |
| clinical patients | #1978 |
| estrogen replacement | #1978 |
| hand foot | #1979 |
| collaborative | #1982 |
| intravaginal | #1982 |
| dose melphalan | #1983 |
| controlled trial | #1985 |
| wasting syndrome | #1989 |
| cancer patient | #1994 |
| androgen antagonists | #1994 |
| current treatments | #2002 |
| stool samples | #2004 |
| patients dose | #2005 |
| effective therapies | #2011 |
| dose reductions | #2012 |
| gastrointestinal neoplasms | #2017 |
| form36 | #2018 |
| phytotherapy plant | #2018 |
| fallopian tube | #2019 |
| topic clinical trials | #2022 |
| steroidal aspirin | #2023 |
| critics | #2025 |
| perimenopausal | #2025 |
| neuromuscular diseases | #2026 |
| cardiotoxicity | #2029 |
| testing patients | #2031 |
| patients arm | #2032 |
| outpatient visits | #2034 |
| doses | #2036 |
| eortc qlqc30 | #2038 |
| transcutaneous | #2041 |
| exercise interventions | #2042 |
| recurrence survival | #2044 |
| dnr | #2045 |
| functional impairment | #2046 |
| breast cancer treatment | #2047 |
| status patients | #2056 |
| evidence base | #2056 |
| concentration time | #2058 |
| doxorubicin female | #2059 |
| 35 patients | #2063 |
| antibodies monoclonal antibodies | #2064 |
| head neck cancers | #2065 |
| chest | #2066 |
| cancer population | #2069 |
| relaxation therapy | #2069 |
| 120 patients | #2070 |
| contention | #2073 |
| inhibitor treatment | #2074 |
| daily | #2075 |
| hb level | #2075 |
| safety pharmacokinetics | #2075 |
| 50 reduction | #2076 |
| vinblastine | #2076 |
| nk1 | #2077 |
| benefit | #2080 |
| methysergide | #2081 |
| 20 day | #2082 |
| younger women | #2087 |
| iii | #2087 |
| patients caregivers | #2088 |
| antidote | #2090 |
| nursing practice | #2090 |
| advanced cancers | #2090 |
| cco | #2094 |
| major bleeding | #2094 |
| 66 years | #2097 |
| weekly paclitaxel | #2097 |
| anticonvulsants | #2102 |
| density bone | #2103 |
| mcg | #2104 |
| mitomycins | #2107 |
| therapy chemotherapy | #2109 |
| eicosapentaenoic acid | #2110 |
| tmt | #2111 |
| orally administered | #2111 |
| menopausal status | #2113 |
| day 1 | #2114 |
| 65 | #2115 |
| bmd lumbar spine | #2121 |
| ≥2 | #2121 |
| 5fluorouracil | #2122 |
| 96 patients | #2124 |
| treatment study | #2124 |
| journals | #2125 |
| mildly | #2126 |
| hb levels | #2126 |
| ttr | #2127 |
| bpi | #2128 |
| hormone concentrations | #2129 |
| hepcidins | #2130 |
| neoplasms clinical | #2133 |
| osteolytic | #2135 |
| concerned | #2136 |
| 525 | #2136 |
| egfr inhibitors | #2136 |
| secondary objectives | #2136 |
| aggressive disease | #2140 |
| qol | #2142 |
| levamisole | #2150 |
| tolerable | #2153 |
| carcinoembryonic antigen | #2154 |
| regimens | #2157 |
| item | #2158 |
| prt | #2160 |
| preventive strategies | #2161 |
| baseline | #2166 |
| evidence efficacy | #2166 |
| anemic | #2169 |
| treatment acute | #2169 |
| aloe | #2175 |
| women | #2177 |
| album | #2179 |
| worst | #2179 |
| pain syndromes | #2179 |
| tosyl | #2181 |
| physician | #2182 |
| detailed description | #2185 |
| fatigue pain | #2188 |
| 44 patients | #2195 |
| nervous | #2197 |
| severe symptoms | #2204 |
| questionnaires survivors | #2207 |
| 455 | #2208 |
| dose intensity | #2208 |
| age race | #2210 |
| prescription drugs | #2210 |
| female head | #2210 |
| 1 7 | #2212 |
| ensuing | #2213 |
| hypnosis | #2213 |
| weight loss | #2214 |
| 1–4 | #2220 |
| recurrences | #2220 |
| cmt | #2224 |
| adenosyl | #2225 |
| premenopausal | #2226 |
| myalgia | #2233 |
| 9 weeks | #2235 |
| osteonecrosis jaw | #2235 |
| 138 | #2242 |
| 60 minutes | #2243 |
| failed | #2247 |
| adrenal axis | #2247 |
| patient populations | #2251 |
| dermatologic | #2256 |
| life severity | #2257 |
| preliminary evidence | #2262 |
| summarized | #2265 |
| exercise female humans | #2266 |
| clinically meaningful | #2270 |
| patients metastatic melanoma | #2271 |
| 566 | #2272 |
| differences patients | #2273 |
| irritation | #2277 |
| bioelectrical impedance | #2284 |
| 1 year patients | #2285 |
| oophorectomy | #2285 |
| occult | #2288 |
| metastatic melanoma | #2290 |
| osteoporosis postmenopausal | #2291 |
| sloan | #2292 |
| gastrointestinal cancer | #2293 |
| likewise | #2298 |
| 800 | #2299 |
| therapy adt | #2301 |
| life illness | #2301 |
| regular | #2302 |
| dysfunction physiological | #2303 |
| incisional | #2308 |
| future trials | #2309 |
| polymerase inhibitors | #2310 |
| conclusionthe | #2310 |
| patch | #2311 |
| recommendation | #2311 |
| cramp | #2312 |
| genetic variations | #2314 |
| therapeutic strategies | #2320 |
| topic risk | #2326 |
| 74 | #2327 |
| baclofen | #2327 |
| weight breast | #2328 |
| worse | #2329 |
| 36 | #2333 |
| mastectomy segmental | #2333 |
| burning | #2333 |
| modest | #2334 |
| toxicity | #2334 |
| subcutaneously | #2335 |
| receptor positive | #2337 |
| exclusion criteria | #2338 |
| week | #2342 |
| opioid analgesics | #2347 |
| society | #2347 |
| improve quality | #2349 |
| androgen deprivation | #2349 |
| curve analysis | #2352 |
| 46 patients | #2352 |
| endorsed | #2357 |
| adult antineoplastic | #2359 |
| cyp2d6 | #2365 |
| density bmd | #2365 |
| increased risks | #2367 |
| baseline treatment | #2367 |
| nonrandomized | #2371 |
| 669 | #2373 |
| agent | #2374 |
| bibliometric | #2375 |
| rom | #2378 |
| health practice guidelines | #2379 |
| taste | #2389 |
| cancer clinical | #2390 |
| ornithine | #2391 |
| treatment duration | #2393 |
| difference 95 | #2396 |
| justification | #2397 |
| neoplasms survival | #2399 |
| neurological complications | #2400 |
| counteract | #2405 |
| 266 | #2405 |
| titles | #2406 |
| treatment baseline | #2407 |
| inadequate | #2407 |
| remaining patients | #2412 |
| postural | #2418 |
| rectal cancer patients | #2419 |
| poor performance | #2419 |
| ovid | #2420 |
| documenting | #2421 |
| 5 patients | #2425 |
| advanced prostate cancer | #2425 |
| symptom scores | #2426 |
| limited evidence | #2426 |
| debate | #2433 |
| 761 | #2436 |
| practiced | #2437 |
| 71 patients | #2437 |
| estrogen deficiency | #2439 |
| patients crc | #2439 |
| acupuncture | #2442 |
| response evaluation | #2442 |
| outpatient treatment | #2443 |
| phase trials | #2449 |
| 56 years | #2452 |
| chemotherapy adjuvant | #2453 |
| receptor antagonist | #2460 |
| common cancers | #2462 |
| iiic | #2463 |
| common adverse | #2464 |
| factor inhibitors | #2469 |
| assessment scale | #2469 |
| fallopian | #2474 |
| 207 | #2474 |
| patients quality life | #2477 |
| weight gain | #2478 |
| bleomycin | #2480 |
| guidelines patients | #2481 |
| practical approach | #2485 |
| network metaanalysis | #2491 |
| crossed | #2493 |
| approached | #2494 |
| melanomas | #2495 |
| raloxifene | #2496 |
| discontinuing | #2497 |
| 6 patients | #2502 |
| sexual function | #2507 |
| ginkgo | #2510 |
| locoregional | #2510 |
| 61 | #2510 |
| patients colorectal cancer | #2519 |
| children cancer | #2524 |
| topic clinical | #2526 |
| venous thromboembolism | #2527 |
| regimen | #2531 |
| cooperative | #2537 |
| amitriptyline | #2542 |
| asked | #2542 |
| radiation induced | #2544 |
| rescue | #2545 |
| 12 24 | #2556 |
| treatment methods | #2556 |
| carryover | #2557 |
| symptom | #2558 |
| galectin3 | #2562 |
| mandated | #2564 |
| randomised clinical trial | #2567 |
| telopeptide | #2567 |
| nitriles | #2568 |
| reuptake | #2570 |
| treatment selection | #2570 |
| stage small | #2573 |
| earlystage breast cancer | #2573 |
| conjunctivitis | #2574 |
| secondary analyses | #2592 |
| trials | #2592 |
| ideally | #2595 |
| carboplatin | #2597 |
| effects drugs | #2598 |
| 2 cycles | #2602 |
| erbb2 receptors | #2608 |
| parenteral | #2610 |
| arm | #2612 |
| pruritus | #2614 |
| patient education | #2617 |
| outcome united | #2624 |
| antineoplastic combined | #2624 |
| apr | #2626 |
| consented | #2626 |
| suspicious | #2627 |
| symptoms quality | #2629 |
| dorsal root | #2629 |
| life hrqol | #2631 |
| increased likelihood | #2639 |
| managing | #2642 |
| prefer | #2644 |
| remedy | #2648 |
| 55 | #2649 |
| races | #2657 |
| thromboembolism | #2657 |
| 0001 patients | #2657 |
| attenuate | #2662 |
| scores | #2663 |
| total parenteral nutrition | #2663 |
| lasted | #2667 |
| basal cell | #2670 |
| testosterone | #2672 |
| cancer outcomes | #2673 |
| imprecise | #2675 |
| comparable | #2676 |
| poorer survival | #2677 |
| symptoms treatment | #2685 |
| 817 | #2686 |
| prescribed | #2687 |
| prevention interventions | #2692 |
| statistically | #2696 |
| randomized controlled | #2699 |
| direct oral anticoagulants | #2701 |
| prevalence smoking | #2705 |
| impotence | #2707 |
| advanced colorectal | #2711 |
| data synthesis | #2713 |
| primary lung | #2717 |
| myelosuppression | #2724 |
| 1000 | #2735 |
| 01 | #2741 |
| chemotherapy protocols | #2745 |
| modestly | #2745 |
| thermal hyperalgesia | #2748 |
| multiple factors | #2749 |
| acp | #2749 |
| patients pain | #2750 |
| topic drug | #2752 |
| efficacies | #2753 |
| taxane | #2758 |
| advanced breast | #2760 |
| male medical | #2761 |
| ttf | #2762 |
| 250 | #2764 |
| neurotoxicity | #2769 |
| pyrazoles | #2774 |
| 1 4 | #2775 |
| male neoplasms | #2775 |
| 237 | #2776 |
| breast carcinoma | #2777 |
| convenience sample | #2780 |
| selfreport | #2781 |
| syndrome aged | #2788 |
| cryosurgery | #2789 |
| paraneoplastic syndromes | #2790 |
| pooled data | #2790 |
| neoplasia | #2791 |
| undergone | #2792 |
| adverse | #2793 |
| isoflavones | #2794 |
| ascites | #2794 |
| agents | #2797 |
| complete data | #2799 |
| thrice | #2801 |
| nv | #2801 |
| doacs | #2802 |
| acid epa | #2806 |
| cox model | #2812 |
| additional studies | #2813 |
| shortness | #2814 |
| continuous infusion | #2815 |
| preferred | #2817 |
| neurofeedback | #2823 |
| 750 | #2827 |
| breast | #2834 |
| sexual health | #2837 |
| muscle weakness | #2840 |
| 1 3 | #2842 |
| meeting | #2844 |
| opioids | #2844 |
| 38 | #2845 |
| primary outcomes | #2845 |
| cancer aged | #2854 |
| cohen | #2857 |
| n31 | #2857 |
| breakthrough | #2859 |
| linseed | #2859 |
| pharmacogenomic | #2860 |
| neoplasms | #2860 |
| sham | #2861 |
| statistical methods | #2866 |
| breaths | #2867 |
| activity level | #2867 |
| anticipate | #2869 |
| purposethe | #2869 |
| covariate | #2870 |
| fertility preservation | #2875 |
| surveillance patients | #2876 |
| 5 years patients | #2886 |
| task force | #2886 |
| ellipse | #2893 |
| survival dose | #2895 |
| p04 | #2895 |
| decarboxylase | #2912 |
| functional assessment | #2915 |
| endodermal | #2917 |
| packyears | #2918 |
| screening tests | #2920 |
| measurable | #2922 |
| p0002 | #2927 |
| placebo response | #2930 |
| prior | #2931 |
| condylomata | #2931 |
| phase clinical | #2933 |
| p008 | #2941 |
| topic design | #2945 |
| review articles | #2949 |
| identifier | #2949 |
| dosing regimens | #2949 |
| colonoscopy colorectal | #2951 |
| auc | #2954 |
| laser treatment | #2955 |
| utility | #2956 |
| week 12 | #2961 |
| 2 groups | #2962 |
| humans infusions | #2963 |
| hirsutism | #2966 |
| combined chemotherapy | #2969 |
| search terms | #2971 |
| curable | #2974 |
| chest wall | #2975 |
| intraepithelial neoplasia | #2977 |
| prophylactic | #2982 |
| placebo difference | #2983 |
| questionnaires | #2985 |
| eicosapentaenoic | #2986 |
| calculator | #2988 |
| testimony | #2989 |
| stopped | #2990 |
| calories | #2991 |
| started | #2991 |
| severity symptoms | #2995 |
| positive breast | #2998 |
| fatigue | #3000 |
| resected | #3004 |
| long acting | #3010 |
| objective response | #3012 |
| n5 | #3012 |
| topically | #3013 |
| discomfort | #3014 |
| time progression | #3014 |
| pathologic complete response | #3019 |
| patients 5 | #3022 |
| mianserin | #3026 |
| bone fractures | #3029 |
| ifosfamide | #3033 |
| nci | #3034 |
| skeletal muscle mass | #3038 |
| reuptake inhibitors | #3041 |
| her2 status | #3041 |
| dermatoses | #3042 |
| placebo week | #3052 |
| sided | #3053 |
| risk colorectal | #3058 |
| dukes | #3058 |
| relief | #3058 |
| tumor activity | #3066 |
| outcome measure | #3067 |
| curve auc | #3067 |
| 264 | #3068 |
| clonidine | #3069 |
| malignancy | #3071 |
| hyperhidrosis | #3072 |
| ctx | #3074 |
| sternal | #3076 |
| histograms | #3092 |
| sexual dysfunction | #3097 |
| nicotine dependence | #3098 |
| loss adult | #3099 |
| intergroup | #3103 |
| patients day | #3107 |
| tumor grade | #3108 |
| bmd | #3111 |
| vera | #3111 |
| cancer female humans | #3111 |
| 66 | #3116 |
| neurokinin1 | #3121 |
| 26 | #3121 |
| reversing | #3135 |
| cognitive dysfunction | #3139 |
| schedule | #3143 |
| 12 weeks | #3144 |
| treatment oral | #3146 |
| life measures | #3147 |
| clinical stage | #3150 |
| trpv1 | #3154 |
| infusions intravenous | #3155 |
| randomized controlled study | #3161 |
| χ2 | #3165 |
| subsequent development | #3166 |
| strongest association | #3168 |
| lifestyle factors | #3178 |
| phase 3 | #3180 |
| reasonable | #3181 |
| systematic literature search | #3183 |
| current approaches | #3185 |
| supportive | #3185 |
| leuprolide | #3186 |
| relevant articles | #3188 |
| 617 | #3189 |
| intravenous | #3190 |
| wore | #3192 |
| cannabinoids | #3193 |
| 64 | #3196 |
| podophyllotoxin | #3197 |
| abstracted | #3201 |
| menopausal | #3208 |
| case reports | #3210 |
| constellation | #3218 |
| 42 | #3222 |
| intervention trial | #3225 |
| joint committee | #3225 |
| nonsmallcell lung cancer | #3226 |
| 39 | #3226 |
| cochrane central register | #3231 |
| pain perception | #3235 |
| enrolled | #3238 |
| breathing | #3239 |
| medical record | #3240 |
| paraneoplastic | #3245 |
| therapy combination | #3260 |
| itch | #3260 |
| intervention patients | #3263 |
| oral mucosa | #3264 |
| designed | #3264 |
| 236 | #3266 |
| prior studies | #3269 |
| disagree | #3269 |
| treatment efficacy | #3270 |
| n30 | #3271 |
| 5 10 | #3272 |
| skin biopsies | #3278 |
| supplementary | #3279 |
| finished | #3282 |
| expert panel | #3284 |
| 2030 | #3287 |
| root ganglia | #3287 |
| 80 antibodies | #3288 |
| 695 | #3290 |
| lymphoma patients | #3290 |
| 885 | #3290 |
| previous analyses | #3291 |
| 576 | #3294 |
| understudied | #3296 |
| 0026 | #3303 |
| neuralgia | #3313 |
| suffer | #3314 |
| undertook | #3316 |
| resection colorectal | #3319 |
| impression | #3320 |
| treatment placebo | #3320 |
| electronic health | #3321 |
| chlorhexidine | #3322 |
| prostate cancer risk | #3328 |
| 171 | #3334 |
| acuminata | #3334 |
| risk vte | #3339 |
| systemically | #3350 |
| platinum based | #3352 |
| terminology | #3356 |
| erythema | #3358 |
| historic | #3360 |
| female breast | #3365 |
| breast prostate | #3368 |
| bone metastases | #3370 |
| doubt | #3370 |
| thirty | #3374 |
| preclinical studies | #3375 |
| relapse free | #3380 |
| chemoprevention | #3386 |
| acute chronic | #3392 |
| equivalency | #3395 |
| advanced prostate | #3396 |
| iii trials | #3399 |
| answers | #3400 |
| preceding | #3406 |
| oral | #3408 |
| lymph node excision | #3411 |
| prostatic neoplasms | #3415 |
| delaying | #3417 |
| anilides | #3418 |
| severity | #3422 |
| delineated | #3425 |
| axillary lymph | #3426 |
| administering | #3437 |
| npy | #3438 |
| higher scores | #3444 |
| screening methods | #3446 |
| 012 | #3446 |
| subsequent | #3452 |
| aminoquinolines | #3460 |
| utilizing | #3463 |
| 64 patients | #3463 |
| sprays | #3464 |
| survival benefits | #3468 |
| listed | #3468 |
| pts | #3468 |
| chemotherapy radiation | #3471 |
| anthracyclines | #3471 |
| multicenter randomized | #3473 |
| lidocaine | #3475 |
| lower rate | #3477 |
| mailed | #3479 |
| cross validation | #3480 |
| cessation smoking | #3481 |
| 3 6 | #3484 |
| attempt | #3489 |
| antidepressants | #3490 |
| intent | #3495 |
| reviewing | #3499 |
| ctc | #3500 |
| malignant disease | #3501 |
| — | #3505 |
| chemotherapeutic agent | #3512 |
| recommend | #3524 |
| allodynia | #3529 |
| carries | #3539 |
| metastatic disease | #3544 |
| points | #3545 |
| opiates | #3559 |
| stage breast | #3561 |
| 148 | #3565 |
| faced | #3566 |
| patients metastatic | #3574 |
| phase topic | #3583 |
| survival women | #3583 |
| correlational | #3583 |
| carboplatin paclitaxel | #3586 |
| 135 | #3586 |
| oestrogen | #3587 |
| chemotherapy cycles | #3588 |
| patients experiences | #3588 |
| treatment decisions | #3595 |
| 211 | #3596 |
| gold standard | #3607 |
| objective measures | #3608 |
| life qol | #3608 |
| periodically | #3610 |
| thiotepa | #3615 |
| stage iiia | #3618 |
| oral adult | #3619 |
| survival cancer | #3620 |
| ≥30 | #3620 |
| benefits risks | #3620 |
| therapeutic benefit | #3623 |
| improvement quality | #3629 |
| antacids | #3630 |
| 29 patients | #3631 |
| survivals | #3634 |
| racial differences | #3639 |
| complete responses | #3648 |
| patients adjuvant chemotherapy | #3650 |
| colon cancer | #3650 |
| ordinal | #3650 |
| adjuvant chemotherapy patients | #3652 |
| ≥18 years | #3655 |
| parp inhibitor | #3660 |
| bodymass | #3661 |
| 34 patients | #3666 |
| acid antagonists | #3674 |
| sigmoidoscopy | #3682 |
| 673 | #3682 |
| preceded | #3685 |
| 580 | #3686 |
| proportion | #3686 |
| aps | #3688 |
| thirty patients | #3689 |
| cardio | #3690 |
| chemotherapies | #3695 |
| redness | #3700 |
| moxibustion | #3702 |
| options | #3705 |
| electron rats | #3706 |
| relapsefree survival | #3707 |
| study evidence | #3708 |
| cancer chemotherapy | #3712 |
| annually | #3714 |
| instructed | #3716 |
| adjuvant chemotherapy | #3718 |
| 5000 | #3719 |
| exception | #3721 |
| 911 | #3725 |
| breast tissue | #3731 |
| impressive | #3738 |
| combination female | #3741 |
| foams | #3742 |
| randomized clinical trial | #3742 |
| practicing | #3743 |
| anabolic | #3746 |
| late effects | #3752 |
| lymphatic vessels | #3754 |
| weight status | #3758 |
| longterm survival | #3768 |
| menopausal women | #3774 |
| symptom severity | #3782 |
| vertigo | #3788 |
| adversely | #3789 |
| cancer drugs | #3795 |
| compassionate | #3800 |
| 567 | #3801 |
| hormone replacement therapy | #3804 |
| external beam | #3805 |
| sixth | #3806 |
| 600 | #3807 |
| terminal | #3811 |
| hormone replacement | #3811 |
| anesthetics | #3811 |
| colchicine | #3815 |
| phase trial | #3816 |
| centric | #3817 |
| etoposide | #3822 |
| pain control | #3825 |
| cancer prostate | #3830 |
| ploidies | #3831 |
| patients experienced | #3834 |
| intramuscularly | #3834 |
| 16 weeks | #3839 |
| 136 | #3839 |
| patients moderate | #3843 |
| cutaneous | #3846 |
| trpv | #3847 |
| contraindications | #3847 |
| blinding | #3854 |
| seventy | #3854 |
| sharks | #3855 |
| patients grade | #3855 |
| internally | #3858 |
| treatment metastatic | #3861 |
| 23 | #3861 |
| 04 | #3866 |
| futility | #3867 |
| 786 | #3875 |
| individually | #3880 |
| queried | #3882 |
| flushing | #3886 |
| midwestern | #3888 |
| adenomas | #3895 |
| compelling | #3897 |
| dfs survival | #3905 |
| modulators | #3906 |
| received chemotherapy | #3909 |
| sponsored | #3917 |
| bone turnover | #3919 |
| 24 weeks | #3921 |
| hyperactivation | #3922 |
| keywords | #3927 |
| vte patients | #3928 |
| therapies | #3933 |
| myoclonus | #3940 |
| publication clinical trials | #3940 |
| discontinued | #3942 |
| grade 1 | #3945 |
| 61 patients | #3947 |
| bf | #3950 |
| food drug administration | #3951 |
| difficulty | #3953 |
| colorectal | #3955 |
| inhibitors female | #3956 |
| prostate carcinoma | #3961 |
| capsaicin | #3969 |
| manifested | #3970 |
| study drug | #3973 |
| 25 | #3975 |
| accidental | #3976 |
| pain severity | #3977 |
| adenosine triphosphate | #3980 |
| pluronic | #3983 |
| 20 | #3988 |
| 30 years | #3991 |
| toxic effects | #3993 |
| 449 | #3994 |
| lasting | #4002 |
| weight | #4002 |
| 370 | #4004 |
| gait | #4005 |
| sideeffects | #4006 |
| 692 | #4008 |
| kras mutations | #4014 |
| surgery radiation | #4018 |
| estrogenic | #4023 |
| audio | #4034 |
| patients intervention | #4034 |
| year patients | #4039 |
| lumbar spine | #4044 |
| thirteen patients | #4047 |
| tid | #4052 |
| erythropoietin | #4062 |
| prostatic | #4062 |
| nonusers | #4066 |
| flax | #4068 |
| conjunction | #4069 |
| cancer therapy | #4069 |
| 516 | #4075 |
| intravenously | #4077 |
| extremities | #4084 |
| strong evidence | #4087 |
| meaningful | #4099 |
| revisions | #4102 |
| rose | #4108 |
| 2–4 | #4116 |
| iii study | #4120 |
| bone neoplasms | #4124 |
| dermatitis | #4125 |
| noninfiltrating | #4126 |
| favoring | #4126 |
| sphase | #4131 |
| documentation | #4132 |
| 7 months | #4134 |
| tablets | #4138 |
| topic practice patterns | #4138 |
| definitions | #4138 |
| malignant melanoma | #4139 |
| femoral neck | #4139 |
| 269 | #4143 |
| combination therapy | #4144 |
| mbc | #4157 |
| interleukin6 il6 | #4159 |
| 4 months | #4164 |
| 326 | #4175 |
| effective | #4194 |
| noxious | #4196 |
| 10 months | #4199 |
| calcium vitamin | #4201 |
| cancer bone | #4210 |
| depressants | #4210 |
| undertaken | #4211 |
| 2006 | #4220 |
| treatment option | #4223 |
| twothirds | #4232 |
| 18 months | #4236 |
| platinumbased chemotherapy | #4238 |
| drug response | #4250 |
| quinazolines | #4254 |
| anemia patients | #4256 |
| contraindication | #4258 |
| neoplasms colorectal | #4258 |
| serially | #4268 |
| treatment discontinuation | #4268 |
| cation channels | #4271 |
| 58 patients | #4278 |
| 2 4 | #4283 |
| bone density | #4284 |
| survival quality | #4284 |
| day | #4285 |
| utilized | #4289 |
| inconsistencies | #4289 |
| colorectal neoplasms | #4297 |
| rheumatism | #4301 |
| node negative | #4307 |
| aged breast | #4313 |
| bioavailable | #4314 |
| chemotherapy treatment | #4323 |
| reductions | #4326 |
| prednisolone | #4326 |
| vast | #4327 |
| bone diseases | #4330 |
| healthy women | #4331 |
| primary endpoints | #4331 |
| reply | #4340 |
| firstline chemotherapy | #4343 |
| treatment studies | #4355 |
| equally | #4357 |
| neoplasms combined | #4359 |
| institute | #4359 |
| participated | #4360 |
| detrimental effects | #4367 |
| outcome data | #4368 |
| 3 months | #4373 |
| sleeping | #4376 |
| discontinuation | #4381 |
| preliminary | #4385 |
| carcinoma ductal | #4389 |
| time surgery | #4393 |
| therapies patients | #4394 |
| judgment | #4395 |
| 12 week | #4396 |
| drug combinations | #4402 |
| repeatedly | #4402 |
| hyperalgesia | #4411 |
| grouping | #4414 |
| minnesota | #4415 |
| purpose | #4417 |
| “ | #4424 |
| evaluate | #4425 |
| 1015 | #4427 |
| 14 months | #4429 |
| balance | #4430 |
| studies colorectal | #4431 |
| 80 breast | #4431 |
| low doses | #4436 |
| drg neurons | #4437 |
| pain relief | #4438 |
| documented | #4440 |
| relevant studies | #4445 |
| day patients | #4446 |
| improve patient | #4446 |
| summarize | #4450 |
| clinical predictors | #4455 |
| clinical parameters | #4460 |
| humanized antineoplastic | #4464 |
| pain measurement | #4465 |
| 80 | #4465 |
| fecal | #4466 |
| clinical practice guidelines | #4490 |
| 05 | #4494 |
| risk breast cancer | #4499 |
| humans lymph | #4501 |
| received | #4504 |
| drug administration | #4505 |
| stimulants | #4510 |
| axillary | #4521 |
| daily activities | #4523 |
| 5 | #4523 |
| sedation | #4529 |
| ganglion | #4530 |
| gynecologic | #4530 |
| ductal breast | #4530 |
| disease recurrence | #4531 |
| cancer methods | #4534 |
| hematology | #4535 |
| stimulant | #4536 |
| disabling | #4536 |
| natural | #4537 |
| sphingolipids | #4537 |
| diarrhea | #4540 |
| drug effects | #4540 |
| journal | #4544 |
| impairments | #4546 |
| 3 4 | #4550 |
| ganglia spinal | #4552 |
| continuation | #4558 |
| outcome measures | #4561 |
| financial | #4562 |
| rescue therapy | #4564 |
| clinical | #4564 |
| 376 | #4567 |
| rbc | #4569 |
| reliability validity | #4575 |
| 4 | #4575 |
| successes | #4577 |
| single blind | #4583 |
| tumor regression | #4587 |
| explore | #4588 |
| risk bleeding | #4591 |
| hydroxytryptamine | #4591 |
| mmf | #4592 |
| cumulative | #4604 |
| tenderness | #4606 |
| 115 | #4609 |
| longer duration | #4612 |
| chemopreventive | #4617 |
| emphasizes | #4620 |
| neoplasms dna | #4626 |
| throat | #4633 |
| caf | #4636 |
| patients increase | #4642 |
| daily dose | #4647 |
| neuropathies | #4647 |
| 6 12 | #4647 |
| tumor recurrence | #4653 |
| 1 study | #4661 |
| data studies | #4662 |
| 96 | #4664 |
| dose chemotherapy | #4665 |
| adpribose | #4665 |
| increased incidence | #4669 |
| treatments | #4674 |
| qol patients | #4679 |
| vitality | #4683 |
| peaked | #4684 |
| hazards | #4689 |
| deprivation | #4691 |
| 29 | #4693 |
| secondary analysis | #4699 |
| treatment survival | #4701 |
| dose | #4704 |
| low dose | #4708 |
| dose reduction | #4712 |
| reference lists | #4722 |
| preliminary study | #4733 |
| mediastinum | #4734 |
| ” | #4734 |
| assessment tool | #4740 |
| phase 2 trial | #4741 |
| vigor | #4751 |
| percentage patients | #4752 |
| cgy | #4762 |
| efficacy tolerability | #4773 |
| analysis neoplasm | #4783 |
| recommended | #4785 |
| adt | #4790 |
| invasive breast cancer | #4792 |
| 353 | #4795 |
| proven | #4798 |
| 009 | #4806 |
| corticosteroid | #4806 |
| 538 | #4810 |
| tears | #4810 |
| evaluations | #4813 |
| circulating concentrations | #4817 |
| improved quality | #4818 |
| cancer compared | #4818 |
| acetylcysteine | #4821 |
| capecitabine | #4829 |
| musculoskeletal | #4830 |
| multicenter | #4836 |
| symptom burden | #4836 |
| bridged | #4837 |
| carcinoma small | #4837 |
| tubulin | #4841 |
| seer program | #4841 |
| aes | #4846 |
| 60 | #4848 |
| 55 patients | #4854 |
| receipt | #4857 |
| 381 | #4861 |
| patients recurrence | #4868 |
| patients prostate | #4870 |
| individual patient data | #4876 |
| amines | #4886 |
| neck neoplasms humans | #4890 |
| 048 | #4901 |
| receptor egfr | #4904 |
| fisher | #4910 |
| crc patients | #4911 |
| lastly | #4917 |
| systemic therapy | #4921 |
| harms | #4922 |
| platinum | #4924 |
| stage iiib | #4925 |
| abstinence | #4926 |
| unfavorable | #4927 |
| existed | #4928 |
| basal cell carcinoma | #4933 |
| ≥1 | #4937 |
| 727 | #4942 |
| coadministration | #4946 |
| screening tool | #4956 |
| sensitization | #4956 |
| 9 months | #4960 |
| plethora | #4970 |
| subsequently | #4974 |
| eligibility | #4975 |
| equivocal | #4980 |
| cancer background | #4981 |
| optimal management | #4983 |
| depot | #4989 |
| deep vein thrombosis | #4992 |
| cumulative dose | #4996 |
| recurrence free | #4997 |
| exercise intervention | #5003 |
| lessons | #5005 |
| metastatic prostate | #5016 |
| situ carcinoma | #5017 |
| based cohort | #5018 |
| combined treatment | #5027 |
| routine clinical | #5028 |
| biphasic | #5029 |
| multicenter trial | #5039 |
| initiate | #5045 |
| sedative | #5055 |
| actively | #5058 |
| missing data | #5060 |
| favorably | #5071 |
| osteoporosis | #5073 |
| physical symptoms | #5075 |
| 3 trials | #5076 |
| methotrexate | #5077 |
| genistein | #5084 |
| karnofsky performance | #5084 |
| study incidence | #5086 |
| phenobarbital | #5091 |
| 100 patients | #5098 |
| 342 | #5099 |
| pyrimidinones | #5104 |
| version | #5104 |
| bortezomib | #5105 |
| cisplatin treatment | #5106 |
| published | #5116 |
| skin neoplasms | #5121 |
| ntprobnp | #5124 |
| conventional chemotherapy | #5126 |
| physical therapy | #5131 |
| reducing | #5131 |
| 120 | #5141 |
| topical application | #5142 |
| indomethacin | #5143 |
| medicine humans | #5149 |
| higher rate | #5154 |
| women early | #5155 |
| lower rates | #5157 |
| bisphosphonates | #5165 |
| resolve | #5169 |
| prognostic | #5176 |
| analysis randomized | #5177 |
| compiled | #5181 |
| cycle | #5186 |
| antiinflammatory agents | #5187 |
| supplement | #5201 |
| thalidomide | #5207 |
| 30 patients | #5214 |
| references | #5218 |
| cisplatin | #5225 |
| april | #5231 |
| medications | #5239 |
| dying | #5243 |
| identical | #5243 |
| randomised controlled trial | #5244 |
| humans lung | #5249 |
| article | #5249 |
| insomnia | #5255 |
| conventionally | #5257 |
| patients time | #5257 |
| mitoxantrone | #5265 |
| progestins | #5266 |
| resectable | #5269 |
| caring | #5270 |
| low molecular | #5270 |
| negative impact | #5277 |
| health disparities | #5278 |
| sed | #5291 |
| undergo | #5306 |
| gynecology | #5309 |
| parenteral nutrition | #5310 |
| vaporizers | #5317 |
| cancer prevention | #5319 |
| conflicting | #5325 |
| pelvic | #5326 |
| ineligible | #5327 |
| 404 | #5333 |
| anticipated | #5335 |
| alkaloids | #5335 |
| administered | #5339 |
| methods design | #5344 |
| patient data | #5349 |
| monophenol | #5351 |
| sensation | #5359 |
| perceived | #5359 |
| current practice | #5361 |
| colorectal cancers | #5362 |
| answered | #5376 |
| neurologists | #5377 |
| 346 | #5385 |
| adenosylmethionine | #5393 |
| isotretinoin | #5394 |
| declining | #5396 |
| judged | #5403 |
| responding | #5412 |
| study women | #5421 |
| stage iii | #5423 |
| officinalis | #5423 |
| 33 | #5425 |
| colonic polyps | #5444 |
| axilla | #5468 |
| 57 | #5470 |
| manner | #5473 |
| p0006 | #5481 |
| minutes | #5482 |
| baseline characteristics | #5486 |
| health records | #5490 |
| pufas | #5492 |
| based interventions | #5496 |
| 167 | #5504 |
| preclinical models | #5506 |
| methylases | #5508 |
| ovary | #5512 |
| thromboembolic events | #5518 |
| patient demographics | #5521 |
| neoplasms humans | #5525 |
| 410 | #5535 |
| pooled | #5548 |
| medical conditions | #5556 |
| 03 | #5571 |
| cancer center | #5573 |
| ready | #5580 |
| acne | #5582 |
| routine clinical practice | #5583 |
| stage patients | #5590 |
| dropped | #5593 |
| 002 | #5594 |
| current literature | #5598 |
| patient quality | #5604 |
| woman | #5605 |
| 41 | #5611 |
| polyps | #5620 |
| carnitine | #5623 |
| enteral | #5633 |
| sensory | #5638 |
| treatment approaches | #5638 |
| new therapies | #5642 |
| lung carcinoma | #5642 |
| 0007 | #5648 |
| concurrent | #5672 |
| treatment regimens | #5676 |
| guideline | #5679 |
| constipation | #5683 |
| sf36 | #5684 |
| n6 | #5687 |
| standard chemotherapy | #5688 |
| neuromodulation | #5689 |
| 50 | #5693 |
| renewed | #5694 |
| dexamethasone | #5694 |
| desire | #5695 |
| preserve | #5696 |
| online | #5699 |
| patients therapy | #5701 |
| nonsignificant | #5703 |
| multiplied | #5704 |
| raise | #5705 |
| cancer type | #5708 |
| androgen | #5716 |
| trials rcts | #5722 |
| complete | #5730 |
| specialist | #5730 |
| dna content | #5733 |
| serial | #5736 |
| provider | #5761 |
| interruption | #5762 |
| tumor stage | #5762 |
| tumor breast | #5762 |
| total score | #5766 |
| impair | #5770 |
| versus | #5773 |
| chance | #5779 |
| carcinoma situ | #5783 |
| nicotine | #5783 |
| mucous | #5783 |
| exploratory study | #5790 |
| node excision | #5795 |
| 345 | #5805 |
| higher doses | #5806 |
| 395 | #5814 |
| vitamin | #5817 |
| systemic effects | #5827 |
| patients aspirin | #5828 |
| patient experience | #5830 |
| 4 5 | #5837 |
| cancer breast | #5842 |
| leukocyte count | #5850 |
| intermediate risk | #5852 |
| selfreported | #5855 |
| patients survival | #5857 |
| stools | #5858 |
| subgroups patients | #5873 |
| 405 | #5877 |
| interfere | #5877 |
| excitatory amino | #5883 |
| enrollment | #5886 |
| neoplasm recurrence | #5887 |
| exercises | #5888 |
| totally | #5898 |
| response relationship | #5899 |
| potential mechanisms | #5909 |
| 3 | #5910 |
| 0 1 | #5917 |
| trastuzumab | #5925 |
| alternating | #5926 |
| gel | #5930 |
| acids omega3 | #5935 |
| humans injections | #5940 |
| pooled analysis | #5946 |
| dysplastic | #5947 |
| questionnaires adult | #5952 |
| treatment toxicity | #5954 |
| previous | #5955 |
| treatment failure | #5964 |
| symptoms depression | #5967 |
| returned | #5979 |
| confounding | #5990 |
| analogue | #5995 |
| devoted | #5996 |
| 239 | #5997 |
| evaluation studies | #5997 |
| icd9 | #6000 |
| sectional survey | #6002 |
| validated | #6007 |
| serum patients | #6010 |
| insulinlike growth factor | #6013 |
| 1977 | #6013 |
| prognostic indicator | #6018 |
| descriptions | #6019 |
| minute | #6019 |
| worsened | #6026 |
| sentinel node | #6028 |
| 0013 | #6041 |
| chemotherapy radiotherapy | #6041 |
| grade 3 | #6042 |
| 243 | #6045 |
| new evidence | #6049 |
| month | #6052 |
| institutional | #6061 |
| syndrome | #6065 |
| protective agents | #6066 |
| caution | #6067 |
| stool | #6070 |
| 480 | #6082 |
| subscales | #6083 |
| approved | #6097 |
| aspect | #6098 |
| 20 years | #6102 |
| 43 | #6104 |
| hormone therapy | #6108 |
| increment | #6109 |
| tests prognosis | #6116 |
| spitzer | #6118 |
| conducted | #6120 |
| randomized controlled trial | #6125 |
| routes | #6128 |
| surviving | #6156 |
| antiepileptic | #6164 |
| kilogram | #6167 |
| endpoints | #6173 |
| inception | #6184 |
| skin diseases | #6188 |
| 241 | #6189 |
| omega3 | #6193 |
| selective serotonin | #6195 |
| boronic | #6199 |
| intraepithelial | #6204 |
| 16 | #6215 |
| 900 | #6218 |
| female | #6221 |
| central venous | #6229 |
| combination treatment | #6232 |
| 62 | #6234 |
| epa | #6239 |
| randomized clinical trials | #6242 |
| invasive breast | #6249 |
| patients colorectal | #6253 |
| treated mice | #6255 |
| exploratory | #6257 |
| 58 | #6258 |
| asymptomatic patients | #6260 |
| metastasis neoplasm | #6261 |
| receptors progesterone | #6265 |
| historically | #6269 |
| palliative | #6270 |
| protocols | #6275 |
| psychotropic drugs | #6280 |
| disclosure | #6280 |
| ease | #6282 |
| 2000 | #6283 |
| xerostomia | #6284 |
| followup patients | #6293 |
| innovations | #6299 |
| scopus | #6300 |
| insignificant | #6302 |
| benzhydryl | #6302 |
| survival female | #6312 |
| 328 | #6314 |
| chi2 | #6320 |
| prospective | #6330 |
| lobular | #6343 |
| counseling | #6344 |
| 59 | #6346 |
| rigorous | #6347 |
| clinically | #6350 |
| endocrine therapy | #6365 |
| fentanyl | #6372 |
| aged | #6372 |
| 2007 | #6385 |
| venous thromboembolism vte | #6385 |
| infusions | #6393 |
| epidermal growth | #6393 |
| breadth | #6395 |
| physicians | #6402 |
| cronbach | #6404 |
| narcotic | #6407 |
| vitro model | #6413 |
| early intervention | #6424 |
| sexes | #6425 |
| initial treatment | #6426 |
| endocrinology | #6432 |
| 2 3 | #6433 |
| pittsburgh | #6439 |
| psychotropic | #6439 |
| entire | #6440 |
| multinational | #6440 |
| 361 | #6445 |
| counts | #6446 |
| soybeans | #6449 |
| sex hormones | #6452 |
| logs | #6453 |
| congeners | #6455 |
| quality | #6458 |
| termed | #6470 |
| 75 | #6471 |
| intraluminal | #6471 |
| life health | #6478 |
| n16 | #6481 |
| treatment guidelines | #6482 |
| patients 2 | #6485 |
| time diagnosis | #6486 |
| mcf7 cells | #6496 |
| records | #6498 |
| abcb1 | #6499 |
| ≥18 | #6501 |
| usual patients | #6512 |
| disease stage | #6515 |
| adenoma | #6520 |
| complementary | #6521 |
| consultation | #6524 |
| guidance | #6531 |
| iu | #6533 |
| ranked | #6536 |
| developments | #6540 |
| transfusions | #6551 |
| 004 | #6552 |
| tumor location | #6554 |
| 86 | #6567 |
| 0004 | #6575 |
| analog | #6576 |
| 53 | #6591 |
| abstracts | #6593 |
| baseline patients | #6598 |
| initiated | #6602 |
| acting | #6604 |
| colonic neoplasms | #6605 |
| pyrazines | #6608 |
| hemoglobins | #6612 |
| l3 | #6612 |
| decisions | #6614 |
| 287 | #6614 |
| fourth | #6615 |
| phase | #6617 |
| 02 | #6618 |
| surveys questionnaires | #6621 |
| hrt | #6622 |
| curative resection | #6623 |
| familiar | #6641 |
| guidelines | #6646 |
| pellet | #6646 |
| crf | #6648 |
| hormone receptor | #6651 |
| patients health | #6651 |
| courses | #6664 |
| randomized controlled trials | #6666 |
| emerging evidence | #6681 |
| osseous | #6682 |
| physical health | #6683 |
| tools | #6685 |
| figure | #6689 |
| dex | #6691 |
| erectile dysfunction | #6694 |
| caloric | #6694 |
| develops | #6696 |
| neoplasm metastasis | #6699 |
| hypothesized | #6702 |
| radiotherapy chemotherapy | #6702 |
| ketamine | #6710 |
| consecutive | #6717 |
| colorectal cancer patients | #6717 |
| interprofessional | #6728 |
| detailed | #6731 |
| testicular cancer | #6743 |
| score | #6745 |
| 295 | #6750 |
| replacement therapy | #6751 |
| quit | #6751 |
| difference | #6763 |
| grade | #6770 |
| lower incidence | #6773 |
| true | #6776 |
| ocular | #6783 |
| prevents | #6784 |
| titration | #6787 |
| pain management | #6793 |
| search strategy | #6801 |
| frequently | #6801 |
| longest | #6801 |
| chart review | #6802 |
| rounds | #6804 |
| 344 | #6806 |
| hepcidin | #6809 |
| fulfilled | #6810 |
| controlled studies | #6810 |
| participating | #6811 |
| mice treated | #6818 |
| detect | #6826 |
| ovarian function | #6841 |
| treatment advanced | #6842 |
| integrative | #6851 |
| early treatment | #6853 |
| exercise therapy | #6861 |
| classification | #6874 |
| inventory | #6877 |
| narrative | #6879 |
| drg | #6883 |
| routinely | #6887 |
| new drugs | #6889 |
| secondary | #6891 |
| concerns | #6896 |
| strength muscle | #6898 |
| differ | #6903 |
| 277 | #6904 |
| serum concentrations | #6912 |
| tumor formation | #6917 |
| 5 ht | #6918 |
| controversial | #6930 |
| summarizes | #6932 |
| mass loss | #6941 |
| factors breast | #6942 |
| cbd | #6942 |
| iiib | #6944 |
| laparotomy | #6953 |
| diarrhoea | #6955 |
| tartrate | #6960 |
| quarter | #6970 |
| skin temperature | #6981 |
| regressions | #6981 |
| ais | #6986 |
| quiet | #6990 |
| calorie | #6990 |
| wearing | #6990 |
| definition | #6994 |
| 35 | #6994 |
| seer | #7001 |
| promise | #7002 |
| patients developed | #7006 |
| 1 year | #7011 |
| initially | #7015 |
| women study | #7019 |
| hemorrhage humans | #7020 |
| breast cancers | #7030 |
| 051 | #7045 |
| metaanalyses | #7049 |
| animal doseresponse relationship | #7050 |
| neoplasms risk | #7063 |
| patients 1 | #7067 |
| interested | #7067 |
| 50 patients | #7068 |
| 31 | #7083 |
| screening middle | #7089 |
| total | #7097 |
| overview | #7098 |
| asian patients | #7111 |
| neu | #7113 |
| approval | #7114 |
| 97 | #7121 |
| neoplasms treatment | #7122 |
| polyadp | #7124 |
| prostate cancer | #7130 |
| neoplasms female | #7130 |
| 261 | #7131 |
| female gastrointestinal | #7143 |
| strengthened | #7144 |
| neuroprotection | #7147 |
| 833 | #7154 |
| therapy humans | #7165 |
| estrogens | #7171 |
| appropriateness | #7179 |
| breast cancer risk | #7187 |
| expect | #7188 |
| pik3ca | #7201 |
| confirm | #7211 |
| uncontrolled | #7220 |
| estrogen | #7228 |
| entity | #7234 |
| discusses | #7238 |
| agents steroidal | #7255 |
| 203 | #7262 |
| questionnaire | #7264 |
| ameliorates | #7264 |
| chosen | #7266 |
| popularity | #7283 |
| additionally | #7295 |
| neoplasms primary | #7296 |
| outpatients | #7296 |
| cinahl | #7333 |
| node biopsy | #7334 |
| increased survival | #7336 |
| 10 | #7340 |
| aged anti | #7343 |
| stages | #7347 |
| superficial | #7353 |
| evaluates | #7353 |
| radiotherapy adjuvant | #7358 |
| prognosis prospective | #7361 |
| firstline therapy | #7376 |
| epo | #7378 |
| eating | #7379 |
| short | #7384 |
| square distribution | #7390 |
| 47 | #7393 |
| noradrenergic | #7407 |
| curative | #7416 |
| rfs | #7416 |
| esr1 | #7417 |
| radiotherapy | #7433 |
| genital | #7435 |
| receptor agonists | #7436 |
| confirmatory | #7436 |
| emphasis | #7436 |
| naphthalenes | #7437 |
| cancer treated | #7438 |
| established | #7449 |
| 25 patients | #7456 |
| clinical evaluation | #7467 |
| 199 | #7478 |
| 1st | #7482 |
| 058 | #7484 |
| wasting | #7488 |
| prognosis proportional | #7488 |
| treatment strategy | #7489 |
| bolus | #7496 |
| genetic factors | #7499 |
| metastatic colorectal | #7501 |
| gonadotropin | #7504 |
| 259 | #7507 |
| november | #7509 |
| dysplasia | #7523 |
| transaminases | #7524 |
| objectively | #7526 |
| melanoma patients | #7528 |
| cancer vaccines | #7531 |
| infertility | #7534 |
| investigators | #7534 |
| october | #7539 |
| tumor colorectal | #7541 |
| local neoplasm | #7543 |
| 315 | #7558 |
| primary treatment | #7559 |
| adequacy | #7564 |
| concurrently | #7578 |
| kaplanmeier method | #7583 |
| intraductal | #7586 |
| 00001 | #7589 |
| patients head | #7594 |
| grades | #7605 |
| single dose | #7607 |
| tretinoin | #7608 |
| discussions | #7609 |
| chronic pain | #7615 |
| coumarins | #7616 |
| gain | #7620 |
| opinions | #7621 |
| ploidy | #7624 |
| interval | #7624 |
| receptor antagonists | #7632 |
| receptor erbb2 | #7633 |
| pharmacists | #7641 |
| local neoplasms | #7642 |
| sequelae | #7645 |
| metastatic colorectal cancer | #7656 |
| clinical benefit | #7666 |
| retinoids | #7678 |
| corticosteroids | #7684 |
| visits | #7691 |
| longterm effects | #7695 |
| evident | #7696 |
| 1 day | #7699 |
| monitored | #7699 |
| 026 | #7710 |
| publication biomarkers | #7713 |
| 021 | #7725 |
| surveys | #7725 |
| recurrence | #7726 |
| risk breast | #7728 |
| thrombophilia | #7734 |
| washout | #7744 |
| administration | #7744 |
| onethird | #7749 |
| nicotinic | #7751 |
| rank | #7758 |
| cancer recurrence | #7763 |
| independent predictors | #7776 |
| omega3 fatty | #7779 |
| treatment time | #7780 |
| serotonergic | #7785 |
| pathophysiology | #7796 |
| negative effects | #7805 |
| 14 | #7807 |
| ovarian neoplasms | #7811 |
| erectile | #7812 |
| clinicians | #7820 |
| gonadal | #7839 |
| 12 months | #7842 |
| swallowing | #7843 |
| subcutaneous | #7855 |
| pain intensity | #7856 |
| patient centered | #7866 |
| thiophenes | #7869 |
| 0 | #7876 |
| hemoglobins humans | #7892 |
| statistic | #7900 |
| physical function | #7917 |
| impacted | #7927 |
| ago | #7927 |
| 40 | #7933 |
| dysfunctions | #7950 |
| androgens | #7955 |
| comparing | #7956 |
| 5year survival | #7956 |
| advanced | #7957 |
| generally | #7963 |
| 305 | #7965 |
| ductal carcinoma | #7968 |
| ≤ | #7972 |
| actuarial | #7973 |
| 055 | #7975 |
| individualized | #7981 |
| collect | #7982 |
| situation | #7983 |
| female genital | #7985 |
| 062 | #8006 |
| 278 | #8020 |
| noninferiority | #8032 |
| powered | #8051 |
| preclinical | #8062 |
| genders | #8063 |
| intractable | #8063 |
| colorectal cancer crc | #8064 |
| 45 | #8065 |
| 208 | #8069 |
| 105 | #8086 |
| sixteen | #8088 |
| humans longitudinal | #8090 |
| relating | #8096 |
| expand | #8099 |
| resultant | #8100 |
| trial background | #8102 |
| occurred | #8107 |
| irrespective | #8127 |
| analgesics opioid | #8128 |
| 5 years | #8132 |
| reduce | #8141 |
| receptors estrogen | #8142 |
| methodswe | #8150 |
| entering | #8154 |
| translational | #8164 |
| facilitating | #8173 |
| dose escalation | #8185 |
| specific antigen | #8189 |
| edetic | #8191 |
| ondansetron | #8204 |
| withdrawal | #8206 |
| tnf alpha | #8213 |
| cancer detection | #8218 |
| popular | #8220 |
| b4 | #8224 |
| mild | #8234 |
| spearman | #8242 |
| regard | #8249 |
| patients adult | #8249 |
| committees | #8252 |
| stage | #8255 |
| parp | #8258 |
| dietary supplements | #8265 |
| treated | #8266 |
| modalities | #8269 |
| tobramycin | #8285 |
| antitumor activity | #8287 |
| neoplasms male | #8289 |
| patient groups | #8315 |
| 201 | #8324 |
| estradiol | #8325 |
| risk cancer | #8327 |
| triazines | #8331 |
| wellbeing | #8341 |
| sertraline | #8344 |
| concern | #8345 |
| cell lung | #8349 |
| pubmed | #8352 |
| patient treatment | #8362 |
| pharmacogenetics | #8372 |
| year follow | #8372 |
| calcium | #8389 |
| clinical activity | #8395 |
| choose | #8397 |
| 6 cycles | #8403 |
| predisposing | #8405 |
| costly | #8417 |
| undergoing | #8422 |
| preparations | #8422 |
| neck neoplasms | #8435 |
| expense | #8447 |
| married | #8448 |
| detecting | #8460 |
| testing | #8465 |
| underestimate | #8466 |
| composition body | #8478 |
| 3 trial | #8482 |
| 37 | #8482 |
| eruptions | #8486 |
| oncologic | #8488 |
| neuromuscular | #8489 |
| clinical experience | #8509 |
| 39 patients | #8527 |
| respond | #8553 |
| cyclophosphamide | #8562 |
| 253 | #8570 |
| average | #8576 |
| 020 | #8587 |
| stratified | #8596 |
| exists | #8598 |
| ttp | #8610 |
| standard therapy | #8620 |
| 81 | #8624 |
| 015 | #8629 |
| estrogen receptors | #8637 |
| morphine | #8637 |
| cancer female | #8639 |
| remain | #8643 |
| fda | #8646 |
| legs | #8657 |
| initial | #8658 |
| relative risks | #8659 |
| practitioners | #8676 |
| functional status | #8679 |
| syndrome patients | #8684 |
| 6 months | #8685 |
| egfr | #8692 |
| grip | #8695 |
| notable | #8700 |
| single nucleotide polymorphisms | #8700 |
| molecular markers | #8705 |
| threatening | #8705 |
| loss | #8714 |
| aged 80 | #8715 |
| selfreports | #8722 |
| leptin | #8728 |
| 32 patients | #8731 |
| colorectal cancer | #8743 |
| drug | #8748 |
| perspectives | #8751 |
| majority | #8756 |
| illustrates | #8757 |
| inhibitors | #8764 |
| repeated | #8765 |
| 123 | #8769 |
| 2001 | #8774 |
| survivorship | #8779 |
| 066 | #8786 |
| aged models | #8792 |
| mouth | #8800 |
| real | #8800 |
| prospective randomized | #8808 |
| providers | #8813 |
| question | #8814 |
| advanced stage | #8823 |
| accumulating | #8842 |
| groups patients | #8847 |
| ferric | #8858 |
| uremic | #8865 |
| concomitant | #8886 |
| highrisk | #8893 |
| enteral nutrition | #8908 |
| publication aged aged | #8919 |
| predefined | #8929 |
| supplemental | #8938 |
| negatively | #8961 |
| 017 | #8966 |
| 145 | #8971 |
| ovaries | #8984 |
| demographics | #8989 |
| ribose | #8990 |
| 28 patients | #8996 |
| 2 study | #9000 |
| acceptability | #9006 |
| dna neoplasm | #9008 |
| 304 | #9013 |
| lung neoplasms | #9014 |
| analyses | #9017 |
| bivariate | #9019 |
| favored | #9020 |
| longer | #9020 |
| 300 | #9035 |
| 18 | #9037 |
| literature | #9043 |
| 223 | #9060 |
| vagina | #9062 |
| analgesics | #9073 |
| women risk | #9074 |
| 116 | #9084 |
| venous | #9089 |
| 275 | #9107 |
| consisted | #9112 |
| medical treatment | #9114 |
| 70 | #9117 |
| instability | #9124 |
| oral anticoagulants | #9131 |
| referred | #9132 |
| 286 | #9133 |
| gene expression profiling | #9135 |
| rated | #9162 |
| 232 | #9167 |
| 1987 | #9170 |
| 103 | #9180 |
| germ cell | #9183 |
| erbb receptors | #9195 |
| feeling | #9196 |
| moderate | #9197 |
| embryonal | #9202 |
| erythropoiesis | #9216 |
| 12 patients | #9228 |
| predict | #9230 |
| approaches | #9232 |
| 320 | #9249 |
| psycinfo | #9250 |
| update | #9253 |
| incidence | #9265 |
| eighteen | #9277 |
| stimulate | #9281 |
| manifestation | #9291 |
| primary | #9292 |
| administrative | #9293 |
| greater risk | #9301 |
| favorable | #9308 |
| hypnotics | #9310 |
| systematic literature | #9317 |
| 94 | #9317 |
| 15 | #9332 |
| possess | #9332 |
| participant | #9336 |
| grip strength | #9341 |
| metastatic | #9361 |
| lives | #9367 |
| cycles | #9371 |
| mechanisms action | #9383 |
| acceptable | #9383 |
| drug female | #9385 |
| ambulatory | #9385 |
| postulated | #9389 |
| 177 | #9431 |
| 82 | #9435 |
| 28 | #9436 |
| consisting | #9437 |
| neurologic | #9443 |
| partial response | #9454 |
| definitive | #9454 |
| abdomen | #9468 |
| 3 groups | #9499 |
| death patients | #9509 |
| ophthalmic | #9514 |
| recurrence patients | #9518 |
| serving | #9539 |
| cancer crc | #9542 |
| 500 | #9542 |
| 006 | #9545 |
| 065 | #9547 |
| jaw | #9565 |
| decisionmaking | #9568 |
| imbalance | #9575 |
| melphalan | #9579 |
| similarities | #9580 |
| add | #9583 |
| sentinel lymph | #9619 |
| 68 | #9624 |
| progesterone receptor | #9627 |
| addressed | #9641 |
| oral cavity | #9657 |
| prednisone | #9662 |
| electroacupuncture | #9668 |
| publications | #9669 |
| referrals | #9677 |
| items | #9695 |
| p0004 | #9696 |
| fell | #9698 |
| 149 | #9702 |
| nerve injury | #9707 |
| adenocarcinoma aged | #9733 |
| logistic regression analysis | #9737 |
| smokers | #9746 |
| cope | #9749 |
| erbb | #9762 |
| experts | #9767 |
| carcinoma patients | #9777 |
| sleep disorders | #9784 |
| food intake | #9785 |
| priority | #9791 |
| monoclonal humanized | #9791 |
| 0002 | #9797 |
| remission induction | #9812 |
| exercise female | #9831 |
| trends | #9835 |
| 7 | #9836 |
| patient age | #9855 |
| saponins | #9856 |
| palliation | #9857 |
| neuroprotective agents | #9871 |
| clinical outcomes patients | #9872 |
| avoid | #9872 |
| 95ci | #9875 |
| goals | #9882 |
| bleeding | #9884 |
| axonal | #9897 |
| illness | #9909 |
| 89 | #9921 |
| injections | #9941 |
| zinc | #9942 |
| mitigate | #9952 |
| provision | #9954 |
| variety | #9963 |
| telephone | #9968 |
| recurrence rates | #9969 |
| education topic | #9980 |
| 88 | #9985 |
| behavioral therapy | #9988 |
| ethics | #9991 |
| 400 | #9997 |
| growing | #9999 |
| square | #10005 |
| reactions female | #10007 |
| prescribing | #10007 |
| advanced disease | #10009 |
| dosedependent manner | #10013 |
| exist | #10016 |
| art | #10020 |
| bone resorption | #10023 |
| progressed | #10053 |
| women health | #10061 |
| autonomic | #10070 |
| ortho | #10071 |
| reason | #10076 |
| percentages | #10095 |
| candidates | #10096 |
| exceptions | #10097 |
| 76 | #10099 |
| node dissection | #10100 |
| il1β | #10101 |
| criterion | #10109 |
| disease adult | #10113 |
| 56 | #10120 |
| predictive factors | #10154 |
| preference | #10168 |
| micronutrients | #10188 |
| categorized | #10215 |
| measures | #10218 |
| monoamine | #10221 |
| 12 | #10224 |
| 40 patients | #10233 |
| demonstrate | #10251 |
| lack | #10261 |
| curve | #10266 |
| guideline adherence | #10267 |
| 256 | #10271 |
| developed | #10274 |
| achieving | #10279 |
| caused | #10317 |
| higher incidence | #10325 |
| sarcomas | #10341 |
| epidermal | #10345 |
| variables | #10354 |
| bone mineral density | #10369 |
| anemia | #10385 |
| cell transplant | #10386 |
| morning | #10392 |
| survival dfs | #10400 |
| changed | #10400 |
| 3 5 | #10407 |
| 142 | #10413 |
| 141 | #10436 |
| smoking cessation | #10437 |
| chart | #10440 |
| 041 | #10450 |
| revised | #10485 |
| 24 hours | #10489 |
| lvef | #10497 |
| masked | #10500 |
| syndromes | #10508 |
| longitudinal studies | #10522 |
| mineral density | #10522 |
| effort | #10550 |
| instruments | #10555 |
| 154 | #10558 |
| define | #10560 |
| 650 | #10565 |
| surveillance | #10571 |
| persisted | #10581 |
| elucidate | #10582 |
| informed | #10584 |
| trend | #10585 |
| months 95 | #10586 |
| encountered | #10600 |
| 667 | #10608 |
| fewer | #10613 |
| counselling | #10617 |
| doxorubicin | #10617 |
| academic | #10623 |
| include | #10636 |
| concert | #10640 |
| european society | #10663 |
| histories | #10672 |
| curative intent | #10673 |
| upper extremity | #10688 |
| vitamins | #10697 |
| examinations | #10703 |
| treatment chronic | #10721 |
| prognostic significance | #10733 |
| median followup | #10743 |
| tests | #10751 |
| edema | #10753 |
| anticoagulants | #10757 |
| enter | #10757 |
| fat mass | #10763 |
| median duration | #10779 |
| iiia | #10779 |
| patients response | #10788 |
| induction chemotherapy | #10795 |
| 60 years | #10802 |
| 182 | #10803 |
| clinic | #10803 |
| columbia | #10805 |
| 73 | #10812 |
| insufficient | #10814 |
| rcts | #10818 |
| internal consistency | #10826 |
| 21 | #10828 |
| advisory | #10839 |
| noradrenaline | #10843 |
| recurrent | #10863 |
| randomised controlled | #10873 |
| determine | #10873 |
| hydroxy | #10874 |
| neck cancer | #10884 |
| clinicaltrialsgov | #10885 |
| nighttime | #10888 |
| felt | #10892 |
| held | #10899 |
| 1 patient | #10911 |
| 9 patients | #10922 |
| limited | #10928 |
| occurring | #10934 |
| supplements | #10937 |
| kits | #10950 |
| head neck cancer | #10956 |
| cognition disorders | #10958 |
| start | #10961 |
| retrospective review | #10966 |
| failure | #10978 |
| needed | #10981 |
| squamous cell carcinoma | #10982 |
| registry | #10999 |
| physiology | #11017 |
| 155 | #11028 |
| 030 | #11031 |
| agents drug | #11051 |
| rationale | #11080 |
| ascertained | #11084 |
| interventions | #11094 |
| soft tissue | #11097 |
| smoking | #11105 |
| international society | #11105 |
| 3 years | #11121 |
| 043 | #11122 |
| editorial | #11123 |
| years diagnosis | #11128 |
| sleep wake | #11133 |
| practice guidelines | #11135 |
| sick | #11135 |
| 091 | #11146 |
| decrease | #11150 |
| extensive | #11160 |
| head neck | #11164 |
| reduces | #11166 |
| 127 | #11168 |
| subclinical | #11185 |
| decreases | #11199 |
| progesterone | #11207 |
| facilitate | #11216 |
| gamma | #11222 |
| 2004 | #11246 |
| secondary outcome | #11250 |
| anticoagulation | #11251 |
| 1983 | #11257 |
| survival | #11259 |
| prostate | #11267 |
| contributed | #11278 |
| cognitive behavioral | #11279 |
| diploid | #11281 |
| therapy neoplasm | #11287 |
| snps | #11295 |
| closer | #11307 |
| reviews | #11329 |
| benzimidazoles | #11334 |
| vincristine | #11361 |
| 168 | #11373 |
| thrombocytopenia | #11377 |
| 129 | #11387 |
| affect | #11397 |
| radiation therapy | #11423 |
| subgroup analyses | #11428 |
| apparent | #11439 |
| clinical signs | #11439 |
| point | #11449 |
| rating scale | #11457 |
| 78 | #11468 |
| 092 | #11469 |
| label | #11482 |
| 2 trial | #11486 |
| patients patient | #11493 |
| multidimensional | #11498 |
| alive | #11501 |
| caregivers | #11509 |
| 235 | #11509 |
| recombinant human | #11530 |
| 6 | #11541 |
| 130 | #11548 |
| lymphatic metastasis | #11549 |
| 040 | #11553 |
| helps | #11582 |
| computerized | #11583 |
| 109 | #11585 |
| enhancing | #11586 |
| 20 patients | #11588 |
| analgesic | #11591 |
| humans mass | #11616 |
| incontinence | #11617 |
| opioid | #11645 |
| benefits | #11651 |
| pulmonary embolism | #11652 |
| minimal | #11660 |
| peritoneal | #11670 |
| 028 | #11674 |
| gefitinib | #11675 |
| adenocarcinoma adult | #11688 |
| camptothecin | #11691 |
| body image | #11717 |
| docetaxel | #11732 |
| sarcopenia | #11745 |
| lumbar | #11751 |
| small cell | #11764 |
| rheumatic | #11765 |
| comparisons | #11767 |
| nerves | #11789 |
| reduction | #11791 |
| oxidative damage | #11822 |
| aged postoperative | #11823 |
| 128 | #11825 |
| resultsthe | #11835 |
| risk recurrence | #11837 |
| definite | #11855 |
| 024 | #11855 |
| neoplasms cell | #11862 |
| interim | #11864 |
| hematologic | #11897 |
| investigation | #11910 |
| testicular | #11913 |
| cured | #11926 |
| haloperidol | #11938 |
| pelvis | #11956 |
| thirteen | #11969 |
| humanized | #11970 |
| ≥3 | #11995 |
| 1998 | #11997 |
| referral | #11997 |
| involving | #11999 |
| 90 patients | #12014 |
| 24 patients | #12015 |
| humans | #12017 |
| negative breast | #12030 |
| effectively | #12047 |
| thirds | #12053 |
| single nucleotide | #12063 |
| muscarinic | #12067 |
| triphosphate | #12068 |
| committee | #12069 |
| rating | #12071 |
| bone mineral | #12074 |
| − | #12078 |
| toxic | #12079 |
| cumulative incidence | #12103 |
| greater | #12144 |
| expectancy | #12147 |
| dosage | #12148 |
| rectal cancer | #12163 |
| 119 | #12183 |
| 104 | #12187 |
| unadjusted | #12191 |
| validity | #12205 |
| aspirin | #12207 |
| deoxycytidine | #12226 |
| alternatively | #12248 |
| believed | #12251 |
| malignant | #12268 |
| peri | #12270 |
| sodium channel | #12270 |
| 2 weeks | #12279 |
| disease specific | #12302 |
| igf | #12308 |
| compliance | #12317 |
| categories | #12322 |
| cognitive | #12338 |
| terms | #12340 |
| grading | #12342 |
| classic | #12345 |
| tolerability | #12360 |
| sexual | #12361 |
| psychometrics | #12376 |
| 27 | #12378 |
| adjuvants | #12396 |
| falls | #12402 |
| searched | #12414 |
| relapse | #12415 |
| qualitative study | #12416 |
| sentinel | #12421 |
| p21ras | #12426 |
| 1 2 | #12446 |
| anticancer drugs | #12449 |
| science | #12462 |
| drug humans | #12482 |
| 90 | #12485 |
| predictive | #12492 |
| 194 | #12495 |
| embase | #12496 |
| transfusion | #12502 |
| consistency | #12511 |
| reasons | #12523 |
| prognostic factor | #12536 |
| mitomycin | #12540 |
| 010 | #12573 |
| predictors | #12577 |
| bladder cancer | #12581 |
| explored | #12591 |
| bioavailability | #12611 |
| sleep | #12615 |
| attempts | #12621 |
| test | #12626 |
| psychometric | #12641 |
| therapeutic approaches | #12642 |
| supports | #12643 |
| fourteen | #12657 |
| rank test | #12657 |
| recommendations | #12691 |
| problem | #12710 |
| 2013 | #12714 |
| patient outcome | #12719 |
| reliability | #12747 |
| translated | #12749 |
| stiffness | #12752 |
| crc | #12777 |
| missed | #12783 |
| develop | #12817 |
| 023 | #12853 |
| segmental | #12865 |
| cancer nsclc | #12868 |
| patients surgery | #12874 |
| statistics | #12876 |
| subject | #12882 |
| ice | #12886 |
| normal tissue | #12931 |
| interviewed | #12944 |
| inform | #12945 |
| irreversible | #12946 |
| poorer | #12947 |
| coded | #12950 |
| 184 | #12952 |
| single agent | #12954 |
| scale | #12961 |
| univariate | #12983 |
| monoclonal antibodies monoclonal | #13009 |
| 193 | #13020 |
| n4 | #13025 |
| defining | #13026 |
| cancers | #13041 |
| ovariectomy | #13045 |
| paired | #13049 |
| future | #13082 |
| humans logistic | #13082 |
| suggests | #13099 |
| longterm followup | #13101 |
| pharmacotherapy | #13121 |
| trial comparing | #13126 |
| gains | #13129 |
| alter | #13132 |
| aged neoadjuvant | #13151 |
| inflammatory cytokines | #13153 |
| demographic | #13159 |
| originally | #13160 |
| cox regression | #13163 |
| responsiveness | #13183 |
| 44 | #13192 |
| tpa | #13230 |
| multiple myeloma | #13238 |
| epidemiologic | #13262 |
| humans lymphatic | #13262 |
| 21 patients | #13267 |
| longitudinal data | #13270 |
| myeloma | #13286 |
| racial | #13299 |
| requiring | #13322 |
| outpatient | #13334 |
| symptomatic | #13346 |
| cognitive function | #13351 |
| hours | #13376 |
| steroidal | #13380 |
| pg | #13393 |
| measure | #13408 |
| formal | #13409 |
| therapeutic potential | #13414 |
| intermediate | #13433 |
| muscle mass | #13492 |
| ductal | #13505 |
| eventually | #13506 |
| randomised trial | #13513 |
| attending | #13528 |
| psychometric properties | #13563 |
| discriminate | #13564 |
| pharmacological | #13578 |
| typically | #13588 |
| diminished | #13609 |
| improves | #13630 |
| agonists | #13630 |
| 196 | #13634 |
| skin cancer | #13649 |
| tended | #13650 |
| frequency | #13652 |
| participants | #13674 |
| infective | #13701 |
| hypothesis | #13703 |
| tested | #13723 |
| attempted | #13739 |
| initiation | #13758 |
| distress | #13778 |
| foods | #13785 |
| severe | #13795 |
| 192 | #13800 |
| clinical manifestations | #13803 |
| marked | #13813 |
| 18 years | #13813 |
| conditional | #13831 |
| 018 | #13858 |
| colonic | #13890 |
| solid tumors | #13891 |
| negative patients | #13900 |
| march | #13918 |
| lymphatic | #13928 |
| sleep quality | #13935 |
| mechanisms underlying | #13938 |
| 102 | #13944 |
| p00001 | #13946 |
| focus | #13988 |
| aged muscle | #13991 |
| conducting | #13996 |
| estimate male | #13999 |
| igf1 | #14032 |
| calcitonin | #14038 |
| head | #14056 |
| eastern | #14057 |
| substances | #14080 |
| lung cancer | #14080 |
| 0001 | #14090 |
| respondents | #14106 |
| skin | #14109 |
| 169 | #14117 |
| breast cancer cells | #14121 |
| physiologic | #14122 |
| antagonist | #14137 |
| led | #14139 |
| risk death | #14180 |
| her2 | #14186 |
| modality | #14195 |
| protective | #14195 |
| risk developing | #14199 |
| etiology | #14201 |
| 189 | #14202 |
| cytotoxic | #14234 |
| demonstrating | #14236 |
| 124 | #14251 |
| life style | #14259 |
| suboptimal | #14279 |
| states aged | #14282 |
| careful | #14282 |
| cetuximab | #14293 |
| hypothesize | #14318 |
| efficacy safety | #14319 |
| 32 | #14329 |
| recurrence risk | #14331 |
| analysis performed | #14341 |
| instance | #14341 |
| virtually | #14371 |
| 188 | #14375 |
| clinical impact | #14379 |
| cessation | #14403 |
| alpha2 | #14412 |
| produces | #14420 |
| 144 | #14420 |
| 4 patients | #14436 |
| nodal | #14440 |
| extremity | #14440 |
| transitional | #14454 |
| stat | #14456 |
| 178 | #14484 |
| 1997 | #14487 |
| distant metastases | #14504 |
| trial registration | #14517 |
| 2008 | #14518 |
| 8 | #14521 |
| univariate multivariate | #14524 |
| nsclc | #14525 |
| erbb2 | #14544 |
| gm | #14553 |
| 035 | #14567 |
| year survival | #14570 |
| heavily | #14577 |
| iron | #14583 |
| 34 | #14587 |
| prospectively | #14607 |
| 09 | #14626 |
| episodes | #14626 |
| 007 | #14634 |
| tumor response | #14639 |
| hypothetical | #14647 |
| additional | #14648 |
| initial diagnosis | #14674 |
| estrogen receptor | #14679 |
| prophylaxis | #14686 |
| 5 year | #14689 |
| dermal | #14710 |
| adult | #14729 |
| 008 | #14729 |
| menstrual | #14740 |
| examine | #14743 |
| practice | #14751 |
| reflecting | #14758 |
| 15 years | #14762 |
| neoplasm | #14762 |
| neoplasm staging | #14774 |
| interferons | #14781 |
| clarify | #14785 |
| health professionals | #14804 |
| erlotinib | #14821 |
| asian | #14838 |
| relevant | #14863 |
| peer | #14921 |
| 1990 | #14930 |
| cancer cases | #14942 |
| incorporate | #14956 |
| emerged | #14959 |
| cancer diagnosis | #14977 |
| median | #15008 |
| colorectal carcinoma | #15030 |
| cognitive decline | #15047 |
| 07 | #15052 |
| premature | #15064 |
| overexpressing | #15067 |
| expected | #15111 |
| september | #15115 |
| proportions | #15119 |
| 011 | #15123 |
| medical | #15125 |
| 2 | #15153 |
| clear | #15163 |
| p004 | #15169 |
| assessments | #15187 |
| colonoscopy | #15187 |
| odds ratios | #15193 |
| replacement | #15198 |
| ganglia | #15220 |
| specific | #15227 |
| portion | #15240 |
| intervals | #15241 |
| acute | #15247 |
| agreed | #15266 |
| subjective | #15290 |
| area | #15293 |
| subgroups | #15325 |
| achieved | #15344 |
| proliferative | #15352 |
| routine | #15362 |
| releasing hormone | #15390 |
| 131 | #15404 |
| 197 | #15404 |
| 072 | #15431 |
| 070 | #15436 |
| december | #15459 |
| investigate | #15464 |
| reports | #15470 |
| 51 | #15487 |
| race | #15509 |
| education | #15510 |
| 1 | #15515 |
| medication | #15554 |
| basis | #15598 |
| standard | #15614 |
| life expectancy | #15626 |
| ranging | #15639 |
| safely | #15648 |
| estimate | #15652 |
| male | #15673 |
| survival benefit | #15674 |
| 24 months | #15681 |
| criteria | #15693 |
| 502 | #15702 |
| measuring | #15712 |
| animals antineoplastic | #15714 |
| individual | #15716 |
| offered | #15728 |
| updated | #15749 |
| option | #15749 |
| colon | #15751 |
| period | #15756 |
| nutrition | #15780 |
| antagonists | #15789 |
| globulin | #15792 |
| quartile | #15810 |
| nonparametric | #15815 |
| kappa | #15831 |
| rate treatment | #15867 |
| societies medical | #15873 |
| glandular | #15882 |
| local | #15882 |
| 87 | #15905 |
| focused | #15931 |
| pharmacokinetics | #15932 |
| longitudinally | #15937 |
| dfs | #15988 |
| usa | #16013 |
| phenomenon | #16013 |
| roughly | #16039 |
| distant metastasis | #16044 |
| squared | #16045 |
| improvement | #16107 |
| 118 | #16114 |
| 079 | #16120 |
| february | #16127 |
| naïve | #16154 |
| decision | #16179 |
| 95 patients | #16188 |
| analysis survival | #16209 |
| 161 | #16209 |
| drug interactions | #16211 |
| lung | #16212 |
| 081 | #16213 |
| neoadjuvant | #16222 |
| supported | #16222 |
| 162 | #16223 |
| serotonin | #16242 |
| cold | #16243 |
| cation | #16245 |
| cochrane library | #16265 |
| 93 | #16278 |
| alternatives | #16284 |
| exceeded | #16313 |
| colleagues | #16319 |
| detection cancer | #16320 |
| neurotransmitter | #16320 |
| channel blockers | #16348 |
| supplemented | #16355 |
| papillomavirus | #16362 |
| 14 patients | #16380 |
| excision | #16385 |
| releasing | #16393 |
| kras | #16396 |
| neoplasm grading | #16407 |
| progressively | #16413 |
| 0006 | #16416 |
| improvements | #16418 |
| diagnostic imaging | #16418 |
| osteonecrosis | #16452 |
| scales | #16460 |
| 30 | #16525 |
| protect | #16536 |
| declined | #16537 |
| ranged | #16562 |
| black | #16565 |
| support | #16576 |
| population surveillance | #16580 |
| improving | #16587 |
| 13 patients | #16588 |
| condition | #16625 |
| systematic review metaanalysis | #16649 |
| radiation | #16657 |
| understand | #16705 |
| male neoplasm | #16705 |
| tumor size | #16709 |
| treat | #16715 |
| mucosa | #16717 |
| broader | #16719 |
| broadly | #16748 |
| 082 | #16750 |
| 106 | #16760 |
| 10 years | #16780 |
| post operative | #16791 |
| mimic | #16818 |
| studying | #16832 |
| demonstrated | #16842 |
| bayes | #16878 |
| safety | #16885 |
| major | #16886 |
| rarely | #16886 |
| maintained | #16890 |
| inpatient | #16921 |
| aware | #16924 |
| drugs | #16939 |
| 67 | #16962 |
| depletion | #16977 |
| sex | #16982 |
| hormone | #16988 |
| confer | #16998 |
| hemoglobin | #17005 |
| 125 | #17019 |
| maximum | #17031 |
| muscles | #17039 |
| investigating | #17045 |
| issues | #17053 |
| neoadjuvant therapy | #17063 |
| genotype humans | #17068 |
| publication adaptation | #17073 |
| 84 | #17091 |
| directed | #17099 |
| iron deficiency | #17162 |
| diseasefree survival | #17162 |
| disseminated | #17164 |
| utilize | #17166 |
| feasible | #17197 |
| energy intake | #17217 |
| inconsistent | #17247 |
| mineral | #17315 |
| 088 | #17335 |
| valid | #17344 |
| tnfα | #17364 |
| percentage | #17396 |
| interleukin6 | #17416 |
| raf | #17421 |
| describing | #17520 |
| centered | #17529 |
| neck | #17557 |
| functioning | #17582 |
| locally | #17585 |
| physical activity | #17586 |
| survival outcomes | #17596 |
| traditional | #17602 |
| fact | #17609 |
| original | #17648 |
| 080 | #17655 |
| 2019 | #17720 |
| current evidence | #17735 |
| log | #17761 |
| adding | #17766 |
| unrelated | #17776 |
| carcinogenesis | #17789 |
| lactic | #17816 |
| impairment | #17825 |
| assayed | #17837 |
| decreased | #17874 |
| confirms | #17879 |
| 094 | #17886 |
| examination | #17892 |
| graded | #17909 |
| meta | #17936 |
| monoclonal antibodies | #17955 |
| 200 | #17981 |
| minimum | #18048 |
| clinical presentation | #18052 |
| structured | #18083 |
| primary prevention | #18124 |
| 48 | #18131 |
| primary tumors | #18132 |
| formulated | #18148 |
| il6 | #18159 |
| metastasis male | #18162 |
| bone | #18174 |
| medline | #18185 |
| uncommon | #18193 |
| mass screening | #18244 |
| 80 biomarkers | #18256 |
| critically | #18295 |
| assessing | #18322 |
| retinoic | #18359 |
| hazards models | #18394 |
| reporting | #18396 |
| healthrelated quality | #18416 |
| relationships | #18418 |
| respective | #18423 |
| carry | #18439 |
| humans intestinal | #18447 |
| 096 | #18450 |
| 83 | #18485 |
| staging prognosis | #18489 |
| consistently | #18499 |
| akt | #18504 |
| adjustment | #18519 |
| equal | #18526 |
| 2 years | #18534 |
| maintain | #18583 |
| negligible | #18617 |
| nutritional | #18643 |
| 003 | #18655 |
| address | #18711 |
| raised | #18739 |
| 3 patients | #18741 |
| meier estimate | #18762 |
| kaplan meier | #18769 |
| mucosal | #18825 |
| promising | #18832 |
| highlighted | #18856 |
| includes | #18858 |
| 098 | #18862 |
| chronic diseases | #18875 |
| poor | #18878 |
| hormones | #18887 |
| tailored | #18923 |
| status | #18942 |
| united states | #18948 |
| pyridines | #18950 |
| serum | #18956 |
| orr | #18990 |
| histologic | #19009 |
| stimulating | #19056 |
| dysfunction | #19111 |
| meier | #19125 |
| cohort | #19137 |
| inhibitor | #19177 |
| mood | #19177 |
| ≥ | #19195 |
| excessive | #19215 |
| irinotecan | #19250 |
| agents apoptosis | #19258 |
| consensus | #19281 |
| accepted | #19282 |
| candidate | #19292 |
| recombinant proteins | #19298 |
| recorded | #19302 |
| ovarian | #19337 |
| metaanalysis | #19377 |
| newly | #19381 |
| staging | #19391 |
| global | #19431 |
| evidenced | #19433 |
| fats | #19483 |
| inflammatory agents | #19496 |
| proportional hazards | #19507 |
| prone | #19520 |
| asymptomatic | #19544 |
| surgically | #19614 |
| hospitalized | #19617 |
| pretreated | #19680 |
| degree | #19687 |
| predicted | #19728 |
| adaptation psychological | #19769 |
| emotional | #19779 |
| making | #19782 |
| humans kaplan | #19803 |
| scored | #19840 |
| kaplan | #19866 |
| neoplasms carcinoma | #19874 |
| 3 year | #19944 |
| 1995 | #19991 |
| procedures | #20019 |
| 2002 | #20057 |
| cervical | #20082 |
| tumor necrosis factor | #20104 |
| observational studies | #20128 |
| randomised | #20168 |
| mediator | #20189 |
| beneficial | #20254 |
| 24 | #20258 |
| patients risk | #20262 |
| maximal | #20273 |
| log rank | #20282 |
| small | #20300 |
| endocrine | #20301 |
| rates | #20333 |
| involves | #20398 |
| allcause mortality | #20422 |
| exploring | #20500 |
| assess | #20503 |
| adjusting | #20553 |
| successful | #20677 |
| usual | #20690 |
| women aged | #20722 |
| 95 confidence interval | #20729 |
| invasiveness neoplasm | #20747 |
| addressing | #20782 |
| 19 | #20821 |
| concluded | #20831 |
| july | #20847 |
| node | #20854 |
| finding | #21019 |
| remaining | #21031 |
| relationship | #21070 |
| collected | #21085 |
| male mass | #21107 |
| reliable | #21137 |
| year | #21139 |
| january | #21202 |
| statistical | #21265 |
| 1999 | #21287 |
| absence | #21319 |
| mri | #21400 |
| comparison | #21403 |
| extended | #21420 |
| proportional | #21490 |
| feasibility | #21521 |
| rectal | #21541 |
| prognosis | #21551 |
| gradually | #21576 |
| implementing | #21589 |
| models male | #21936 |
| improved | #21939 |
| death | #21941 |
| apply | #21969 |
| morbidity | #22004 |
| intervention | #22038 |
| insulin growth | #22054 |
| verbal | #22139 |
| 10 patients | #22157 |
| urinary | #22186 |
| combination | #22213 |
| authors | #22223 |
| 2005 | #22223 |
| alterations | #22302 |
| aimed | #22386 |
| predictive tests | #22416 |
| event | #22426 |
| fibroblast | #22446 |
| reviewed | #22573 |
| status humans | #22597 |
| elevated | #22633 |
| frequent | #22673 |
| setting | #22759 |
| cox proportional | #22797 |
| malignancies | #22798 |
| allocated | #22808 |
| 95 | #22862 |
| diverse | #23033 |
| imaging mri | #23033 |
| superior | #23111 |
| post | #23144 |
| selected | #23153 |
| june | #23240 |
| surgical resection | #23266 |
| aged neoplasm | #23452 |
| persistent | #23460 |
| term | #23463 |
| represent | #23526 |
| antibodies monoclonal | #23543 |
| comprehensive | #23553 |
| continuously | #23560 |
| remained | #23674 |
| classified | #23739 |
| body | #23757 |
| strong | #23813 |
| monoclonal | #23861 |
| physical | #23883 |
| gastrointestinal | #23900 |
| exclude | #23924 |
| 2011 | #23997 |
| 2017 | #23997 |
| severely | #24141 |
| median follow | #24342 |
| partial | #24353 |
| abnormal | #24383 |
| systemic | #24466 |
| recruited | #24477 |
| general | #24560 |
| dietary | #24683 |
| 1996 | #24713 |
| carcinoma | #24787 |
| susceptible | #24878 |
| providing | #25068 |
| acids | #25078 |
| consistent | #25119 |
| implemented | #25293 |
| attributed | #25373 |
| 17 | #25476 |
| early | #25506 |
| markedly | #25526 |
| inhibition | #25536 |
| free | #25571 |
| lymph | #25627 |
| international | #25729 |
| regional | #25737 |
| sought | #25746 |
| selective | #25748 |
| 0003 | #25751 |
| single | #25859 |
| mechanism | #26084 |
| unclear | #26339 |
| putative | #26419 |
| surgery | #26438 |
| 13 | #26589 |
| unknown | #26785 |
| electronic | #26810 |
| predisposition disease | #26997 |
| accompanied | #26998 |
| multiple | #27050 |
| follow studies | #27065 |
| polymorphism single | #27142 |
| united | #27151 |
| histologically | #27323 |
| inherited | #27404 |
| neoplasm proteins | #27717 |
| prognosis retrospective | #27768 |
| systematic | #27775 |
| functional | #27808 |
| 0005 | #28001 |
| predisposition | #28007 |
| preoperative | #28036 |
| skeletal | #28185 |
| longitudinal | #28189 |
| estimated | #28229 |
| leads | #28238 |
| missing | #28264 |
| acid | #28356 |
| anti inflammatory | #28360 |
| correlate | #28365 |
| larger | #28581 |
| sex factors | #28629 |
| causing | #28688 |
| sensitivity | #28740 |
| vary | #28851 |
| 11 | #28869 |
| matched | #28979 |
| represents | #29258 |
| detection | #29343 |
| active | #29413 |
| differentiate | #29510 |
| objectives | #29543 |
| completely | #29721 |
| factual | #29750 |
| databases factual | #29793 |
| varied | #30036 |
| excluded | #30077 |
| quantified | #30091 |
| occurs | #30143 |
| adjusted | #30189 |
| logistic | #30241 |
| underlying | #30508 |
| allowed | #30520 |
| national | #30765 |
| odds | #30909 |
| 001 | #30996 |
| regression | #31005 |
| unchanged | #31053 |
| separately | #31068 |
| characterize | #31283 |
| recombinant | #31415 |
| adolescent | #31473 |
| dose dependent | #31787 |
| age | #31875 |
| lacking | #31939 |
| attenuated | #31971 |
| lower | #32078 |
| correlated | #32273 |
| postoperative | #32309 |
| negative | #32666 |
| growth factor | #33089 |
| positive | #33861 |
| understood | #33957 |
| confirmed | #33982 |
| reduced | #34048 |
| implicated | #34054 |
| confidence | #34153 |
| defined | #34517 |
| occur | #34659 |
| requires | #35112 |
| directly | #35347 |
| followup | #36532 |
| diagnosed | #36787 |
| suggesting | #37604 |
| remains | #37899 |
| multivariate | #38132 |
| independent | #38886 |
| measured | #38991 |
| proto oncogene | #39186 |
| proto | #39814 |
| biomarkers tumor | #39899 |
| examined | #40295 |
| retrospective studies | #42973 |
| underwent | #43365 |
| 95 confidence | #44196 |
Rapport d'exécution | |
Prominent publications by Charles L Loprinzi
KOL-Index: 16482
Importance: Zoledronic acid, a third-generation aminobisphosphonate, reduces the incidence of skeletal-related events and pain in patients with bone metastases. The optimal dosing interval for zoledronic acid is uncertain.
Objective: To determine whether zoledronic acid administered every 12 weeks is noninferior to zoledronic acid administered every 4 weeks.
Design, Setting, Participants: Randomized, open-label clinical trial conducted at 269 academic and community sites in the United ...
| Connu pour Zoledronic Acid | Bone Metastases | 2 Years | Patients Breast Cancer | Skeletal Events |
KOL-Index: 16399
Postmenopausal women with breast cancer (BC) are at increased risk for bone loss. Bisphosphonates improve bone mineral density (BMD) in normal postmenopausal women. The purpose of this study was to determine if immediate treatment with zoledronic acid preserves BMD in postmenopausal women with BC starting letrozole after tamoxifen. Postmenopausal women with BC completing tamoxifen were treated with daily letrozole 2.5 mg/vitamin D 400 I.U., calcium 500 mg twice daily and were randomized ...
| Connu pour Postmenopausal Women | Bone Loss | Zoledronic Acid | Breast Cancer | Versus Delayed |
KOL-Index: 13693
PURPOSE: Risedronate prevents bone loss in postmenopausal women. The purpose of this study was to determine whether risedronate prevents bone loss in premenopausal women undergoing chemotherapy for breast cancer.
PATIENTS AND METHODS: Premenopausal women undergoing chemotherapy for breast cancer were treated with oral calcium 600 mg and vitamin D 400 U daily and randomly assigned to receive oral risedronate 35 mg weekly or placebo, with all these therapies beginning within a month of the ...
| Connu pour Bone Loss | Premenopausal Women | Breast Cancer | 1 Year | Bmd Baseline |
Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice
[ PUBLICATION ]
BACKGROUND: Cisplatin is primarily used for treatment of ovarian and testicular cancer. Oxaliplatin is the only effective treatment for metastatic colorectal cancer. Both are known to cause dose related, cumulative toxic effects on the peripheral nervous system and thirty to forty percent of cancer patients receiving these agents experience painful peripheral neuropathy. The mechanisms underlying painful platinum-induced neuropathy remain poorly understood. Previous studies have ...
| Connu pour Trpv1 Trpa1 | Transient Receptor | Cisplatin Oxaliplatin | Mechanical Allodynia | Treated Mice |
KOL-Index: 13187
PURPOSE: Functional iron deficiency may impair response to erythropoiesis-stimulating agents (ESAs) in iron-replete patients with chemotherapy-associated anemia (CAA). This study evaluated whether coadministration of parenteral iron improves ESA efficacy in patients with CAA.
PATIENTS AND METHODS: This prospective, multicenter, randomized trial enrolled 502 patients with hemoglobin (Hb) less than 11 g/dL who were undergoing chemotherapy for nonmyeloid malignancies. All patients received ...
| Connu pour Oral Iron | Darbepoetin Alfa | Erythropoietic Response | Phase Iii | Ferric Gluconate |
KOL-Index: 12870
To develop a framework for the definition and classification of cancer cachexia a panel of experts participated in a formal consensus process, including focus groups and two Delphi rounds. Cancer cachexia was defined as a multifactorial syndrome defined by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment. Its pathophysiology is characterised by a ...
| Connu pour Cancer Cachexia | International Consensus | Definition Classification | Weight Loss | Reduced Food Intake |
Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?
[ PUBLICATION ]
PURPOSE: Although it is well-established that fluorouracil- (FU-) based adjuvant therapy improves survival for patients with resected high-risk colon cancer, the magnitude of adjuvant therapy benefit across specific subgroups and for individual patients has been uncertain.
PATIENTS AND METHODS: Using a pooled data set of 3,302 patients with stage II and III colon cancer from seven randomized trials comparing FU + leucovorin or FU + levamisole to surgery alone, we performed an analysis ...
| Connu pour Adjuvant Therapy | Nodal Status | Colon Cancer | Survival Stage | Pooled Analysis |
Randomized Comparison of a Nicotine Inhaler and Bupropion for Smoking Cessation and Relapse Prevention
[ PUBLICATION ]
OBJECTIVE: To compare the combination of a nicotine inhaler and bupropion to either treatment alone for initiating smoking abstinence and relapse prevention.
METHODS: Smokers were randomized to receive a nicotine inhaler, bupropion, or both for 3 months. At 3 months, smoking-abstinent study participants were randomized to their initial medications or placebo. Participants who were smoking at 3 months were randomized to an alternative treatment regimen or placebo. This study was conducted ...
| Connu pour Relapse Prevention | Nicotine Inhaler | Bupropion Placebo | Smoking Abstinence | Treatment Phase |
A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal Cancer
[ PUBLICATION ]
BACKGROUND: Experimental studies in animals and observational studies in humans suggest that regular aspirin use may decrease the risk of colorectal adenomas, the precursors to most colorectal cancers.
METHODS: We conducted a randomized, double-blind trial to determine the effect of aspirin on the incidence of colorectal adenomas. We randomly assigned 635 patients with previous colorectal cancer to receive either 325 mg of aspirin per day or placebo. We determined the proportion of ...
| Connu pour Colorectal Adenomas | Patients Aspirin | Observational Studies | Relative Risks | Cancer Adenoma |
KOL-Index: 12619
BACKGROUND: Stool DNA testing is a new approach to colorectal cancer detection. Few data are available from the screening setting.
OBJECTIVE: To compare stool DNA and fecal blood testing for detection of screen-relevant neoplasia (curable-stage cancer, high-grade dysplasia, or adenomas >1 cm).
DESIGN: Blinded, multicenter, cross-sectional study.
SETTING: Communities surrounding 22 participating academic and regional health care systems in the United States.
PARTICIPANTS: 4482 ...
| Connu pour Stool Dna | Blood Test | Screen Detection | Colorectal Neoplasia | Humans Specificity |
Trends in Mastectomy Rates at the Mayo Clinic Rochester: Effect of Surgical Year and Preoperative Magnetic Resonance Imaging
[ PUBLICATION ]
PURPOSE: Recent changes have occurred in the presurgical planning for breast cancer, including the introduction of preoperative breast magnetic resonance imaging (MRI). We sought to analyze the trends in mastectomy rates and the relationship to preoperative MRI and surgical year at Mayo Clinic, Rochester, MN.
PATIENTS AND METHODS: We identified 5,405 patients who underwent surgery between 1997 and 2006. Patients undergoing MRI were identified from a prospective database. Trends in ...
| Connu pour Mastectomy Rates | Magnetic Resonance | Patients Mri | Surgery Type | Surgical Year |
Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia.
[ PUBLICATION ]
PURPOSE: Previous double-blind, placebo-controlled, randomized clinical trials have demonstrated that both corticosteroids and progestational agents do partially alleviate cancer anorexia/cachexia. Pilot information suggested that an anabolic corticosteroid might also improve appetite in patients with cancer anorexia/cachexia. The current trial was developed to compare and contrast a progestational agent, a corticosteroid, and an anabolic corticosteroid for the treatment of cancer ...
| Connu pour Cancer Anorexia | Megestrol Acetate | Cachexia Patients | Progestational Agents | Corticosteroid Treatment |
KOL-Index: 12321
BACKGROUND: Vasomotor hot flashes are a common symptom in women during menopause and in men who have undergone androgen-deprivation therapy for prostate cancer. Although treatment with estrogens in women and androgens in men can attenuate these symptoms, these hormones may be contraindicated in women with breast cancer and in men with prostate cancer. Pilot trials have suggested that the progestational agent megestrol acetate can ameliorate hot flashes in both groups of ...
| Connu pour Megestrol Acetate | Hot Flashes | Women Breast Cancer | Deprivation Therapy | Weeks Placebo |
Des personnes clés pour Hot Flashes
Top Kols dans le monde
Sélectionnez une phrase de recherche hot flashes , hot flashes women , hot flashes sweats , hot flashes patients , hot flashes hfs
Charles L Loprinzi:Impact expert
Concepts pour lesquelsCharles L Loprinzia une influence directe:Hot flashes, Breast cancer, Megestrol acetate, Peripheral neuropathy, Scrambler therapy, Phase iii, Newer antidepressants, Hot flash.
Charles L Loprinzi:Impact de Kol
Concepts liés au travail d'autres auteurs pour lesquelsfor which Charles L Loprinzi a une influence:Breast cancer, Hot flashes, Adjuvant chemotherapy, Quality life, Weight loss, Oral mucositis, Neuropathic pain.
Tools
Est-ce votre profil? Réclamez votre profil Copier le lien ENCHED LIEN À VOTRE PROFIL |